

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

### Saving Legs & Lives: The efficacy of cardiovascular rehabilitation versus usual care on exercise capacity and quality of life in patients who have undergone lower limb revascularisation for peripheral arterial disease: Protocol for a randomised-controlled trial

en-2024-089203 ol v-2024
)
/-2024
Crist; University of the Sunshine Coast, School of Health; Sunshine Health Institute nkaj; Sunshine Coast University Hospital, Vascular Surgery lichelle; Sunshine Coast University Hospital, Cardiology loseph; University of the Sunshine Coast, School of Education and y Access nberg, Mia; University of the Sunshine Coast, School of Health n, Tony; Sunshine Coast University Hospital, Cardiology Christopher; University of the Sunshine Coast, School of Health; ne Coast Health Institute roup, Saving Legs & Lives Trial Group; University of the Sunshine School of Health
ILITATION MEDICINE, VASCULAR SURGERY, Exercise Test, Quality Cardiovascular Disease

### SCHOLARONE<sup>™</sup> Manuscripts

Title:

### **BMJ** Open

**BMJ** Open

Saving Legs & Lives: The efficacy of cardiovascular rehabilitation versus usual care on

### 

2 3 4	saving Legs & Lives: The efficacy of cardiovascular rehabilitation versus usual care on exercise capacity and quality of life in patients who have undergone lower limb revascularisation for peripheral arterial disease: Protocol for a randomised-controlled trial
5	
6	Authors:
7 8	Krist Feka <sup>1,2</sup> , Pankaj Jha <sup>3</sup> , Michelle Aust <sup>4</sup> , Joseph J. Scott <sup>5</sup> , Mia Schaumberg <sup>1,2</sup> , Tony Stanton <sup>4</sup> , Christopher D. Askew <sup>1,2</sup> on behalf of the Saving Legs & Lives Trial Group
9	
10	Saving Legs & Lives Trial Group
11 12 13	Kim Greaves, Norman Morris, Fraser D. Russell, Meegan Walker, Mathew Summers, Jill O'Donnell, Karl Schulze, Rebecca Magee, Daniel McGlade, Vivienne Moult, Amanda Shepherd, Michael Shanahan, Tuppence Richman, Caitlin Coppock, Helen Rodgers
14	
15	Affiliations:
16	<sup>1</sup> VasoActive Research Group, School of Health, University of the Sunshine Coast, Australia
17	<sup>2</sup> Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service, Australia
18	<sup>3</sup> Department of Vascular Surgery, Sunshine Coast University Hospital, Australia
19	<sup>4</sup> Department of Cardiology, Sunshine Coast University Hospital, Australia
20 21	<sup>5</sup> School of Education and Tertiary Access, University of the Sunshine Coast, Australia
22	Corresponding Author:
23	Professor Christopher D. Askew
24	VasoActive Research Group, School of Health, University of the Sunshine Coast
25	90 Sippy Downs Dr, Sippy Downs, Sunshine Coast, QLD 4556, Australia
26	Tel: +61 7 5456 5961 / 0412 332 987
27	Email: caskew@usc.edu.au
28	
29	
30	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

### 31 ABSTRACT:

Introduction: Peripheral artery disease (PAD) is characterised by stenosis or occlusion of the arteries in the lower limbs. Patients with PAD commonly report intermittent claudication (leg pain/discomfort) during physical activities, which significantly limits the ability to walk and perform activities of daily living. Supervised exercise training is an effective therapy that can improve walking capacity in people with PAD. Emerging evidence also suggests that supervised exercise therapy following lower limb revascularisation can further enhance walking capacity when compared with revascularisation alone. However, access to dedicated exercise programs for patients with PAD is limited in most countries, and there is a need to test the efficacy of alternative rehabilitation strategies and referral pathways. This randomised-controlled study aims to assess the efficacy of referral to a cardiovascular rehabilitation program versus usual care on walking capacity and quality of life in patients who have undergone lower limb revascularisation for PAD. 

Methods and analysis: This will be a single-centre, prospective, parallel group, randomised-controlled trial. Sixty-six participants who have undergone a lower limb revascularisation procedure for PAD, in the previous 12 months will be randomly allocated to a cardiovascular rehabilitation program or a usual care (control) group. The cardiovascular rehabilitation program will include two supervised exercise sessions per week for 6 weeks, home-based exercise advice, and one education seminar in total (5.5 hours) which will cover topics such as diet, medications, exercise training, and lifestyle modifications for the management of cardiovascular diseases. The control group will receive usual care and medical advice from their local doctor and vascular surgeon. The primary outcome will be maximum walking distance assessed with the 6-minute walk test (6MWT). Secondary outcomes include pain-free walking distance during the 6MWT, maximal and pain-free walking time during a graded treadmill walking test, cardiorespiratory fitness, self-reported walking capacity, disease-specific quality of life, and self-reported and objectively measured physical activity levels. Exploratory outcomes include brachial artery flow-mediated dilation, arterial stiffness, ankle-brachial blood pressure index, and biomarkers of cardiovascular disease risk. Outcomes will be assessed at baseline (week 1), following the cardiovascular rehabilitation / usual care period (week 8), and again at 6-month follow-up (week 34). 

Ethics and dissemination: This study has received ethics approval from the Human Research Ethics Committees (HREC) of Queensland Health Metro North Hospital and Health Service (94155), and the University of the Sunshine Coast (S231914). Findings from this study will be disseminated in peer-reviewed journals and through national and international conference presentations. 

### 66 Trial registration number: ACTRN12623000190606

1 2		
3		
4 5	70	STRENGTHS AND LIMITATIONS OF THIS STUDY:
6 7	71	• A world-first randomised-controlled trial investigating the efficacy of referral to a
8	72	cardiovascular rehabilitation program compared to usual care on walking capacity and
9	73	quality of life in people who have undergone lower limb revascularisation for peripheral
10 11	74	arterial disease (PAD).
12	75	• A multidisciplinary clinical collaboration including cardiology, vascular surgery,
13	76	nursing, exercise physiology and other areas of allied health to improve clinical
14 15	77	outcomes following lower limb revascularisation in people with PAD.
16	78	• The same investigators who will deliver the cardiovascular rehabilitation exercise
17 18	79	program will also be involved in the collection of outcome data. While it is not feasible
19	80	to blind participants and investigators to group allocation in an exercise intervention
20	81	study, all data analysis will be undertaken in blinded fashion using coded data.
21 22	82	
23	83	
24 25	84	
25 26	85	
27	65	
28 29	86	
30	87	
31 32		
32 33	88	
34	89	
35 36	90	
37		
38 39	91	
40	92	
41	93	
42 43		
44	94	
45 46	95	
40 47	06	
48	96	
49 50	97	
51	98	
52 53		
55 54	99	
55	100	
56 57	101	
58		
59 60	102	
60		

# 103 INTRODUCTION:

Peripheral artery disease (PAD) is an atherosclerotic condition characterised by stenosis or occlusion of the arteries of the lower limbs. Worldwide, PAD affects over 230 million adults and its prevalence is expected to further increase over the coming years due to the ageing of the population (1). People with PAD are limited by intermittent claudication (leg pain/discomfort) which significantly impairs walking capacity, physical activity levels and quality of life (2–4). Reduced walking capacity and physical inactivity further contribute to the elevated risk of secondary cardiovascular events (stroke, myocardial infarction, cardiovascular death) and associated hospitalisation (5-8).

The initial treatment for PAD includes medical management of symptoms and cardiovascular disease risk factors with pharmacotherapies and lifestyle modification (9). In patients with advanced PAD, including limiting claudication or chronic limb-threatening ischemia, lower limb revascularisation procedures are indicated to restore blood flow and 'save' the affected limb (9). Lower limb revascularisation procedures are associated with improvements in limb blood flow (10), walking capacity (11), and quality of life (12,13). However, despite improvements in limb blood flow, the improvements in walking capacity are generally only modest after lower limb revascularisation (~60% improvement) when compared with exercise therapy (~110%) (14). Furthermore, the benefits of revascularisation for walking capacity and quality of life are short-lived, with prospective studies reporting deteriorations in walking capacity as early as 26 months after revascularisation (15–17). This highlights an important limitation of lower limb revascularisation procedures for the long-term improvement of walking capacity in patients with PAD. 

Supervised exercise is an effective therapy that is widely recommended in several international guidelines for the management of patients with PAD (9,18–21). A large body of evidence suggests that supervised exercise programs, incorporating aerobic and resistance exercises of the lower limbs, improve walking capacity (22–24), physical activity levels (25,26) and quality of life (27,28) in patients with PAD. A commonly used assessment of walking capacity for patients with PAD is the six-minute walk test; and evidence shows gains in six-minute walk distance ranging between 45-80 meters following supervised exercise programs (25,29–32). Beyond the recommendation that supervised exercise should be included as part of the initial treatment of PAD, there is emerging evidence that outcomes following lower limb revascularisation can also be enhanced when combined with exercise therapy (33-35). This aligns with a recent systematic review that reported significant improvements in maximum walking distance (mean difference range: 82-321 m) and pain-free walking distance (mean difference range: 38-408 m) favouring a combined therapy approach over supervised exercise training or revascularisation alone (36). 

Despite this strong evidence supporting the benefits of supervised exercise therapy, access to dedicated exercise programs is very limited for patients with PAD. Previous studies report that as few as 43-48% of vascular units in the United States and the United Kingdom have access to dedicated supervised exercise programs for the referral of patients with PAD (37,38). Similarly, a survey of 378 vascular surgeons across 43 European countries reported that only 

30% (N=115/378) of surgeons have access to supervised exercise programs for the referral of patients with PAD (39). This highlights a need for alternative rehabilitation strategies and referral pathways to increase the access to supervised exercise therapy for patients with PAD. 

Cardiovascular rehabilitation is a well-established multidisciplinary approach for the care and rehabilitation of patients with heart disease, particularly those recovering from myocardial infarction or cardiac surgery (40). Cardiovascular rehabilitation (CR) programs typically consist of supervised exercise training, dietary and lifestyle advice, psychological support, and education on the management of cardiovascular disease risk factors. Studies report that CR programs are cost-effective for improving functional capacity, physical activity levels and quality of life, and reducing the risk of secondary cardiovascular events in patients with cardiac diseases (41–44). While CR programs are widely accessible in most countries, patients with PAD are historically seen as out of scope and are not usually referred for CR (40,45). To date very few studies have investigated the effectiveness of routine CR for patients with PAD (46-51). Most of these studies have been limited to the investigation of patients with coronary artery disease referred for CR who also had PAD as a comorbidity (47-50). In Canada, of 23,215 patient referrals with coronary artery disease, 5.9% (N=1,366 patients) were identified as having a comorbidity of PAD (47). The identified patients with PAD had significantly impaired cardiorespiratory fitness and a lower 10-year survival rate when compared with patients without PAD. Importantly, this study demonstrated that completion of CR led to significant reductions in mortality rate (adjusted hazard ratio 0.62 [95%CI 0.57, 0.67]) in patients with PAD, when compared with patients who did not attend CR (47). 

Recently, a small (N = 20 participants), non-randomised pilot study of CR in patients who had undergone lower limb revascularisation for PAD, reported that CR was safe and feasible, and led to greater improvements in six-minute walk distance (mean difference: 53 m; P=0.04) when compared with usual care (52). These findings highlight the potential for CR to be used as a standard referral pathway for patients with PAD who are recovering from a lower limb revascularisation procedure. To test this, we will conduct a randomised-controlled trial to assess the efficacy of referral to a 6-week community-based CR program versus usual care on walking capacity and quality of life in patients who have recently (< 12 months) undergone lower limb revascularisation for PAD. 

#### **Primary** aim

To assess the efficacy of a 6-week community-based CR exercise program versus usual care on maximum walking distance during a six-minute walk test (6MWT) in patients who have recently (< 12 months) undergone lower limb revascularisation for PAD. 

Secondary aims 

To assess the efficacy of a 6-week community-based CR exercise program on: 1) pain-free walking distance during a 6MWT, 2) maximal walking time and pain-free walking time during a graded treadmill walking test, 3) cardiorespiratory fitness measured as peak oxygen uptake during a graded treadmill walking test, 4) disease-specific quality of life and self-reported functional capacity, and 5) self-reported and objectively measured physical activity levels. 

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

### 184 Exploratory aims

To assess the efficacy of a 6-week community-based CR exercise program on: 1) brachial artery flow-mediated dilation, 2) arterial stiffness (augmentation index, carotid-femoral artery pulse wave velocity), 3) ankle-brachial blood pressure index, and 4) circulating biomarkers of cardiovascular disease risk.

13 189

### 15 190 METHODS AND ANALYSIS

## 16191 Study design and overview

An overview of the study is shown in Figure 1. This is a single centre, prospective, parallel-group, randomised-controlled trial conducted at the University of the Sunshine Coast and the Sunshine Coast University Hospital (Australia). Patients with PAD who have recently ( < 12months) undergone a lower limb revascularisation procedure will be identified and randomly allocated to either usual care or usual care plus a 6-week community-based CR program (N=33 per group; refer to power and sample size estimate). Participants allocated to the usual care group will receive usual care and medical advice from their local doctor and vascular surgeon. The community-based CR program will comprise two supervised exercise sessions per week for 6 weeks, home-based exercise advice, and an education seminar (5.5 hours). The CR program will be delivered by the Cardiovascular Rehabilitation Service of the Sunshine Coast University Hospital. Primary, secondary, and exploratory outcomes will be assessed at baseline (week 1), after the completion of the CR program / usual care period (week 8) and again 6 months after the completion of the CR program / usual care period (week 34). Maximal exercise assessments such as graded treadmill walking tests will be conducted at the Clinical Investigations Unit at the Sunshine Coast University Hospital to facilitate access to medical supervision. Other outcome measures will be conducted at the VasoActive Laboratory at the University of the Sunshine Coast. As per Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), a schedule of participant enrolment, intervention and assessments is presented in Table 1 (53). 

1 2		
3 4		ין וייניס אייר א
5	214	Participants & eligibility criteria
6 7	215	Potential participants will be identified from the Sunshine Coast region through: 1) an existing
8	216	database of participants who have previously provided consent to be contacted, 2) collaborating
9	217	vascular surgery clinics including the Sunshine Coast University Hospital, and 3) community
10 11	218	sources and advertising.
12 13	219	Participants will be eligible to participate in the study if they:
14 15	220	1. Are 18 years of age or older and have a formal diagnosis of PAD made by a vascular
16	221	surgeon.
17	222	2. Have undergone a lower limb revascularisation procedure (endovascular procedure,
18 19	223	open surgical procedure or hybrid procedure) in the previous 12 months.
20	224	3. Have clearance to participate from their treating vascular surgeon, including
21	225	verification that they have adequately recovered from any lower limb revascularisation
22	226	procedure.
23 24	227	4. Can understand and communicate in English sufficient to provide informed consent.
25 26	228	Participants will be excluded from participation if they meet any of the following criteria:
27		
28	229	1. Unable to walk independently (e.g., depend on assistance from a walking aid).
29 30	230	2. Previous lower limb amputation or current tissue necrosis (ulceration or gangrene) that
31	231	limits the ability to undertake walking tests.
32	232	3. Deemed not eligible to participate in CR by the CR clinical staff as per standard
33 34	233	contraindications for exercise (54). These contraindications include unstable angina,
35	234	acute heart failure, recent cerebrovascular event, uncontrolled resting hypertension,
36	235	symptomatic hypotension, uncontrolled diabetes, uncontrolled sinus tachycardia,
37	236	uncontrolled/complex arrythmias.
38 39	237	4. Currently participating in a supervised exercise rehabilitation program.
40	238	5. Terminal illness or other medical condition or planned treatment that may affect the
41	239	ability to participate in or complete the trial.
42 43	240	Intervention
44 45	241	Eligible participants will be randomised in equal proportions (1:1) to one of the study groups.
45 46	271 	
47	242	1. Usual care (control group).
48 49	243	2. Usual care plus a 6-week community-based CR program (intervention group).
50	-	I I I I I I I I I I I I I I I I I I I
51 52	244	Usual care
52		
54	245	All participants will continue to receive usual care and medical advice from their local doctor
55	246	and vascular surgeon throughout the study. Usual care for PAD will not be altered by this
56 57	247	protocol.
58 59	248	Usual care plus community-based CR program
60		r in the state of

### **BMJ** Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

In addition to usual care, participants who are randomised to the community-based CR program will be referred to the CR program of the Sunshine Coast Hospital and Health Service. The CR program will be delivered at a community fitness facility (The Sports Hub, Bokarina, QLD 4575, Australia). The CR program will be structured in accordance with current exercise recommendations for people with PAD (9,18-21). The CR program will include twelve 60minute sessions of supervised exercises, delivered twice per week over a period of 6 weeks, and one education seminar (5.5 hours with breaks). While the recommended duration of supervised exercise training for patients with PAD is 12 weeks (18,19), improvements in walking capacity are reported after 3-6 weeks (55-57). Furthermore, the recommended duration for CR ranges between 6-12 weeks (58). To ensure outcomes are applicable to a wide range of CR programs, the minimum duration for CR was selected (i.e., 6 weeks). During the 6-week CR program participants will also be provided with exercise guidelines and advice to complete at least three home-based walking sessions per week. Following the completion of the CR program, participants will be provided with individualised exercise and physical activity advice with the goal to meet the recommended 150-300 minutes of moderate intensity physical activity levels per week (54). 

The program exercise sessions will be supervised by CR staff (nurses, exercise physiologist) and research personnel. The research personnel will be responsible for the prescription and progression of the exercises. As outlined in Table 2, the supervised exercise sessions will primarily consist of bouts of intermittent treadmill walking that are interspersed by periods of upper body activity and lower limb resistance exercises. Each supervised exercise session will last for 60 minutes, including a warm-up and a cool-down (10 minutes each). The total duration of treadmill walking for each session will be 10 minutes (e.g., 5 x 2-minute bouts) at the beginning of the program (i.e., week 1) and will progress to 30 minutes (e.g., 15 x 2-minute bouts) by the end of the program (i.e., week 6). The total duration of upper body and lower limb resistance training for each session will begin at 30 minutes (e.g., 15 x 2-minute bouts) at the beginning of the program and will decrease to 10 minutes (e.g., 5 x 2-minute bouts) by the end of the program. Exercise intensity and severity of claudication pain will be monitored with the modified rate of perceived exertion Borg scale and the intermittent claudication pain scale, respectively (59,60). Participants will be instructed to exercise at moderate to near-maximal claudication pain thresholds (i.e., 3/4 on claudication scale) or if asymptomatic, exercise at a moderate exercise intensity (i.e., 3/10 on Borg scale) (18,61). The initial exercise intensity will be individually prescribed based on the exercise workload achieved during the baseline exercise tests (e.g., workload achieved at stage prior to treadmill test cessation). 

The home-based walking sessions will also align with the current PAD exercise recommendations (9,18–21). Participants will be provided with individualised weekly walking goals which will be set and reviewed by the study team. During the home-based walking sessions, participants will be instructed to complete intermittent bouts of walking separated by periods of rest. Similar to the supervised exercise sessions, the total duration of walking for each home-based session will begin at 10 minutes (e.g., 5 x 2-minute bouts) at the beginning of the program (i.e., week 1) and will progress to 30 minutes (e.g., 15 x 2-minute bouts) by the end of the program (i.e., week 6). The total period of rest for each home-based session will be 

### **BMJ** Open

20 minutes at the beginning of the program (e.g., 10 x 2-minute bouts) and will decrease until participants are able to walk continuously for 30 minutes. Exercise intensity and severity of claudication pain will be self-monitored using the modified rate of perceived exertion Borg scale, and the intermittent claudication pain scale (59,60). Participants will be instructed to walk at moderate to near-maximal claudication pain thresholds (i.e., 3/4 on claudication scale) or if asymptomatic, walk at a moderate exercise intensity (i.e., 3/10 on Borg scale) (18,61). Participants will be provided with a diary to record their home-based walking sessions. 

Participants in the CR program will attend an education seminar (5.5 hours with breaks). The education seminar will be delivered by health specialists (e.g., nurse, dietitian, psychologist, exercise physiologist) and will cover topics such as diet, medications, exercise training, physical activity, and lifestyle modifications for the management and prevention of cardiovascular diseases. The seminar information will be based on the current Australian guidelines for the management of acute coronary syndromes (62–64). 

#### Adherence

Strategies are incorporated into the protocol to promote and monitor adherence to the study intervention. The importance of attending the weekly supervised exercise sessions and accumulating the recommended weekly amount of exercise and physical activity levels will be explained to the participants in the participant information and consent form (PICF) and upon starting the CR program. Participants will also be provided with individualised weekly goals for the supervised and the home-based exercise sessions which will be set and reviewed by the study team. Adherence to the supervised and home-based exercise sessions will be assessed by recording the number of exercise sessions that participants complete each week against the goal/target for that specific week. Participants will keep a daily diary to record their home-based exercise sessions that they complete during the 6-week CR program. Attendance to the education seminar will be assessed using an attendance checklist. The assessment of protocol adherence for the purpose of statistical analysis is described in the statistical analysis section. 

#### Screening and enrolment (visit 1)

Prior to screening assessments, participants will be required to provide their informed consent to participate in the study which will occur at the commencement of the initial study visit (visit 1). A trained study staff member authorised by the Principal Investigator will take the participant through the information sheet and obtain informed consent. All participants will be fully informed of the potential risks and benefits of the study. Participants will be screened for co-morbidities and cardiovascular risk factors prior to inclusion in the study. During this visit, anthropometric measurements (e.g., height, weight) and resting blood pressure will be conducted. Participants will also be familiarised with the 6MWT to minimise test variability. 

#### **Randomisation and blinding**

Following baseline outcome measures (i.e., visit 3), participants will be randomly allocated to either the usual care group (N=33) or the usual care plus community-based CR exercise group (N=33). To ensure allocation concealment, randomisation will be generated using a secure, 

independent web-based randomisation system (SealedEnvelope.com). Prior to randomisation, participants will be stratified to account for type of procedure (e.g., open surgical vs endovascular procedure) and time since procedure (< 12 weeks vs > 12 weeks). This will allow stratification of participants who have recently undergone a revascularisation procedure (< 12 weeks) from those who have undergone a revascularisation procedure more than 12 weeks ago and have fully resumed normal activities of daily living, recreation, and work activities. Block randomisation, using random block sizes of two to four participants will be used to ensure that group allocation at any point in time remains similar. Enrolment, allocation, follow-up, and final analysis will be conducted and reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement for randomised clinical trials (65). 

**Outcome measures and procedures** 

As outlined in Table 1, primary, secondary, and exploratory outcomes will be assessed at baseline (week 1), after the completion of the 6-week CR program / usual care period (week 8) and again 6 months after the completion of the CR program / usual care period (week 34). During weeks 1 and 8, participants will carry out the assessments over two visits to ensure that participants are sufficiently recovered between walking tests. As the treadmill test is a secondary outcome measure, participants will be given the option to opt out of performing this test. The treadmill test requires participants to walk until maximal exertion. Although this is an important outcome measure, only 34 participants are required to establish an effect (refer to power and sample size estimate). Therefore, participants who are unwilling to exert themselves to maximal effort, or those who are unable to maintain the walking speed of the treadmill will be given the option to opt out of this test. At 6-month follow-up (week 34) participants will make a single visit for the assessment of the six-minute walking test, quality of life, self-reported functional capacity, physical activity levels, vascular function, and biomarkers of cardiovascular disease risk. The 6-month follow-up visit aims to provide an indication of longer-term durability of the effect of CR following revascularisation. For the post-intervention and follow-up assessments at weeks 8 and 34, the assessment window may be extended by up to 7 days to accommodate unforeseen circumstances (e.g., participant illness). 

- **Primary outcome**
- Six-minute walk test (6MWT):

The 6MWT will be conducted at weeks 1, 8, and 34. Change in maximum walking distance during the 6MWT between baseline and week 8 is the primary outcome for the study. Change in the pain-free walking distance during the 6MWT is a secondary outcome measure. 

As per standard procedures, a course of 30 meters length is marked out in a covered area at least 2 meters in width, with a cone at each end (66). Chairs are also placed every 10 meters along the course so that participants can sit and rest during the test if needed. Participants will be asked to walk up and down the course for 6 minutes and to complete as many laps and cover as much distance as possible in that time. Participants will be asked to indicate to the test supervisor when the onset of claudication occurs, and then to rate the severity of their claudication/discomfort using a hand-signal at the completion of each lap (i.e., every 60 meters) 

370 using the claudication rating scale (60). During the test, heart rate will be continually monitored 371 with a heart rate monitor and recorded at the end of each lap. During the test, participants can 372 stop walking and rest if their claudication pain becomes intolerable; however, the timing 373 continues and participants are requested to resume walking as soon as possible. At the end of 374 the test, the number and timing of any rest breaks, the time and distance to the onset of 375 claudication (pain-free walking distance) and the total distance walked (maximum walking 376 distance) are recorded.

Walking capacity measured during the 6MWT has been chosen as the primary outcome as it has excellent test-retest reliability (interclass correlation coefficient = 0.970, 95% confidence intervals 0.950 to 0.981, N=173) (67), and it correlates strongly with a range of relevant clinical outcomes including physical activity (68), patient-reported outcomes, as well as cardiovascular morbidity and mortality associated with PAD (7). Based on this strong reliability, a reported advantage of the 6MWT for clinical trials is that there is no learning effect (69). Nonetheless, participants will be familiarised with the 6MWT prior to the baseline assessment in the current study. This approach is consistent with recommended practice and reporting of performance outcomes for clinical trials in patients with PAD (70). The minimal clinically important difference (MCID) for 6MWT distance has been established for people with and without PAD. Based on the change in 6MWT distance with exercise therapy and the corresponding change in reported physical function, the MCID thresholds are 12 meters (small effect), 32 meters (moderate effect), and 34 meters (large effect) (71). 

33
 390 Secondary outcome measures

34 391 Graded treadmill walking test:

The graded treadmill walking test including measures of maximum walk time and pain-free walking time will be performed at weeks 1 and 8. The Gardner-Skinner protocol will be used, which was specifically developed for the assessment of walking capacity in patients with PAD (72,73). The treadmill will start at 3.2 km/h at a 0% incline, and then every 2 minutes the gradient of the treadmill will increase by 2%. The treadmill test will be conducted and supervised by an exercise physiologist, a cardiac technician, and a medical doctor. During the test participants will be monitored with a continuous 12-lead electrocardiogram, and heart rate and blood pressure will be measured and recorded at the end of each stage (i.e., every 2 minutes). At the end of the test, participants will be asked to rate the severity of their claudication pain in each leg using the claudication scale, and to provide a rating of their general exertion using the modified rate of perceived exertion Borg scale (59). The MCID values for small, moderate and large changes in maximum treadmill walking time after supervised exercise training are 121, 141, and 241 (seconds), respectively, in patients with PAD (71). 

<sup>55</sup><sub>56</sub> 406 Cardiorespiratory fitness:

407 Cardiorespiratory fitness (peak oxygen uptake) will be assessed during the graded treadmill
408 walking test at weeks 1 and 8. Cardiorespiratory fitness is a strong predictor of cardiovascular
409 disease and all-cause mortality rates in patients with PAD (74,75). Oxygen uptake (VO<sub>2</sub>) will

### **BMJ** Open

Page 12 of 28

be continuously measured with a portable VO<sub>2</sub> system (K5, COSMED, Italy), and a breath-by-breath gas exchange and ventilation face mask. Peak oxygen uptake will be determined as the highest 15-second average during the final 60 seconds of peak exercise. 

Quality of life: 

Disease-specific quality of life will be assessed using the Intermittent Claudication Questionnaire (ICQ) at weeks 1, 8 and 34. The ICQ is a self-administered tool consisting of 16 items that focus on limitations imposed by claudication while performing various tasks, such as walking specific distances or performing activities of daily living (76). The instrument is scored by summing the patient responses to individual items, which are all equally weighted, and transformed to a 0 to 100 composite score, where 0 is the best score. The composite score will be calculated and used as the outcome for analysis. 

Self-reported walking capacity: 

Self-reported walking capacity will be assessed using the Walking Impairment Questionnaire (WIQ) at weeks 1, 8 and 34. The WIQ is a PAD-specific measure of self-reported difficulty during walking with 3 domains: walking distance, walking speed, and stair climbing (77). Each domain is scored on a scale from 0 to 100 (100 indicating the best possible score). A small, moderate, and large MCID for each of the three WIQ domain scores are: 6, 14, 23 for walking distance; 4, 11, 18 for walking speed; and 6, 15, 23 for stair climbing, respectively (71). 

Physical activity levels: 

Objectively assessed physical activity: Free living physical activity levels will be objectively assessed using a GT9XActiGraph accelerometer (ActiGraph, Pensacola, FL, USA) at weeks 1, 8 and 34. Participants will be instructed to wear the device on their non-dominant wrist for 7 full days at each assessment point (78). At the end of the recording period, the accelerometer is removed by the participant and returned to the research team (in person or by reply-paid delivery) for data upload, quality assurance and analysis. The ActiGraph accelerometer will be initialised to collect raw data at 100 Hz (79). The in-built inclinometer will also enable the assessment of body position (i.e., sitting/lying vs standing). At each assessment period, a minimum wear-time criteria of 4 days and 600 minutes per day will be applied (80). The ActiLife software (version 6.13.5; AcriGraph LLC) will be utilised to process the raw data to create 60-second epochs (79). The data will be processed using the Choi algorithm within the ActiLife software to define wear and non-wear minutes (81). The primary outcome measure of physical activity will be steps per day. Other outcome measures will include sedentary time, and time spent (mins/day) engaging in light, moderate and vigorous physical activity. During the 7-day monitoring period, participants will also keep a brief daily physical activity diary to record periods of sleep, work, non-wear time, and structured exercise that are essential for analysis and cannot be inferred from the monitor data alone. The ActiGraph accelerometer has been reported to be reliable and valid in the assessment of walking, body posture, and sedentary behaviour during free-living activity (82-84), and when used in patients with PAD (85-87). The MCID values for small, moderate and large changes in total daily steps after supervised exercise training are 569, 1,423 and 2,277 (steps/day), respectively, in patients with PAD (88). 

Page 13 of 28

### BMJ Open

Self-reported physical activity: Self-reported physical activity levels will be assessed using the International Physical Activity Questionnaire for elderly (IPAQ-E) at weeks 1, 8 and 34. The IPAQ-E is a self-reported questionnaire which has been validated for use for individuals over the age of 65 (89). The IPAQ-E consists of questions about frequency (days per week) and time (minutes per day) spent sitting, walking, and performing physical activities of moderate and vigorous intensity. All self-reported activity domains (sitting, walking, moderate and vigorous physical activities) have been reported to positively correlate with corresponding variables objectively assessed by accelerometers (89). 

# 1516 458 Exploratory outcomes

Ankle to brachial blood pressure index (ABI):

The ABI of both legs will be measured at weeks 1, 8 and 34. After resting in a supine position for 10 minutes, brachial and ankle blood pressures will be measured. Brachial blood pressures will be measured in both arms using an automated blood pressure monitor (90). Systolic blood pressure of the dorsalis pedis artery and posterior tibial artery at the left and right ankles will also be measured using a manual cuff sphygmomanometer and handheld 5-7 MHz Doppler ultrasound probe. The average of the closest two recordings at each artery will be recorded. The ABI for each leg will be calculated by dividing the higher dorsalis pedis artery or posterior tibial artery value by the highest brachial artery value obtained from either side (55). 

31 468 Brachial artery flow-mediated dilation (FMD):32

Brachial artery FMD will be measured in response to a reactive hyperaemia test (cuff occlusion) at weeks 1, 8 and 34. Brachial artery FMD is an independent predictor of cardiovascular events in patients with PAD (91). As per standard procedures (92), brachial artery FMD will be measured with participants in the supine position after 10 minutes of rest. This measurement will involve a rapid inflation of a pressure cuff positioned at the forearm. A 10-MHz multi-frequency linear array probe, attached to a high-resolution ultrasound machine (Terason, Burlington, US) will be used to image the brachial artery (2 cm proximal to the elbow). The ultrasound settings will be optimised for each individual and will be kept constant between all assessments. Continuous Doppler velocity will also be obtained using the ultrasound at an insolation angle of 60°. Following baseline assessments, reactive hyperaemia will be induced by inflating the cuff to 200 mmHg for 5 minutes. Artery diameter and flow recordings will resume 30 seconds before cuff deflation and continue for 3 minutes thereafter (93). Brachial artery FMD will be expressed as a relative change (percent change) in peak arterial diameter from baseline (pre cuff inflation) to post cuff deflation. The analysis of the brachial artery FMD will be undertaken using a continuous edge-detection and wall-tracking software. 

55 485 Arterial stiffness:

Arterial stiffness outcomes incorporate measures of augmentation index (AIx) and carotid femoral artery pulse wave velocity (PWV) and will be assessed at weeks 1, 8 and 34. Arterial
 stiffness is an independent predictor of cardiovascular disease and all-cause mortality rates in

### BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

patients with PAD (94,95). After resting in the supine position for 10 minutes, brachial artery pulse waves will be obtained by partially inflating a cuff over the right brachial artery using a SphygmoCor XCEL system (AtCor Medical Pty Ltd, Sydney, Australia) and following standard guidelines (96,97). The brachial waveforms will be used to generate central aortic pressure waveforms, and to determine AIx, which is the ratio of wave reflection amplitude relative to central pulse pressure. For the PWV assessment, the carotid-femoral PWV will be measured using the applanation tonometry technique. A hand-held tonometer probe (AtCor Medical Pty Ltd, Sydney, Australia) will be held against the skin surface over the right carotid artery to obtain carotid-artery pulse waves, and a pressure cuff will be placed around the right upper thigh to record femoral artery pulse waves. The distance from the carotid site above the suprasternal notch to the proximal edge of a thigh cuff over the femoral artery will be measured using a tape measure over the body area. The carotid and femoral pulse waves will be recorded simultaneously, and the femoral pulse wave requires the thigh cuff to be partially inflated. The PWV will then be automatically calculated as the ratio of the distance between the pulse measuring sites to the time delay between the carotid and femoral pulse waves. PWV will be recorded as the average of triplicate measurements. 

<sup>26</sup><sub>27</sub> 505 Biomarkers of cardiovascular disease (CVD) risk:

Biomarkers of CVD risk will be assessed at weeks 1 and 34. The most recent blood test (within
 8 weeks of baseline and within 8 weeks of follow-up visit) will be retrieved from the medical
 records of each participant. Biomarkers of CVD risk will include total cholesterol,
 triglycerides, high-density lipoprotein, low-density lipoprotein, and haemoglobin A1c levels.

<sup>34</sup>/<sub>35</sub> 510 Sample size calculations

Sample size calculations were conducted for the primary outcome maximum walking distance during the six-minute walk test (6MWT) and the secondary outcome maximal walking time during the graded treadmill walking test.

41 514 6MWT:

Previous studies that assessed the effects of post-revascularisation exercise therapy indicated a potential effect of 53.2 m with a standard deviation of 81 m for 6MWT distance (52,98). This would provide a medium effect size of 0.65. To establish this effect from baseline to week 8 with 80% power and an alpha 0.05, 30 participants would be required in each group. Allowing for 10% dropout, 33 participants will be recruited in each group (total N=66). 

50 520 Graded treadmill walking test:

A previous study that assessed the effects of post-revascularisation exercise therapy indicated a potential effect of 5 minutes and 46 seconds with a standard deviation of 6 minutes and 13 seconds for maximal walking time during the graded treadmill walking test (35). This would provide a large effect size of 0.89. To establish this effect from baseline to week 8 with 80% power and an alpha 0.05, 17 participants would be required in each group (total N=34). As this outcome of maximal walking time during the treadmill test is a secondary outcome, participants will be given the option to opt out of performing this test during the trial. 

### 528 Statistical analysis

Data analysis will follow the CONSORT statement for randomised-controlled trials (65). All data collected will be deidentified and coded throughout the trial. The data collected will remain coded for participant confidentiality purposes. Baseline data for the two groups will be provided using counts and percentages, and means and standard deviations (or non-parametric equivalents) for categorical variables. Furthermore, tables will show the outcome measures at weeks 8 and 34 and percent changes from baseline. 

The primary analysis will be performed based on the intention-to-treat principle, where all participants will be analysed as per their allocation, regardless of the treatment they received. Non-adherence will be assessed through per-protocol analyses. Per protocol analysis will primarily include participants that attend at least 70% of the supervised CR exercise sessions (i.e., 9 exercise sessions overall) during the 6-week intervention period. The total number of supervised exercise sessions completed will be included in the analysis as a covariate. 

Statistical analyses will be conducted using the IBM SPSS software (SPSS Inc, Chicago, IL). The data will be tested for normality using the Shapiro-Wilk test and will be considered normally distributed when P > 0.05. Analyses will be conducted using analysis of variance (ANOVA) for repeated measures. The primary comparison will be change in maximum walking distance during the 6MWT from baseline to post intervention (week 8) in the CR versus the usual care group. Additional analyses will be performed from baseline to 6-month follow-up timepoint (week 34). As required, confounding variables (including comorbidities, age, sex, smoking behaviour, medications) will be adjusted for using analysis of covariance (ANCOVA). In all analyses, P < 0.05 will be considered statistically significant. Post-hoc analysis will be performed when a significant effect is present. 

# <sup>37</sup> 38 551 Data management

All data collected during the study will be coded and stored for a minimum of 15 years. Prospective participants will initially be assigned a screening number, and upon consent into the study they will be assigned a participant identification code. A coding log will be maintained and kept in a secure location (hard copy in locked cabinet and electronic copy on password protected file) in accordance with the International Council on Harmonisation Good Clinical Practice (GCP) guidelines, the study data management plan, and the data security policy of the University of the Sunshine Coast. The only personnel who will have access to participants' individual identity are the Principal Investigator (CDA) and authorised project staff. Access to the coding log would only occur in the case where further medical history information is required in relation to a specific participant, in cases of emergency (e.g., to identify and contact next of kin), or during the investigation of any events (e.g., serious adverse event). 

All individual participant information will be de-identified in the reporting of data and resulting
publications or presentations to fully protect the confidentiality of participants. Participants
will be informed in the PICF that information or reports from the study will be prepared and
will be submitted for publication. Participant information will normally be presented as group

data. If necessary, information obtained from specific individuals may be presented; however, names will not be used to identify the individuals. Participants will only be identified in such publications by an identification number and possibly their age and gender. 

#### **Adverse events**

Information on all adverse events will be recorded immediately in the trial adverse event report form and in the appropriate case report form for the relevant participant. All clearly related signs, symptoms, and abnormal procedural results will be recorded. For all recorded adverse events, the Principal Investigator or delegate will determine the adverse event's causality to the intervention and the severity or intensity of the event. The clinical course of each event will be followed until resolution, stabilisation, or until it has been determined that the study intervention or participation is not the cause. All logged events will be summarised and reported to the participant's general practitioner and the relevant human research ethics committees and governance agencies as part of the reporting requirements. 

#### PATIENT AND PUBLIC INVOLVEMENT

No patient and public involvement. 

#### **ETHICS AND DISSEMINATION**

This study has received ethics approval from the Human Research Ethics Committees (HREC) of Queensland Health Metro North Hospital and Health Service (94155), and the University of the Sunshine Coast (S231914). Any protocol amendments will be submitted to the aforementioned HREC for approval. Findings from this study will be disseminated in peer-reviewed journals and through national and international conference presentations. 

#### **AUTHORS' CONTRIBUTION**

KF and CDA were involved in conceptualising and developing the study protocol and gaining ethical approval. All authors critically reviewed the study protocol and provided input to all aspects of the design and plan. All authors reviewed and edited the manuscript and approved the final version. 

#### **FUNDING STATEMENT**

This work is supported by a Sunshine Coast Health Institute (SCHI) Collaborative Seed Grant Scheme (Grant ID number: 2020-01) awarded to CDA (Principal Investigator). KF is supported by a collaborative University of the Sunshine Coast and Sunshine Coast Hospital and Health Service scholarship as well as a PhD Top-Up Scholarship Award from the Queensland Cardiovascular Research Network (QCVRN). The aforementioned funders had no input in the

		BMJ Open
1 2		
3 4 5 6 7	604 605	design of the study and will have no role in the collection, management, analysis, and interpretation of the data or decision to submit this work for publication.
8	606	
9 10	607	COMPETING INTERESTS STATEMENT
11 12	608	The authors declare no competing interests.
13 14	609	
15 16	610	REFERENCES
17 18 19 20	611 612 613	1. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019 Aug;7(8):e1020–30.
21 22 23	614 615	2. Gardner AW, Montgomery PS, Scott KJ, Afaq A, Blevins SM. Patterns of ambulatory activity in subjects with and without intermittent claudication. J Vasc Surg. 2007 Dec;46(6):1208–14.
24 25 26 27 28 29 30 31 32	616 617 618	3. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002 Jun 18;136(12):873–83.
	619 620 621 622	4. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med Lond Engl. 2008 Feb;13(1):15–24.
33 34 35 36 37	623 624 625	5. Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis. 2020 Jan;293:94–100.
38 39 40 41	626 627 628	6. Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, et al. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust. 2012 Feb 20;196(3):193–7.
42 43 44 45	629 630 631	7. McDermott MM, Greenland P, Tian L, Kibbe MR, Green D, Zhao L, et al. Association of 6- Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. J Am Heart Assoc. 2015 Jul 28;4(7).
46 47 48 49	632 633 634	8. Gardner AW, Addison O, Katzel LI, Montgomery PS, Prior SJ, Serra MC, et al. Association between Physical Activity and Mortality in Patients with Claudication. Med Sci Sports Exerc. 2021 Apr 1;53(4):732–9.
50 51 52 53 54	635 636 637 638	9. Nordanstig J, Behrendt CA, Baumgartner I, Belch J, Bäck M, Fitridge R, et al. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2023 Nov 8;S1078-5884(23)00741-4.
55 56 57 58 59 60	639 640	10. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology. 1993 Jan;44(1):1–10.

Page 17 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

### BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular
revascularisation versus conservative management for intermittent claudication. Cochrane Database
Syst Rev. 2018 Mar 8;3(3):CD010512.

644 12. Je HG, Kim BH, Cho KI, Jang JS, Park YH, Spertus J. Correlation between Patient-Reported
645 Symptoms and Ankle-Brachial Index after Revascularization for Peripheral Arterial Disease. Int J
646 Mol Sci. 2015 May 18;16(5):11355–68.

647 13. Devine EB, Alfonso-Cristancho R, Yanez ND, Edwards TC, Patrick DL, Armstrong CAL, et
648 al. Effectiveness of a Medical vs Revascularization Intervention for Intermittent Leg Claudication
649 Based on Patient-Reported Outcomes. JAMA Surg. 2016 Oct 19;151(10):e162024.

650 14. Perkins JMT, Collin J, Creasy TS, Fletcher EWL, Morris PJ. Reprinted Article "Exercise
651 Training Versus Angioplasty for Stable Claudication. Long and Medium Term Results of a
652 Prospective, Randomised Trial". Eur J Vasc Endovasc Surg. 2011 Sep 1;42:S41–5.

653 15. van Hattum ES, Tangelder MJD, Lawson JA, Moll FL, Algra A. The quality of life in patients
654 after peripheral bypass surgery deteriorates at long-term follow-up. J Vasc Surg. 2011
655 Mar;53(3):643-50.

656 16. Wann-Hansson C, Hallberg IR, Risberg B, Lundell A, Klevsgard R. Health-related quality of
657 life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J Adv Nurs.
658 2005 Aug;51(3):227–35.

659 17. Djerf H, Millinger J, Falkenberg M, Jivegård L, Svensson M, Nordanstig J. Absence of Long 660 Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results
 661 From the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv. 2020 Jan;13(1):e008450.

662 18. Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, et al.
663 Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10–33.

Askew CD, Parmenter B, Leicht AS, Walker PJ, Golledge J. Exercise & Sports Science
 Australia (ESSA) position statement on exercise prescription for patients with peripheral arterial
 disease and intermittent claudication. J Sci Med Sport. 2014 Nov;17(6):623–9.

668 20. Tew GA, Harwood AE, Ingle L, Chetter I, Doherty PJ. The bases expert statement on
669 exercise training for people with intermittent claudication due to peripheral arterial disease. Sport Exerc Sci. 2018;

Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC 21. Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1:39(9):763-816. 

678 22. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial
679 disease: a systematic review and meta-analysis. Sports Med Auckl NZ. 2015 Feb;45(2):231–44.

57 680 23. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane
58 681 Database Syst Rev. 2017 Dec 26;12(12):CD000990.
59

### BMJ Open

BMJ Open

1 2 3		
4 5 6	682 683	24. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 Sep 27;274(12):975–80.
7 8 9 10	684 685 686	25. Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc. 2001 Jun;49(6):755–62.
11 12 13	687 688	26. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996 Jan;23(1):104–15.
14 15 16 17	689 690 691	27. Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med Lond Engl. 2015 Feb;20(1):30–40.
18 19 20 21	692 693 694	28. Lanzi S, Calanca L, Berchtold A, Mazzolai L. Improvement in 6-Minute Walking Distance after Supervised Exercise Training Is Related to Changes in Quality of Life in Patients with Lower Extremity Peripheral Artery Disease. J Clin Med. 2021 Jul 28;10(15).
22 23 24	695 696	29. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg. 2012 May;55(5):1346–54.
25 26 27 28	697 698 699	30. Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity progressive resistance training improves flat-ground walking in older adults with symptomatic peripheral arterial disease. J Am Geriatr Soc. 2013 Nov;61(11):1964–70.
29 30 31 32	700 701 702	31. Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med. 2002 Nov;252(5):448–55.
33 34 35 36	703 704 705	32. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA. 2009 Jan 14;301(2):165–74.
37 38 39 40	706 707 708	33. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial. JAMA. 2015 Nov 10;314(18):1936–44.
41 42 43 44	709 710 711	34. Badger SA, Soong CV, O'Donnell ME, Boreham CAG, McGuigan KE. Benefits of a supervised exercise program after lower limb bypass surgery. Vasc Endovascular Surg. 2007 Mar;41(1):27–32.
45 46 47 48	712 713 714	35. Kruidenier LM, Nicolaï SP, Rouwet EV, Peters RJ, Prins MH, Teijink JAW. Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a randomized clinical trial. J Vasc Interv Radiol JVIR. 2011 Jul;22(7):961–8.
49 50 51 52 53 54	715 716 717 718	36. Menêses AL, Ritti-Dias RM, Parmenter B, Golledge J, Askew CD. Combined Lower Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial Disease: A Systematic Review of Randomised Controlled Trials. Sports Med Auckl NZ. 2017 May;47(5):987– 1002.
55 56 57 58 59 60	719 720 721	37. Dua A, Gologorsky R, Savage D, Rens N, Gandhi N, Brooke B, et al. National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. J Vasc Surg. 2020 May;71(5):1702–7.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exercise 38. services in patients with peripheral artery disease in the United Kingdom. Vascular. 2022 Oct;30(5):874-81. 39. Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2012 Dec;44(6):569-75; discussion 576. 40. Supervia M, Turk-Adawi K, Lopez-Jimenez F, Pesah E, Ding R, Britto RR, et al. Nature of Cardiac Rehabilitation Around the Globe. EClinicalMedicine. 2019 Aug;13:46-56. Martin BJ, Arena R, Haykowsky M, Hauer T, Austford LD, Knudtson M, et al. 41. Cardiovascular fitness and mortality after contemporary cardiac rehabilitation. Mayo Clin Proc. 2013 May;88(5):455-63. Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-42. based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023 Feb 7;44(6):452-69. Tegegne TK, Rawstorn JC, Nourse RA, Kibret KT, Ahmed KY, Maddison R. Effects of 43. exercise-based cardiac rehabilitation delivery modes on exercise capacity and health-related quality of life in heart failure: a systematic review and network meta-analysis. Open Heart. 2022 Jun;9(1). Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise-44. based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. Eur J Heart Fail. 2018 Dec;20(12):1735-43. Ahden S, Ngo V, Hoskin J, Mach V, Magharious S, Tambar A, et al. Inclusion of People 45. With Peripheral Artery Disease in Cardiac Rehabilitation Programs: A Pan-Canadian Survey. Heart Lung Circ. 2021 Jul;30(7):1031-43. Siercke M, Jørgensen LP, Missel M, Thygesen LC, Møller SP, Sillesen H, et al. 46. Cardiovascular Rehabilitation Increases Walking Distance in Patients With Intermittent Claudication. Results of the CIPIC Rehab Study: A Randomised Controlled Trial. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2021 Nov;62(5):768-76. 47. Devrome AN, Aggarwal S, McMurtry MS, Southern D, Hauer T, Lamb B, et al. Cardiac rehabilitation in people with peripheral arterial disease: A higher risk population that benefits from completion. Int J Cardiol. 2019 Jun 15;285:108-14. 48. Ambrosetti M, Temporelli PL, Faggiano P, Febo O, Diaco T, Favretto G, et al. Lower extremities peripheral arterial disease among patients admitted to cardiac rehabilitation: the THINKPAD registry. Int J Cardiol. 2014 Feb 1;171(2):192-8. 49. Jeger RV, Rickenbacher P, Pfisterer ME, Hoffmann A. Outpatient rehabilitation in patients with coronary artery and peripheral arterial occlusive disease. Arch Phys Med Rehabil. 2008 Apr;89(4):618–21. Tam MC, Longenecker CT, Chow C, Vest M, Sukeena R, Madan Mohan SK, et al. Occult 50. peripheral artery disease is common and limits the benefit achieved in cardiac rehabilitation. Vasc Med Lond Engl. 2016 Apr;21(2):130-6. 

### BMJ Open

BMJ Open

Anghel R, Adam CA, Mitu O, Marcu DTM, Onofrei V, Roca M, et al. Cardiac Rehabilitation 51. and Mortality Risk Reduction in Peripheral Artery Disease at 6-Month Outcome. Diagn Basel Switz. 2022 Jun 20;12(6). 52. Sami F, Ranka S, Lippmann M, Weiford B, Hance K, Whitman B, et al. Cardiac rehabilitation in patients with peripheral arterial disease after revascularization. Vascular. 2021 Jun;29(3):350-4. 53. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. 54. Verdicchio C, Freene N, Hollings M, Maiorana A, Briffa T, Gallagher R, et al. A Clinical Guide for Assessment and Prescription of Exercise and Physical Activity in Cardiac Rehabilitation. A CSANZ Position Statement. Heart Lung Circ. 2023 Sep;32(9):1035-48. 55. Sanderson B, Askew C, Stewart I, Walker P, Gibbs H, Green S. Short-term effects of cycle and treadmill training on exercise tolerance in peripheral arterial disease. J Vasc Surg. 2006 Jul;44(1):119–27. 56. Wood RE, Sanderson BE, Askew CD, Walker PJ, Green S, Stewart IB. Effect of training on the response of plasma vascular endothelial growth factor to exercise in patients with peripheral arterial disease. Clin Sci Lond Engl 1979. 2006 Dec;111(6):401-9. 57. Tew GA, Humphreys L, Crank H, Hewitt C, Nawaz S, Al-Jundi W, et al. The development and pilot randomised controlled trial of a group education programme for promoting walking in people with intermittent claudication. Vasc Med Lond Engl. 2015 Aug;20(4):348-57. Astley CM, Beleigoli A, Tavella R, Hendriks J, Gallagher C, Tirimacco R, et al. Assessing 58. the quality of cardiac rehabilitation programs by measuring adherence to the Australian quality indicators. BMC Health Serv Res. 2022 Feb 28;22(1):267. 59. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81. Martinez CA, Carmeli E, Barak S, Stopka CB. Changes in pain-free walking based on time in 60. accommodating pain-free exercise therapy for peripheral arterial disease. J Vasc Nurs Off Publ Soc Peripher Vasc Nurs. 2009 Mar;27(1):2-7. Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise 61. intensity terminology. J Sci Med Sport. 2010 Sep;13(5):496-502. 62. Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Med J Aust. 2016 Aug 1;205(3):128-33. 63. Australian Government Department of Health and Aged Care. Physical activity and exercise guidelines for all Australians [Internet]. Australian Government; 2021. Available from: https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians#order-the-guidelines 64. Australian Government Department of Health and Aged Care. The Australian Dietary Guidelines [Internet]. 2019. Available from: https://www.health.gov.au/resources/publications/the-australian-dietary-guidelines 

### BMJ Open

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for 65. reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726–32. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 66. 1;166(1):111-7. 67. Golledge J, Yip L, Fernando ME, Pinchbeck J, Rowbotham S, Jenkins J, et al. Relationship between requirement to stop during a six-minute walk test and health-related quality of life, physical activity and physical performance amongst people with intermittent claudication. Ann Vasc Surg. 2021 Oct;76:363-9. McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al. Prognostic value of 68. functional performance for mortality in patients with peripheral artery disease. J Am Coll Cardiol. 2008 Apr 15;51(15):1482-9. 69. McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg. 2008 Nov;48(5):1231-7, 1237.e1. Birkett ST, Harwood AE, Caldow E, Ibeggazene S, Ingle L, Pymer S. A systematic review of 70. exercise testing in patients with intermittent claudication: A focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions. PloS One. 2021;16(5):e0249277. 71. Gardner AW, Montgomery PS, Wang M. Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med Lond Engl. 2018 Aug;23(4):349-57. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests 72. for evaluation of claudication. Med Sci Sports Exerc. 1991 Apr;23(4):402-8. 73. Gardner AW, Skinner JS, Vaughan NR, Bryant CX, Smith LK. Comparison of three progressive exercise protocols in peripheral vascular occlusive disease. Angiology, 1992 Aug;43(8):661–71. Leeper NJ, Myers J, Zhou M, Nead KT, Syed A, Kojima Y, et al. Exercise capacity is the 74. strongest predictor of mortality in patients with peripheral arterial disease. J Vasc Surg. 2013 Mar;57(3):728-33. 75. Harber MP, Kaminsky LA, Arena R, Blair SN, Franklin BA, Myers J, et al. Impact of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since 2009. Prog Cardiovasc Dis. 2017 Jul;60(1):11-20. Chong PFS, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The intermittent 76. claudication questionnaire: a patient-assessed condition-specific health outcome measure. J Vasc Surg. 2002 Oct;36(4):764-71; discussion 863-864. 77. Regensteiner J, Steiner J, Panzer R, Hiatt W. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142-152. 78. Hildebrand M, VAN Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc. 2014 Sep;46(9):1816-24. 

### BMJ Open

BMJ Open

Migueles JH, Cadenas-Sanchez C, Ekelund U, Delisle Nyström C, Mora-Gonzalez J, Löf M, 79. et al. Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med Auckl NZ. 2017 Sep;47(9):1821–45. 80. Airlie J, Forster A, Birch KM. An investigation into the optimal wear time criteria necessary to reliably estimate physical activity and sedentary behaviour from ActiGraph wGT3X+ accelerometer data in older care home residents. BMC Geriatr. 2022 Feb 17;22(1):136. Choi L, Ward SC, Schnelle JF, Buchowski MS. Assessment of wear/nonwear time 81. classification algorithms for triaxial accelerometer. Med Sci Sports Exerc. 2012 Oct;44(10):2009–16. 82. Evenson KR, Buchner DM, Morland KB. Objective measurement of physical activity and sedentary behavior among US adults aged 60 years or older. Prev Chronic Dis. 2012;9:E26. 83. Kelly LA, McMillan DG, Anderson A, Fippinger M, Fillerup G, Rider J. Validity of actigraphs uniaxial and triaxial accelerometers for assessment of physical activity in adults in laboratory conditions. BMC Med Phys. 2013 Nov 26;13(1):5. Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, et al. Amount of 84. time spent in sedentary behaviors in the United States, 2003-2004. Am J Epidemiol. 2008 Apr 1;167(7):875-81. 85. McDermott MM, Spring B, Berger JS, Treat-Jacobson D, Conte MS, Creager MA, et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA. 2018 Apr 24;319(16):1665-76. Hernandez H, Myers SA, Schieber M, Ha DM, Baker S, Koutakis P, et al. Quantification of 86. Daily Physical Activity and Sedentary Behavior of Claudicating Patients. Ann Vasc Surg. 2019 Feb;55:112-21. 87. Gerage AM, Correia M de A, Oliveira PML de, Palmeira AC, Domingues WJR, Zeratti AE, et al. Physical Activity Levels in Peripheral Artery Disease Patients. Arg Bras Cardiol. 2019;113(3):410-6. Gardner AW, Montgomery PS, Wang M, Shen B. Minimal clinically important differences in 88. daily physical activity outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med Lond Engl. 2022 Apr;27(2):142-9. Hurtig-Wennlöf A, Hagströmer M, Olsson LA. The International Physical Activity 89. Questionnaire modified for the elderly: aspects of validity and feasibility. Public Health Nutr. 2010 Nov;13(11):1847-54. 90. Gardner AW, Montgomery PS. Comparison of three blood pressure methods used for determining ankle/brachial index in patients with intermittent claudication. Angiology. 1998 Sep;49(9):723-8. 91. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003 Oct 28;108(17):2093-8. 92. Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534-47. 

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Page 24

Bailey TG, Birk GK, Cable NT, Atkinson G, Green DJ, Jones H, et al. Remote ischemic 93. preconditioning prevents reduction in brachial artery flow-mediated dilation after strenuous exercise. Am J Physiol Heart Circ Physiol. 2012 Sep 1;303(5):H533-538. 

94. Kals J, Lieberg J, Kampus P, Zagura M, Eha J, Zilmer M. Prognostic impact of arterial stiffness in patients with symptomatic peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2014 Sep;48(3):308-15. 


95. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010 Feb 2;121(4):505-11. 

96. Hwang MH, Yoo JK, Kim HK, Hwang CL, Mackay K, Hemstreet O, et al. Validity and reliability of aortic pulse wave velocity and augmentation index determined by the new cuff-based SphygmoCor Xcel. J Hum Hypertens. 2014 Aug;28(8):475-81.

97. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertens Dallas Tex 1979. 2015 Sep;66(3):698–722.

Sandberg A, Cider Å, Jivegård L, Nordanstig J, Wittboldt S, Bäck M. Test-retest reliability, 98. agreement, and minimal detectable change in the 6-minute walk test in patients with intermittent claudication. J Vasc Surg. 2020 Jan;71(1):197-203.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




 pressure index; FMD, flow-mediated dilation; AIx, augmentation index; PWV, pulse wave velocity; WIQ, walking impairment questionnaire; ICO, intermittent claudication questionnaire; CVD, cardiovascular disease; VO<sub>2neak</sub>, peak oxygen uptake. NB: Prior to randomisation participane will be stratified to account for type of procedure (e.g., open surgical vs endovascular procedure) and time since procedure (< 12 weeks vs > 12 weeks). Deing weeks 1 and 8 participants will carry out the assessments over two visits. The treadmill walking test and the cardiorespiratory fitness test will be conduced under medical supervision at the Clinical Investigations Unit of the Sunshine Coast University Hospital, and participants will be monitored with a continuous 12-lead electrocardiogram. \*As the treadmill walking test and the cardiorespiratory fitness test are secondary outcomes participants will be give the option to opt out of performing those assessments. The remaining outcome measures will be conducted at the VasoActive laboratory at the University of the Sunshine Coast. At week 34 participants will make a single visit to the VasoActive laboratory. Participants will not undergo the treadmill test or the ardiorespiratory fitness test at week 34. hique

34 TABLES					njopen-2024-089203 on 5 De 1 by convright, including for			
35 <b>Table 1.</b> Schedu MILESTONES	ale of participant enrolment, intervention, and assessmen	it Screen	Baseline (Pr	1	Decen E	Post-int	tervention	Follow-up
WEEK		0		1	er 20 rela	i ost int	8	34
VISIT (timepoint)		1	2	3	2024 nem	4	5	6
RECRUITEMENT	Patient identification	X			ti ownic it Sup			
	Pre-screen checklist for eligibility	X			a o v			
ENROLEMENT & SCREENING	Consent	X			aded rieur nd da			
Serentiatio	Confirm eligibility	X			₫₽₽			
	Demographics and health history	X			om h BES			<u> </u>
	Familiarisation with six-minute walk test	Х		-				ļ
RANDOMISATION	Stratification & randomisation			X				
INTERVENTION	Usual care plus community-based CR program (weeks 2 to 7)			•		-•		
CONTROL	Usual care (weeks 2 to 7)			•				
PRIMARY OUTCOME	Six-minute walk test		X		<mark>n.b</mark> na.	Х		X
SECONDARY	Treadmill walking test & cardiorespiratory fitness test with ECG*		1		mj.		X	
OUTCOMES	Quality of life (WIQ, ICQ)		X			Х		X
	Physical activity levels (7-day accelerometer, physical activity survey)		X		<del>om/ on June</del> similar tech	Х		X
EXPLORATORY	Ankle-to-brachial systolic blood pressure index		X		art J	Х		X
OUTCOMES	Brachial artery flow-mediated dilation assessment		X		ech une	Х		X
	Arterial stiffness assessments (AIx, carotid-femoral artery PWV)		X		nol 13	Х		X
	Markers of CVD (total cholesterol, LDL, HDL triglycerides, HbA1c)		X		<u>13, 20</u> 25 nologies			X
37 community-based ca	ts will continue to receive usual care and medical advice from their generation or usual care group (constrained or the since procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure) and time since procedure (< 12 were a surgical vs endovascular procedure (< 12 were a sur	ontrol) for 6-wee	ks. Prior to rar	and vascular adomisation	surgeo parte	ants will b	e stratified to a	ccount for type of

unforeseen circumstances (e.g., participant illness). CR, cardiovascular rehabilitation; ECG, electrocardiogram; WIQ, walking impairment questionnaire; ICQ, intermittent claudication questionnaire; AIx, augmentation index; PWV, pulse wave velocity; CVD, cardiovascular disease; LDL, low-density lipoprotein; HDL, high-den ty lipoprotein; HbA1c, haemoglobin A1c. 

#### Table 2. Cardiovascular rehabilitation exercise program

	,	Treadmill walking		Lower li	imb resist	ance exercises		C Lappe	er body con	tinuous mo	vements / activit	ies
Week	Walking bouts	Bout duration	Total time	Exercise	Sets	Repetitions	Total time	<u>ک</u> کے ک		Sets	Duration	Total tim
1				1) Sit-to-stand	2	12		1) Upright rowing odur	mbbells)	4	1 minute	
	5	2 minutes	10 minutes	2) Seated leg extensions	2	12	10 minutes	2) Arm cycling n 2 3) Ski ergomor 24		3	1 minute	20 minute
				3) Standing calf raises	1	12		3) Ski ergom		3	1 minute	
				1) Sit-to-stand	2	12		1) Upright rog ig Gur	mbbells)	3	1 minute	
2	7	2 minutes	14 minutes	2) Seated leg extensions	2	12	12 minutes	2) Arm cycli		2	1 minute	14 minute
				3) Standing calf raises	2	12		3) Ski ergometrik 2		2	1 minute	
				1) Sit-to-stand	2	12		1) Upright rowing dur	mbbells)	2	1 minute	
3	10	2 minutes	20 minutes	2) Seated leg extensions	2	12	10 minutes	2) Arm cycling 4		2	1 minute	10 minute
				3) Standing calf raises	1	12	1	3) Ski ergometre 🗧		1	1 minute	
	10			1) Sit-to-stand	2	12	0	1) Upright rozing thur	mbbells)	2	1 minute	0
4	12	2 minutes	24 minutes	2) Standing calf raises	2	12	8 minutes	2) Arm cycling		2	1 minute	8 minutes
-	14		20	1) Sit-to-stand	2	12		1) Upright rowing dur	mbbells)	2	1 minute	
5	14	2 minutes	28 minutes	2) Standing calf raises	1	12	6 minutes	2) Arm cycli		1	1 minute	6 minutes
6	15	2 minutes	30 minutes	1) Sit-to-stand	1	12	4 minutes	1) Upright rowing dur	mbbells)	2	1 minute	6 minutes
			2) Standing calf raises 1 12			2) Arm cycling		1	1 minute	0 minutes		
		gression criteria		Intensi Increase repetitions and/or		ssion criteria		ng, ar	Program	n progressi	on criteria	
<ul> <li>Adjust speed and/or gradient of treadmill to increase the power output by 10 watts for the next walking bout if: <ul> <li>Participant completes walking bout without reaching nearmaximal claudication pain (number 3-4 on claudication pain scale) or rate of perceived exertion on Borg scale is less than 3 (out of 10) by the end of the walking bout.</li> </ul> </li> <li>Adjust speed and/or gradient of treadmill to decrease the power output by 10 watts for the next walking bout if: <ul> <li>Participant fails to complete walking bout</li> <li>Heart rate exceeds 90% of predicted maximum heart rate for 30 seconds</li> <li>Rate of perceived exertion is 8 or higher (out of 10)</li> </ul> </li> <li>Note: If the participant fails to complete a walking bout, provide up to 30 seconds of rest or rest up to the end of the bout and then resume exercise</li> </ul>			optimal exercise Exercise does r claudication pa 3 (out of 10) by Decrease repetitions and/o Participant is u exercise technic	the technique not induce in or rate of the end of the end of the end the end of the end of the end of the end the end of the end of the end of the end of the end the end of the end of t	moderate to near of perceived exer f the set	r-maximal tion is less than rith optimal	- in@reas	lower limb s the exercis admill walk the exercise	e program, i ing time program, re	s is to provide a b cercises. reduce upper body	<i>i</i> activity time a	



 Page 28 of 28

**Figure 1. Overview of the Saving Legs and Lives study.** CR, cardiovascular rehabilitation; 6MWT, six-minute walkiest; ABI, ankle-brachial blood pressure index; FMD, flow-mediated dilation; AIx, augmentation index; PWV, pulse wave velocity; WIQ, walking impairment questionnaire; ICQ, intermittent claudication questionnaire; CVD, cardiovascular disease;  $VO_{2peak}$ , peak oxygen uptake. NB: Prior to randomisation participants will be stratified to account for type of procedure (e.g., open surgical vs endovascular procedure) and time since procedure (< 1 weeks vs > 12 weeks). During weeks 1 and 8 participants will carry out the assessments over two visits. The treadmill walking test and the cardiorespiratory fitness test will be conducted under medical supervision at the Clinical Investigations Unit of the Sunshine Coast University Hospital, and participants will be monitored with a continuous 12-lead electrocardiogram. \*As the treadmill walking test and the cardiorespiratory fitness test are secondare outcomes participants will be given the option to opt out of performing those assessments. The remaining outcome measures will be conducted at the VasoActive laboratory at the University of the Sunshine Coast. At week 34 participants will make a single visit to the VasoActive laboratory. Participants will not undergo the treadmill test or the cardiorespiratory fitness test at week 34.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Saving Legs & Lives: The efficacy of a community-based cardiovascular rehabilitation program versus usual care on exercise capacity and quality of life in patients who have undergone lower limb revascularisation for peripheral arterial disease: Protocol for a randomised-controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-089203.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Sep-2024
Complete List of Authors:	Feka, Krist; University of the Sunshine Coast, School of Health; Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service Jha, Pankaj; Sunshine Coast University Hospital, Vascular Surgery Aust, Michelle; Sunshine Coast University Hospital, Cardiology Scott, Joseph; University of the Sunshine Coast, School of Education and Tertiary Access Schaumberg, Mia; University of the Sunshine Coast, School of Health Stanton, Tony; Sunshine Coast University Hospital, Cardiology Askew, Christopher; University of the Sunshine Coast, School of Health; Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service Trial Group, Saving Legs & Lives Trial Group; University of the Sunshine Coast, School of Health
<b>Primary Subject Heading</b> :	Sports and exercise medicine
Secondary Subject Heading:	Cardiovascular medicine, Rehabilitation medicine, Surgery
Keywords:	VASCULAR SURGERY, Exercise Test, Quality of Life, Cardiovascular Disease, Exercise

### SCHOLARONE<sup>™</sup> Manuscripts

### BMJ Open

BMJ Open

## 1 Title:

Saving Legs & Lives: The efficacy of a community-based cardiovascular rehabilitation
program versus usual care on exercise capacity and quality of life in patients who have
undergone lower limb revascularisation for peripheral arterial disease: Protocol for a
randomised-controlled trial

### 7 Authors:

Krist Feka<sup>1,2</sup>, Pankaj Jha<sup>3</sup>, Michelle Aust<sup>4</sup>, Joseph J. Scott<sup>5</sup>, Mia Schaumberg<sup>1,2</sup>, Tony
Stanton<sup>4</sup>, Christopher D. Askew<sup>1,2</sup> on behalf of the Saving Legs & Lives Trial Group

### 11 Saving Legs & Lives Trial Group

12 Kim Greaves, Norman Morris, Fraser D. Russell, Meegan A. Walker, Mathew J. Summers,

13 Jill O'Donnell, Karl Schulze, Rebecca J. Magee, Daniel McGlade, Vivienne Moult, Amanda

14 Shepherd, Michael D. Shanahan, Tuppence Richman, Caitlin Coppock, Helen J. Rodgers,

15 Ashley R. Samarasinghe, Damien P. Kerley, Lisa M. Polowyi

### 17 Affiliations:

18 <sup>1</sup>VasoActive Research Group, School of Health, University of the Sunshine Coast, Australia

- <sup>35</sup> 19 <sup>2</sup>Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service, Australia
  - <sup>20</sup> <sup>3</sup>Department of Vascular Surgery, Sunshine Coast University Hospital, Australia
  - <sup>4</sup>Department of Cardiology, Sunshine Coast University Hospital, Australia
  - <sup>5</sup>School of Education and Tertiary Access, University of the Sunshine Coast, Australia

### 24 Corresponding Author:

4748 25 Professor Christopher D. Askew

- 26 VasoActive Research Group, School of Health, University of the Sunshine Coast
  - 27 90 Sippy Downs Dr, Sippy Downs, Sunshine Coast, QLD 4556, Australia
- <sup>53</sup><sub>54</sub> 28 Tel: +61 7 5456 5961 / 0412 332 987
- 56 29 Email: caskew@usc.edu.au
- <sup>59</sup> 31

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

### 

### 32 ABSTRACT:

**Introduction:** Peripheral artery disease (PAD) is an atherosclerotic condition characterised by stenosis or occlusion of the arteries in the lower limbs. Patients with PAD commonly report intermittent claudication (leg pain/discomfort) during physical activities, which significantly limits the ability to walk and perform activities of daily living. Supervised exercise training is an effective therapy that can improve walking capacity in people with PAD. Emerging evidence also suggests that supervised exercise therapy following lower limb revascularisation can further enhance walking capacity when compared with revascularisation alone. However, access to dedicated exercise programs for patients with PAD is limited in most countries, and there is a need to test the efficacy of alternative rehabilitation strategies and referral pathways. This randomised-controlled study aims to assess the efficacy of a cardiovascular rehabilitation program versus usual care on walking capacity and quality of life in patients who have undergone lower limb revascularisation for PAD. 

Methods and analysis: This will be a single-centre, prospective, parallel group, randomised-controlled trial. Sixty-six participants who have undergone a lower limb revascularisation procedure for PAD, in the previous 12 months will be randomly allocated to a cardiovascular rehabilitation program or a usual care (control) group. The cardiovascular rehabilitation program will include two supervised exercise sessions per week for 6 weeks primarily consisting of intermittent treadmill walking at a moderate exercise intensity, and home-based walking advice. During the 6-week program, participants will also attend one education seminar (5.5 hours) which will cover topics such as diet, medications, exercise training, and lifestyle modifications for the management of cardiovascular diseases. The control group will receive usual care and medical advice from their local doctor and vascular surgeon. The primary outcome will be 6-minute walk distance. Secondary outcomes include pain-free walking distance during the 6-minute walk test, maximal and pain-free walking time during a graded treadmill walking test, cardiorespiratory fitness, self-reported walking capacity, disease-specific quality of life, and self-reported and objectively measured physical activity levels. Exploratory outcomes include brachial artery flow-mediated dilation, arterial stiffness, ankle-brachial blood pressure index, and biomarkers of cardiovascular disease risk. Outcomes will be assessed at baseline (week 1), following the cardiovascular rehabilitation / usual care period (week 8), and again at 6-month follow-up (week 34). 

Ethics and dissemination: This study has received ethics approval from the Human Research
Ethics Committees (HREC) of Queensland Health Metro North Hospital and Health Service
(94155), and the University of the Sunshine Coast (S231914). Findings from this study will be
disseminated in peer-reviewed journals and through national and international conference
presentations.

- 68 Trial registration number: ACTRN12623000190606

1		
2 3		
4		
5	71	STRENGTHS AND LIMITATIONS OF THIS STUDY:
6 7	72	• A world-first randomised-controlled trial investigating the efficacy of cardiovascular
7 8	73	rehabilitation (CR) compared to usual care on 6-minute walk distance in people who
9	74	have undergone lower limb revascularisation for peripheral arterial disease (PAD).
10		
11	75	• This study will test the implementation of current PAD exercise guidelines into a real-
12 13	76	world community-based CR setting.
13 14	77	• The primary outcome of this study, 6-minute walk distance, is an important clinical
15	78	endpoint which correlates with mortality and morbidity rates in people with PAD.
16	79	• This study includes a large number of outcome measures aiming to assess the efficacy
17	80	of CR on walking capacity, cardiorespiratory fitness, disease-specific quality of life,
18 19	81	accelerometer-derived physical activity, and cardiovascular function.
20	82	• The same investigators who will deliver the CR program will also be involved in the
21	83	collection of outcome data. While it is not feasible to blind participants and
22		
23	84	investigators to group allocation in an exercise intervention study, all data analysis will
24 25	85	be undertaken in blinded fashion using coded data.
26	86	
27	87	
28	88	
29	00	
30 31	89	
32	00	
33	90	
34	91	
35 36		
37	92	
38	93	
39		
40	94	
41 42	95	
42 43	55	
44	96	
45	07	
46	97	
47 48	98	
49		
50	99	
51	100	
52 53		
55 54	101	
55	102	
56	102	
57	103	
58 59	104	
60	104	

### **INTRODUCTION:**

Peripheral artery disease (PAD) is an atherosclerotic condition characterised by stenosis or occlusion of the arteries of the lower limbs. Worldwide, PAD affects over 230 million adults and its prevalence is expected to further increase over the coming years due to the ageing of the population (1). People with PAD are limited by intermittent claudication (leg pain/discomfort) which significantly impairs walking capacity, physical activity levels and quality of life (2–4). Reduced walking capacity and physical inactivity further contribute to the elevated risk of secondary cardiovascular events (stroke, myocardial infarction, cardiovascular death) and associated hospitalisation (5-8).

The initial treatment for PAD includes medical management of symptoms and cardiovascular disease risk factors with pharmacotherapies and lifestyle modification (9). In patients with advanced PAD, including limiting claudication or chronic limb-threatening ischemia, lower limb revascularisation procedures are indicated to restore blood flow and 'save' the affected limb (9). Lower limb revascularisation procedures are associated with improvements in limb blood flow (10), walking capacity (11), and quality of life (12,13). However, despite improvements in limb blood flow, the improvements in walking capacity are generally only modest after lower limb revascularisation (~60% improvement) when compared with exercise therapy (~110%) (14). Furthermore, the benefits of revascularisation for walking capacity and quality of life are short-lived, with prospective studies reporting deteriorations in walking capacity as early as 12 months after revascularisation (15–17). Reintervention rates are also high in people with PAD with a meta-analysis of 52 studies (N=6,769 patients) reporting a reintervention rate of 18.2% (95%CI 14.5 – 22.6) at 12 months following endovascular revascularisation (18). This highlights an important limitation of lower limb revascularisation procedures for the long-term durability, and improvement of walking capacity in patients with PAD. 

Supervised exercise is an effective therapy that is widely recommended in several international guidelines for the management of patients with PAD (9,19-22). A large body of evidence suggests that supervised exercise programs, incorporating aerobic and resistance exercises of the lower limbs, improve walking capacity (23–25), physical activity levels (26,27) and quality of life (28,29) in patients with PAD. A commonly used assessment of walking capacity for patients with PAD is the 6-minute walk test; and evidence shows gains in 6-minute walk distance ranging between 45-80 meters following supervised exercise programs (26,30-34). Beyond the recommendation that supervised exercise should be included as part of the initial treatment of PAD, there is emerging evidence that outcomes following lower limb revascularisation can also be enhanced when combined with exercise therapy (35-37). This aligns with a recent systematic review that reported significant improvements in maximum walking distance (mean difference range: 82-321 m) and pain-free walking distance (mean difference range: 38-408 m) favouring a combined therapy approach over supervised exercise training or revascularisation alone (38). Post-revascularisation exercise therapy has also been associated with reduction in the need for reintervention when compared with revascularisation (39) or supervised exercise therapy alone (odds ratio 0.19 [95% CI 0.09 - 0.40] P < 0.0001) (40). 

### BMJ Open

Despite this strong evidence supporting the benefits of supervised exercise therapy, access to dedicated exercise programs is very limited for patients with PAD. Previous studies report that as few as 43-48% of vascular units in the United States and the United Kingdom have access to dedicated supervised exercise programs for the referral of patients with PAD (41,42). Similarly, a survey of 378 vascular surgeons across 43 European countries reported that only 30% (N=115/378) of surgeons have access to supervised exercise programs for the referral of patients with PAD (43). This highlights a need for alternative rehabilitation strategies and referral pathways to increase the access to supervised exercise therapy for patients with PAD. 

Cardiovascular rehabilitation is a well-established multidisciplinary approach for the care and rehabilitation of patients with heart disease, particularly those recovering from myocardial infarction or cardiac surgery (44). Cardiovascular rehabilitation (CR) programs typically consist of supervised exercise training, dietary and lifestyle advice, psychological support, and education on the management of cardiovascular disease risk factors. Studies report that CR programs are cost-effective for improving functional capacity, physical activity levels and quality of life, and reducing the risk of secondary cardiovascular events in patients with cardiac diseases (45–48). While CR programs are widely accessible in most countries, patients with PAD are historically seen as out of scope and are not usually referred for CR (44,49). To date very few studies have investigated the effectiveness of routine CR for patients with PAD (50-55). Most of these studies have been limited to the investigation of patients with coronary artery disease referred for CR who also had PAD as a comorbidity (51-54). In Canada, of 23,215 patient referrals with coronary artery disease, 5.9% (N=1,366 patients) were identified as having a comorbidity of PAD (51). The identified patients with PAD had significantly impaired cardiorespiratory fitness and a lower 10-year survival rate when compared with patients without PAD. Importantly, this study demonstrated that completion of CR led to significant reductions in mortality rate (adjusted hazard ratio 0.62 [95%CI 0.57 - 0.67]) in patients with PAD, when compared with patients who did not attend CR (51). 

Recently, a small (N=20 participants), non-randomised pilot study of CR in patients who had undergone lower limb revascularisation for PAD, reported that CR was safe and feasible, and led to greater improvements in 6-minute walk distance (mean difference: 53 m; P=0.04) when compared with usual care (56). These findings highlight the potential for CR to be used as a standard referral pathway for patients with PAD who are recovering from a lower limb revascularisation procedure. To test this, we will conduct a randomised-controlled trial to assess the efficacy of a 6-week community-based CR program versus usual care on walking capacity and quality of life in patients who have recently (< 12 months) undergone lower limb revascularisation for PAD. 

53 181 **Primary aim** 

To assess the efficacy of a 6-week community-based CR exercise program versus usual care
 on 6-minute walk distance in patients who have recently (< 12 months) undergone lower limb</li>
 revascularisation for PAD.

5960185Secondary aims

To assess the efficacy of a 6-week community-based CR exercise program on: 1) pain-free walking distance during the 6-minute walk test, 2) maximal walking time and pain-free walking time during a graded treadmill walking test, 3) cardiorespiratory fitness measured as peak oxygen uptake during a graded treadmill walking test, 4) disease-specific quality of life and self-reported functional capacity, and 5) self-reported and objectively measured physical activity levels. 

### **Exploratory** aims

To assess the efficacy of a 6-week community-based CR exercise program on: 1) brachial artery flow-mediated dilation, 2) arterial stiffness (augmentation index, carotid-femoral artery pulse wave velocity), 3) ankle-brachial blood pressure index, and 4) circulating biomarkers of cardiovascular disease risk. 

### 

### **METHODS AND ANALYSIS**

Study design and overview 

An overview of the study is shown in Figure 1. This is a single centre, prospective, parallel-group, randomised-controlled trial conducted at the University of the Sunshine Coast and the Sunshine Coast University Hospital (Australia). Patients with PAD who have recently ( < 12 months) undergone a lower limb revascularisation procedure will be identified and randomly allocated to either usual care or usual care plus a 6-week community-based CR program (N=33 per group; refer to power and sample size estimate). Participants allocated to the usual care group will receive usual care and medical advice from their local doctor and vascular surgeon. The community-based CR program will comprise two supervised exercise sessions per week for 6 weeks, home-based exercise advice, and an education seminar (5.5 hours). The CR program will be delivered by the Cardiovascular Rehabilitation Service of the Sunshine Coast University Hospital. Primary, secondary, and exploratory outcomes will be assessed at baseline (week 1), after the completion of the CR program / usual care period (week 8) and again 6 months after the completion of the CR program / usual care period (week 34). Maximal exercise assessments such as graded treadmill walking tests will be conducted at the Clinical Investigations Unit at the Sunshine Coast University Hospital to facilitate access to medical supervision. Other outcome measures will be conducted at the VasoActive Laboratory at the University of the Sunshine Coast. As per Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), a schedule of participant enrolment, intervention and assessments is presented in Table 1 (57). The study commenced in April 2024, and data collection is planned to be completed in January 2026. 

1 2 3		
3 4 5	223	Participants & eligibility criteria
6	224	Potential participants will be identified from the Sunshine Coast region through: 1) an existing
7 8	225	database of participants who have previously provided consent to be contacted, 2) collaborating
9	226	vascular surgery clinics including the Sunshine Coast University Hospital, and 3) community
10	227	sources and advertising.
11 12 13	228	Participants will be eligible to participate in the study if they:
14	229	1. Are 18 years of age or older and have a formal diagnosis of PAD made by a vascular
15 16	230	surgeon.
17	231	2. Have undergone a lower limb revascularisation procedure (endovascular procedure,
18	232	open surgical procedure or hybrid procedure) in the previous 12 months.
19 20	233	3. Have clearance to participate from their treating vascular surgeon, including
21	234	verification that they have adequately recovered from any lower limb revascularisation
22	235	procedure.
23 24	236	4. Can understand and communicate in English sufficient to provide informed consent.
25 26	237	Participants will be excluded from participation if they meet any of the following criteria:
27 28	238	1. Unable to walk independently (e.g., depend on assistance from a walking aid).
29	239	2. Previous lower limb amputation or current tissue necrosis (ulceration or gangrene) that
30	240	limits the ability to undertake walking tests.
31 32	241	3. Deemed not eligible to participate in CR by the CR clinical staff as per standard
33	242	contraindications for exercise (58). These contraindications include unstable angina,
34	243	acute heart failure, recent cerebrovascular event, uncontrolled resting hypertension,
35 36	244	symptomatic hypotension, uncontrolled diabetes, uncontrolled sinus tachycardia,
37	245	uncontrolled/complex arrythmias.
38	246	4. Currently participating in a supervised exercise rehabilitation program.
39 40	247	5. Terminal illness or other medical condition or planned treatment that may affect the
41	248	ability to participate in or complete the trial.
42	240	Intervention
43 44	249	Intervention
45	250	Eligible participants will be randomised in equal proportions (1:1) to one of the study groups.
46 47	251	1. Usual care (control group).
48 49	252	2. Usual care plus a 6-week community-based CR program (intervention group).
50 51		
52	253	Usual care
53 54	254	All participants will continue to receive usual care and medical advice from their local doctor
55	255	and vascular surgeon throughout the study. Usual care for PAD may include management of
56 57	256	cardiovascular disease risk factors with lifestyle modifications (e.g., smoking cessation, dietary
57 58	257	modifications) and pharmacotherapies (9). While usual care for PAD will not be altered by this
59	258	protocol, upon consent to the study each participant's local doctor and vascular surgeon will
60		

Page 7

be contacted to request to provide their best possible medical care throughout the study.
Furthermore, in order to assess the efficacy of the CR program, each participant's local doctor
and vascular surgeon will be requested to refrain from giving specific advice regarding exercise
until the completion of the study.

# 1011 263 Usual care plus community-based CR program

In addition to usual care, participants who are randomised to the community-based CR program will be referred to the CR program of the Sunshine Coast Hospital and Health Service. The CR program will be delivered at a community fitness facility (The Sports Hub, Bokarina, QLD 4575, Australia). The CR program will be structured in accordance with current exercise recommendations for people with PAD (9,19-22). The CR program will include twelve 60-minute sessions of supervised exercises, delivered twice per week over a period of 6 weeks, and one education seminar (5.5 hours with breaks). While the recommended duration of supervised exercise training for patients with PAD is 12 weeks (19,20), improvements in walking capacity are reported after 3-6 weeks (59-61). Furthermore, the recommended duration for CR ranges between 6-12 weeks (62). To ensure outcomes are applicable to a wide range of CR programs, the minimum duration for CR was selected (i.e., 6 weeks). During the 6-week CR program participants will also be provided with exercise guidelines and advice to complete at least three home-based walking sessions per week. Following the completion of the CR program, participants will be provided with individualised exercise and physical activity advice with the goal to meet the recommended 150-300 minutes of moderate intensity physical activity levels per week (58). 

The program exercise sessions will be supervised by CR staff (nurses, exercise physiologist) and research personnel. The research personnel will be responsible for the prescription and progression of the exercises. As outlined in the Supplementary Table 1, the supervised exercise sessions will primarily consist of bouts of intermittent treadmill walking that are interspersed by periods of upper body activity and lower limb resistance exercises. Each supervised exercise session will last for 60 minutes, including a warm-up and a cool-down (10 minutes each). The total duration of treadmill walking for each session will be 10 minutes (e.g., 5 x 2-minute bouts) at the beginning of the program (i.e., week 1) and will progress to 30 minutes (e.g., 15 x 2-minute bouts) by the end of the program (i.e., week 6). The total duration of upper body and lower limb resistance training for each session will begin at 30 minutes (e.g., 15 x 2-minute bouts) at the beginning of the program and will decrease to 10 minutes (e.g., 5 x 2-minute bouts) by the end of the program. Exercise intensity and severity of claudication pain will be monitored with the modified rate of perceived exertion Borg scale and the intermittent claudication pain scale, respectively (63,64). Participants will be instructed to exercise at moderate to near-maximal claudication pain thresholds (i.e., 3/4 on claudication scale) or if asymptomatic, exercise at a moderate exercise intensity (i.e., 3/10 on Borg scale) (19,65). The initial exercise intensity will be individually prescribed based on the exercise workload achieved during the baseline exercise tests (e.g., workload achieved at stage prior to treadmill test cessation). 

### **BMJ** Open

The home-based walking sessions will also align with the current PAD exercise recommendations (9,19–22). Participants will be provided with individualised weekly walking goals which will be set and reviewed by the study team. During the home-based walking sessions, participants will be instructed to complete intermittent bouts of walking separated by periods of rest. Participants will be instructed to complete their walking sessions outdoors (e.g., local neighbourhood and parks). Similar to the supervised exercise sessions, the total duration of walking for each home-based session will begin at 10 minutes (e.g., 5 x 2-minute bouts) at the beginning of the program (i.e., week 1) and will progress to 30 minutes (e.g., 15 x 2-minute bouts) by the end of the program (i.e., week 6). The total period of rest for each home-based walking session will be 20 minutes at the beginning of the program (e.g., 10 x 2-minute bouts) and will decrease until participants are able to walk continuously for 30 minutes. Exercise intensity and severity of claudication pain will be self-monitored using the modified rate of perceived exertion Borg scale, and the intermittent claudication pain scale (63,64). Participants will be instructed to walk at moderate to near-maximal claudication pain thresholds (i.e., 3/4 on claudication scale) or if asymptomatic, walk at a moderate exercise intensity (i.e., 3/10 on Borg scale) (19,65). Participants will be provided with a diary to record their home-based walking sessions. 

Participants in the CR program will attend one education seminar (5.5 hours with breaks) during the 6-week CR program. The education seminar will be delivered by health specialists (e.g., nurse, dietitian, psychologist, exercise physiologist) and will cover topics such as diet, medications, exercise training, physical activity, and lifestyle modifications for the management and prevention of cardiovascular diseases. The seminar information will be based on the current Australian guidelines for the management of acute coronary syndromes (66–68). 

### Adherence

Strategies are incorporated into the protocol to promote and monitor adherence to the study intervention. The importance of attending the weekly supervised exercise sessions and accumulating the recommended weekly amount of exercise and physical activity levels will be explained to the participants in the participant information and consent form (PICF) and upon starting the CR program. Participants will also be provided with individualised weekly goals for the supervised and the home-based exercise sessions which will be set and reviewed by the study team. Adherence to the supervised and home-based exercise sessions will be assessed by recording the number of exercise sessions that participants complete each week against the goal/target for that specific week. Participants will keep a daily diary to record their home-based exercise sessions that they complete during the 6-week CR program. Attendance to the education seminar will be assessed using an attendance checklist. The assessment of protocol adherence for the purpose of statistical analysis is described in the statistical analysis section. 

Screening and enrolment (visit 1) 

Prior to screening assessments, participants will be required to provide their informed consent to participate in the study which will occur at the commencement of the initial study visit (visit 1). A trained study staff member authorised by the Principal Investigator will take the 

Page 9

### **BMJ** Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

participant through the information sheet and obtain informed consent. All participants will be fully informed of the potential risks and benefits of the study. Participants will be screened for co-morbidities and cardiovascular risk factors prior to inclusion in the study. During this visit, prescribed medications will be captured, and anthropometric measurements (e.g., height, weight) and resting blood pressure will be conducted. Participants will also be familiarised with the 6-minute walk test to minimise test variability. 

### **Randomisation and blinding**

Following baseline outcome measures (i.e., visit 3), participants will be randomly allocated to either the usual care group (N=33) or the usual care plus community-based CR exercise group (N=33). To ensure allocation concealment, randomisation will be generated using a secure, independent web-based randomisation system (SealedEnvelope.com). Prior to randomisation, participants will be stratified to account for type of procedure (e.g., open surgical vs endovascular procedure) and time since procedure (<12 weeks vs > 12 weeks). This will allow stratification of participants who have recently undergone a revascularisation procedure (< 12) weeks) from those who have undergone a revascularisation procedure more than 12 weeks ago and have fully resumed normal activities of daily living, recreation, and work activities. Block randomisation, using random block sizes of two to four participants will be used to ensure that group allocation at any point in time remains similar. Enrolment, allocation, follow-up, and final analysis will be conducted and reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement for randomised clinical trials (69). 

The same investigators who will deliver the CR program will also be involved in the collection of outcome data. Therefore, participants and data collectors will not be blinded to group allocation. While it is not feasible to blind participants and investigators to group allocation in an exercise intervention study, all data analysis will be undertaken in blinded fashion using coded data. 

### **Outcome measures and procedures**

As outlined in Table 1, primary, secondary, and exploratory outcomes will be assessed at baseline (week 1), after the completion of the 6-week CR program / usual care period (week 8) and again 6 months after the completion of the CR program / usual care period (week 34). During weeks 1 and 8, participants will carry out the assessments over two visits to ensure that participants are sufficiently recovered between walking tests. As the treadmill test is a secondary outcome measure, participants will be given the option to opt out of performing this test. The treadmill test requires participants to walk until maximal exertion. Although this is an important outcome measure, only 34 participants are required to establish an effect (refer to power and sample size estimate). Therefore, participants who are unwilling to exert themselves to maximal effort, or those who are unable to maintain the walking speed of the treadmill will be given the option to opt out of this test. At 6-month follow-up (week 34) participants will make a single visit for the assessment of the 6-minute walking test, quality of life, self-reported functional capacity, physical activity levels, vascular function, and biomarkers of cardiovascular disease risk. The 6-month follow-up visit aims to provide an indication of 

BMJ Open

longer-term durability of the effect of CR following revascularisation. For the post-intervention
and follow-up assessments at weeks 8 and 34, the assessment window may be extended by up
to 7 days to accommodate unforeseen circumstances (e.g., participant illness).

- 9 382 **Primary outcome**
- 11 383 Six-minute walk test (6MWT):

The 6MWT will be conducted at weeks 1, 8, and 34. Change in 6-minute walk distance between
 baseline and week 8 is the primary outcome for the study. Change in the pain-free walking
 distance during the 6MWT is a secondary outcome measure.

As per standard procedures, a course of 30 meters length is marked out in a covered area at least 2 meters in width, with a cone at each end (70). Chairs are also placed every 10 meters along the course so that participants can sit and rest during the test if needed. Participants will be asked to walk up and down the course for 6 minutes and to complete as many laps and cover as much distance as possible in that time. Participants will be asked to indicate to the test supervisor when the onset of claudication occurs, and then to rate the severity of their claudication/discomfort using a hand-signal at the completion of each lap (i.e., every 60 meters) using the claudication rating scale (64). During the test, heart rate will be continually monitored with a heart rate monitor and recorded at the end of each lap. During the test, participants can stop walking and rest if their claudication pain becomes intolerable; however, the timing continues and participants are requested to resume walking as soon as possible. At the end of the test, the number and timing of any rest breaks, the time and distance to the onset of claudication (pain-free walking distance) and the total distance walked (6-minute walk distance) are recorded. At the end of the test, participants will be asked to provide a rating of their general exertion using the modified rate of perceived exertion Borg Scale (63). 

Walking capacity measured during the 6MWT has been chosen as the primary outcome as it has excellent test-retest reliability (interclass correlation coefficient = 0.970, 95% confidence intervals 0.950 to 0.981, N=173) (71), and it correlates strongly with a range of relevant clinical outcomes including physical activity (72), patient-reported outcomes, as well as cardiovascular morbidity and mortality associated with PAD (7). Based on this strong reliability, a reported advantage of the 6MWT for clinical trials is that there is no learning effect (73). Nonetheless, participants will be familiarised with the 6MWT prior to the baseline assessment in the current study. This approach is consistent with recommended practice and reporting of performance outcomes for clinical trials in patients with PAD (74). The minimal clinically important difference (MCID) for 6-minute walk distance has been established for people with and without PAD. Based on the change in 6-minute walk distance with exercise therapy and the corresponding change in reported physical function, the MCID thresholds are 12 meters (small effect), 32 meters (moderate effect), and 34 meters (large effect) (75). 

- 56 415 Secondary outcome measures
   57
- 58 416 Graded treadmill walking test:59

### **BMJ** Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The graded treadmill walking test including measures of maximum walk time and pain-free walking time will be performed at weeks 1 and 8. The Gardner-Skinner protocol will be used, which was specifically developed for the assessment of walking capacity in patients with PAD (76,77). The treadmill will start at 3.2 km/h at a 0% incline, and then every 2 minutes the gradient of the treadmill will increase by 2%. Adjustments will be made to the treadmill protocol using standardised procedures for participants who are unable to maintain the 3.2 km/h treadmill speed. The treadmill test will be conducted and supervised by an exercise physiologist, a cardiac technician, and a medical doctor. During the test participants will be monitored with a continuous 12-lead electrocardiogram, and heart rate and blood pressure will be measured and recorded at the end of each stage (i.e., every 2 minutes). At the end of the test, participants will be asked to rate the severity of their claudication pain in each leg using the claudication scale, and to provide a rating of their general exertion using the modified rate of perceived exertion Borg scale (63). The MCID values for small, moderate and large changes in maximum treadmill walking time after supervised exercise training are 121, 141, and 241 (seconds), respectively, in patients with PAD (75). 

Cardiorespiratory fitness: 

Cardiorespiratory fitness (peak oxygen uptake) will be assessed during the graded treadmill walking test at weeks 1 and 8. Cardiorespiratory fitness is a strong predictor of cardiovascular disease and all-cause mortality rates in patients with PAD (78,79). Oxygen uptake (VO<sub>2</sub>) will be continuously measured with a portable VO<sub>2</sub> system (K5, COSMED, Italy), and a breath-by-breath gas exchange and ventilation face mask. Peak oxygen uptake will be determined as the highest 15-second average during the final 60 seconds of peak exercise. 

Quality of life: 

Disease-specific quality of life will be assessed using the Intermittent Claudication Questionnaire (ICQ) at weeks 1, 8 and 34. The ICQ is a self-administered tool consisting of 16 items that focus on limitations imposed by claudication while performing various tasks, such as walking specific distances or performing activities of daily living (80). The instrument is scored by summing the patient responses to individual items, which are all equally weighted, and transformed to a 0 to 100 composite score, where 0 is the best score. The composite score will be calculated and used as the outcome for analysis. 

Self-reported walking capacity: 

Self-reported walking capacity will be assessed using the Walking Impairment Questionnaire (WIQ) at weeks 1, 8 and 34. The WIQ is a PAD-specific measure of self-reported difficulty during walking with 3 domains: walking distance, walking speed, and stair climbing (81). Each domain is scored on a scale from 0 to 100 (100 indicating the best possible score). A small, moderate, and large MCID for each of the three WIQ domain scores are: 6, 14, 23 for walking distance; 4, 11, 18 for walking speed; and 6, 15, 23 for stair climbing, respectively (75). 

Physical activity levels: 

### **BMJ** Open

Objectively assessed physical activity: Free living physical activity levels will be objectively assessed using a GT9XActiGraph accelerometer (ActiGraph, Pensacola, FL, USA) at weeks 1, 8 and 34. Participants will be instructed to wear the device on their non-dominant wrist for 7 full days at each assessment point (82). At the end of the recording period, the accelerometer is removed by the participant and returned to the research team (in person or by reply-paid delivery) for data upload, quality assurance and analysis. The ActiGraph accelerometer will be initialised to collect raw data at 100 Hz (83). The in-built inclinometer will also enable the assessment of body position (i.e., sitting/lying vs standing). At each assessment period, a minimum wear-time criteria of 4 days and 600 minutes per day will be applied (84). The ActiLife software (version 6.13.5; AcriGraph LLC) will be utilised to process the raw data to create 60-second epochs (83). The data will be processed using the Choi algorithm within the ActiLife software to define wear and non-wear minutes (85). The primary outcome measure of physical activity will be steps per day. Other outcome measures will include sedentary time, and time spent (mins/day) engaging in light, moderate and vigorous physical activity. During the 7-day monitoring period, participants will also keep a brief daily physical activity diary to record periods of sleep, work, non-wear time, and structured exercise that are essential for analysis and cannot be inferred from the monitor data alone. The ActiGraph accelerometer has been reported to be reliable and valid in the assessment of walking, body posture, and sedentary behaviour during free-living activity (86–88), and when used in patients with PAD (89–91). The MCID values for small, moderate and large changes in total daily steps after supervised exercise training are 569, 1,423 and 2,277 (steps/day), respectively, in patients with PAD (92). 

Self-reported physical activity: Self-reported physical activity levels will be assessed using the International Physical Activity Questionnaire for elderly (IPAQ-E) at weeks 1, 8 and 34. The IPAQ-E is a self-reported questionnaire which has been validated for use for individuals over the age of 65 (93). The IPAQ-E consists of questions about frequency (days per week) and time (minutes per day) spent sitting, walking, and performing physical activities of moderate and vigorous intensity. All self-reported activity domains (sitting, walking, moderate and vigorous physical activities) have been reported to positively correlate with corresponding variables objectively assessed by accelerometers (93). 

**Exploratory outcomes** 

Ankle to brachial blood pressure index (ABI): 

The ABI of both legs will be measured at weeks 1, 8 and 34. After resting in a supine position for 10 minutes, brachial and ankle blood pressures will be measured. Brachial blood pressures will be measured in both arms using an automated blood pressure monitor (94). Systolic blood pressure of the dorsalis pedis artery and posterior tibial artery at the left and right ankles will also be measured using a manual cuff sphygmomanometer and handheld 5-7 MHz Doppler ultrasound probe. The average of the closest two recordings at each artery will be recorded. The ABI for each leg will be calculated by dividing the higher dorsalis pedis artery or posterior tibial artery value by the highest brachial artery value obtained from either side (59). 

Brachial artery flow-mediated dilation (FMD): 

### BMJ Open

Brachial artery FMD will be measured in response to a reactive hyperaemia test (cuff occlusion) at weeks 1, 8 and 34. Brachial artery FMD is an independent predictor of cardiovascular events in patients with PAD (95). As per standard procedures (96), brachial artery FMD will be measured with participants in the supine position after 10 minutes of rest. This measurement will involve a rapid inflation of a pressure cuff positioned at the forearm. A 10-MHz multi-frequency linear array probe, attached to a high-resolution ultrasound machine (Terason, Burlington, US) will be used to image the brachial artery (2 cm proximal to the elbow). The ultrasound settings will be optimised for each individual and will be kept constant between all assessments. Continuous Doppler velocity will also be obtained using the ultrasound at an insolation angle of 60°. Following baseline assessments, reactive hyperaemia will be induced by inflating the cuff to 200 mmHg for 5 minutes. Artery diameter and flow recordings will resume 30 seconds before cuff deflation and continue for 3 minutes thereafter (97). Brachial artery FMD will be expressed as a relative change (percent change) in peak arterial diameter from baseline (pre cuff inflation) to post cuff deflation. The analysis of the brachial artery FMD will be undertaken using a continuous edge-detection and wall-tracking software. 

<sup>26</sup> 511 Arterial stiffness:

Arterial stiffness outcomes incorporate measures of augmentation index (AIx) and carotid-femoral artery pulse wave velocity (PWV) and will be assessed at weeks 1, 8 and 34. Arterial stiffness is an independent predictor of cardiovascular disease and all-cause mortality rates in patients with PAD (98,99). After resting in the supine position for 10 minutes, brachial artery pulse waves will be obtained by partially inflating a cuff over the right brachial artery using a SphygmoCor XCEL system (AtCor Medical Pty Ltd, Sydney, Australia) and following standard guidelines (100,101). The brachial waveforms will be used to generate central aortic pressure waveforms, and to determine AIx, which is the ratio of wave reflection amplitude relative to central pulse pressure. For the PWV assessment, the carotid-femoral PWV will be measured using the applanation tonometry technique. A hand-held tonometer probe (AtCor Medical Pty Ltd, Sydney, Australia) will be held against the skin surface over the right carotid artery to obtain carotid-artery pulse waves, and a pressure cuff will be placed around the right upper thigh to record femoral artery pulse waves. The distance from the carotid site above the suprasternal notch to the proximal edge of a thigh cuff over the femoral artery will be measured using a tape measure over the body area. The carotid and femoral pulse waves will be recorded simultaneously, and the femoral pulse wave requires the thigh cuff to be partially inflated. The PWV will then be automatically calculated as the ratio of the distance between the pulse measuring sites to the time delay between the carotid and femoral pulse waves. PWV will be recorded as the average of triplicate measurements. 

54 531 Biomarkers of cardiovascular disease (CVD) risk:

56 532 Biomarkers of CVD risk will be assessed at weeks 1 and 34. The most recent blood test (within
57 533 8 weeks of baseline and within 8 weeks of follow-up visit) will be retrieved from the medical
534 records of each participant. Biomarkers of CVD risk will include total cholesterol,
535 triglycerides, high-density lipoprotein, low-density lipoprotein, and haemoglobin A1c levels.

### BMJ Open

BMJ Open

## 536 Sample size calculations

537 Sample size calculations were conducted for the primary outcome 6-minute walk distance and538 the secondary outcome maximal walking time during the graded treadmill walking test.

10 539 6MWT:

> Previous studies that assessed the effects of post-revascularisation exercise therapy indicated a potential effect of 53.2 m with a standard deviation of 81 m for 6-minute walk distance (56,102). This would provide a medium effect size of 0.65. To establish this effect from baseline to week 8 with 80% power and an alpha 0.05, 30 participants would be required in each group. Allowing for 10% dropout, 33 participants will be recruited in each group (total N=66).

<sup>20</sup> 546 Graded treadmill walking test:

A previous study that assessed the effects of post-revascularisation exercise therapy indicated a potential effect of 5 minutes and 46 seconds with a standard deviation of 6 minutes and 13 seconds for maximal walking time during the graded treadmill walking test (37). This would provide a large effect size of 0.89. To establish this effect from baseline to week 8 with 80% power and an alpha 0.05, 17 participants would be required in each group (total N=34). As this outcome of maximal walking time during the treadmill test is a secondary outcome, participants will be given the option to opt out of performing this test during the trial. 

# <sup>32</sup> 554 Statistical analysis

Data analysis will follow the CONSORT statement for randomised-controlled trials (69). All data collected will be deidentified and coded throughout the trial. The data collected will remain coded for participant confidentiality purposes. Baseline data for the two groups will be provided using counts and percentages, and means and standard deviations (or non-parametric equivalents) for categorical variables. Furthermore, tables will show the outcome measures at weeks 8 and 34 and percent changes from baseline. 

The primary analysis will be performed based on the intention-to-treat principle, where all participants will be analysed as per their allocation, regardless of the treatment they received. Non-adherence will be assessed through per-protocol analyses. Per protocol analysis will primarily include participants that attend at least 70% of the supervised CR exercise sessions (i.e., 9 exercise sessions overall) during the 6-week intervention period. The total number of supervised exercise sessions completed will be included in the analysis as a covariate. 

Statistical analyses will be conducted using the IBM SPSS software (SPSS Inc, Chicago, IL). The data will be tested for normality using the Shapiro-Wilk test and will be considered normally distributed when P > 0.05. Analyses will be conducted using analysis of variance (ANOVA) for repeated measures. The primary comparison will be change in 6-minute walk distance from baseline to post intervention (week 8) in the CR versus the usual care group. Additional analyses will be performed from baseline to 6-month follow-up timepoint (week 34). As required, confounding variables (including comorbidities, age, sex, smoking behaviour, 

574 medications) will be adjusted for using analysis of covariance (ANCOVA). In all analyses, P575 < 0.05 will be considered statistically significant. Post-hoc analysis will be performed when a 576 significant effect is present.

# 9 577 **Data management**

All data collected during the study will be coded and stored for a minimum of 15 years. Prospective participants will initially be assigned a screening number, and upon consent into the study they will be assigned a participant identification code. A coding log will be maintained and kept in a secure location (hard copy in locked cabinet and electronic copy on password protected file) in accordance with the International Council on Harmonisation Good Clinical Practice (GCP) guidelines, the study data management plan, and the data security policy of the University of the Sunshine Coast. The only personnel who will have access to participants' individual identity are the Principal Investigator (CDA) and authorised project staff. Access to the coding log would only occur in the case where further medical history information is required in relation to a specific participant, in cases of emergency (e.g., to identify and contact next of kin), or during the investigation of any events (e.g., serious adverse event). 

All individual participant information will be de-identified in the reporting of data and resulting publications or presentations to fully protect the confidentiality of participants. Participants will be informed in the PICF that information or reports from the study will be prepared and will be submitted for publication. Participant information will normally be presented as group data. If necessary, information obtained from specific individuals may be presented; however, names will not be used to identify the individuals. Participants will only be identified in such publications by an identification number and possibly their age and gender. 

# 3738597Adverse events

Information on all adverse events (study-related and non-study related) will be recorded immediately in the trial adverse event report form and in the appropriate case report form for the relevant participant. All clearly related signs, symptoms, and abnormal procedural results will be recorded. For all recorded adverse events, the Principal Investigator or delegate will determine the adverse event's causality to the intervention and the severity or intensity of the event. The clinical course of each event will be followed until resolution, stabilisation, or until it has been determined that the study intervention or participation is not the cause. All logged events will be summarised and reported to the participant's general practitioner and the relevant human research ethics committees and governance agencies as part of the reporting requirements. 

54 608

## 609 PATIENT AND PUBLIC INVOLVEMENT

610 No patient and public involvement.

# 612 ETHICS AND DISSEMINATION

This study has received ethics approval from the Human Research Ethics Committees (HREC)
of Queensland Health Metro North Hospital and Health Service (94155), and the University of
the Sunshine Coast (S231914). Any protocol amendments will be submitted to the
aforementioned HREC for approval. Findings from this study will be disseminated in peerreviewed journals and through national and international conference presentations.

14 618

# 1516 619 AUTHORS' CONTRIBUTION

CDA is the guarantor for the study and takes overall responsibility. KF and CDA conceptualised the study protocol and are responsible for ethical approvals. JJS assisted with protocol development and is responsible for physical activity outcomes. PJ has oversight of participant screening recruitment and the main study site. KF and MA will be responsible for the delivery of the cardiovascular rehabilitation intervention. KF will be involved in the collection of all outcome data. CDA, TS, and MS will provide oversight of data collection including the supervision of trial personnel and will support the analysis and interpretation of findings. All authors critically reviewed the study protocol and provided input to all aspects of the design and plan. All authors reviewed and edited the manuscript and approved the final version. The Saving Legs & Lives Trial Group consists of clinical investigators who are responsible for the screening and recruitment of participants and will provide support during data collection and data analysis activities including the delivery of the cardiovascular rehabilitation intervention. 

36 633

# 37<br/>38634FUNDING STATEMENT

635 This work is supported by a Sunshine Coast Health Institute (SCHI) Collaborative Seed Grant 636 Scheme (Grant ID number: 2020-01) awarded to CDA (Principal Investigator). KF is supported 637 by a collaborative University of the Sunshine Coast and Sunshine Coast Hospital and Health 638 Service scholarship as well as a PhD Top-Up Scholarship Award from the Queensland 639 Cardiovascular Research Network (QCVRN). The aforementioned funders had no input in the 640 design of the study and will have no role in the collection, management, analysis, and 641 interpretation of the data or decision to submit this work for publication.

- <sup>49</sup> 50 642
- 52 643 COMPETING INTERESTS STATEMENT
  - 644 The authors declare no competing interests.

## **REFERENCES**

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

### **BMJ** Open

### BMJ Open

Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and 1. national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019 Aug;7(8):e1020-30. 2. Gardner AW, Montgomery PS, Scott KJ, Afaq A, Blevins SM. Patterns of ambulatory activity in subjects with and without intermittent claudication. J Vasc Surg. 2007 Dec;46(6):1208–14. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, et al. The ankle 3. brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002 Jun 18;136(12):873-83. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. 4. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med Lond Engl. 2008 Feb;13(1):15-24. 5. Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis. 2020 Jan;293:94-100. 6. Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, et al. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust. 2012 Feb 20;196(3):193-7. 7. McDermott MM, Greenland P, Tian L, Kibbe MR, Green D, Zhao L, et al. Association of 6-Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. J Am Heart Assoc. 2015 Jul 28;4(7). Gardner AW, Addison O, Katzel LI, Montgomery PS, Prior SJ, Serra MC, et al. Association 8. between Physical Activity and Mortality in Patients with Claudication. Med Sci Sports Exerc. 2021 Apr 1;53(4):732–9. 9. Nordanstig J, Behrendt CA, Baumgartner I, Belch J, Bäck M, Fitridge R, et al. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2023 Nov 8;S1078-5884(23)00741-4. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral 10. vascular bypass surgery for patients with intermittent claudication. Angiology. 1993 Jan;44(1):1-10. Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular 11. revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018 Mar 8;3(3):CD010512. Je HG, Kim BH, Cho KI, Jang JS, Park YH, Spertus J. Correlation between Patient-Reported 12. Symptoms and Ankle-Brachial Index after Revascularization for Peripheral Arterial Disease. Int J Mol Sci. 2015 May 18;16(5):11355-68. Devine EB, Alfonso-Cristancho R, Yanez ND, Edwards TC, Patrick DL, Armstrong CAL, et 13. al. Effectiveness of a Medical vs Revascularization Intervention for Intermittent Leg Claudication Based on Patient-Reported Outcomes. JAMA Surg. 2016 Oct 19;151(10):e162024. Perkins JMT, Collin J, Creasy TS, Fletcher EWL, Morris PJ. Reprinted Article "Exercise 14. Training Versus Angioplasty for Stable Claudication. Long and Medium Term Results of a Prospective, Randomised Trial". Eur J Vasc Endovasc Surg. 2011 Sep 1;42:S41-5. van Hattum ES, Tangelder MJD, Lawson JA, Moll FL, Algra A. The quality of life in patients 15. after peripheral bypass surgery deteriorates at long-term follow-up. J Vasc Surg. 2011 Mar;53(3):643-50.

## BMJ Open

BMJ Open

Wann-Hansson C, Hallberg IR, Risberg B, Lundell A, Klevsgard R. Health-related quality of 16. life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J Adv Nurs. 2005 Aug;51(3):227-35. 17. Djerf H, Millinger J, Falkenberg M, Jivegård L, Svensson M, Nordanstig J. Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv. 2020 Jan;13(1):e008450. Mustapha JA, Finton SM, Diaz-Sandoval LJ, Saab FA, Miller LE. Percutaneous Transluminal 18. Angioplasty in Patients With Infrapopliteal Arterial Disease: Systematic Review and Meta-Analysis. Circ Cardiovasc Interv. 2016 May;9(5):e003468. Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, et al. 19. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10-33. 20. Askew CD, Parmenter B, Leicht AS, Walker PJ, Golledge J. Exercise & Sports Science Australia (ESSA) position statement on exercise prescription for patients with peripheral arterial disease and intermittent claudication. J Sci Med Sport. 2014 Nov;17(6):623-9. 21. Tew GA, Harwood AE, Ingle L, Chetter I, Doherty PJ. The bases expert statement on exercise training for people with intermittent claudication due to peripheral arterial disease. Sport Exerc Sci. 2018; 22. Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763-816. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial 23. disease: a systematic review and meta-analysis. Sports Med Auckl NZ. 2015 Feb;45(2):231-44. 24. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD000990. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of 25. claudication pain. A meta-analysis. JAMA. 1995 Sep 27;274(12):975-80. Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, et al. Exercise 26. rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc. 2001 Jun;49(6):755-62. 27. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996 Jan;23(1):104-15. Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of 28. life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med Lond Engl. 2015 Feb;20(1):30-40. Lanzi S, Calanca L, Berchtold A, Mazzolai L. Improvement in 6-Minute Walking Distance 29. after Supervised Exercise Training Is Related to Changes in Quality of Life in Patients with Lower Extremity Peripheral Artery Disease. J Clin Med. 2021 Jul 28;10(15). Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with 30. claudication. J Vasc Surg. 2012 May;55(5):1346-54. 

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- 1 2 3 4 5 6 7 8 9 11 12 13 14 15 17 19 20 24 25 27 28 35 36 37
  - 736 31. Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity
    737 progressive resistance training improves flat-ground walking in older adults with symptomatic
    738 peripheral arterial disease. J Am Geriatr Soc. 2013 Nov;61(11):1964–70.
    739 32. Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training
- 739
   740
   740
   741
   741
   741
   742
   743
   744
   744
   745
   745
   746
   747
   748
   748
   749
   749
   740
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
   741
- 742 742 33. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA. 2009 Jan 14;301(2):165–74.
- 745 745 34. Whipple MO, Burt MA, Pergolski AL, McArthur P, Treat-Jacobson D, Salisbury DL. Uptake
  746 and outcomes of supervised exercise therapy for peripheral artery disease: The importance of vascular
  747 medicine specialists at a large midwestern health care system during the first 5 years of CMS
  748 reimbursement. Vasc Med Lond Engl. 2024 Apr;29(2):112–9.
- 749 35. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al.
  750 Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and
  751 Intermittent Claudication: A Randomized Clinical Trial. JAMA. 2015 Nov 10;314(18):1936–44.
- 752 752 36. Badger SA, Soong CV, O'Donnell ME, Boreham CAG, McGuigan KE. Benefits of a supervised exercise program after lower limb bypass surgery. Vasc Endovascular Surg. 2007 Mar;41(1):27–32.
- 755
  755
  756
  757
  757
  758
  759
  759
  759
  750
  750
  750
  750
  751
  752
  753
  754
  755
  755
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  757
  758
  758
  758
  759
  759
  759
  757
  757
  757
  758
  758
  758
  759
  759
  757
  757
  757
- 758
   758
   759
   760
   760
   761
   761
   762
   763
   764
   765
   765
   761
   765
   766
   767
   768
   768
   769
   760
   760
   761
   761
   761
   762
   763
   764
   765
   765
   766
   766
   767
   768
   768
   769
   760
   760
   761
   761
   762
   763
   764
   765
   765
   766
   766
   767
   768
   768
   769
   769
   760
   760
   761
   761
   761
   762
   763
   764
   764
   765
   765
   766
   767
   768
   769
   769
   760
   760
   761
   760
   761
   761
   761
   762
   763
   764
   764
   765
   765
   766
   767
   768
   769
   769
   760
   760
   761
   761
   761
   762
   763
   764
   765
   765
   766
   767
   768
   768
   769
   769
   760
   760
   761
   761
   762
   763
   764
   764
   765
   766
   766
   767
   768
   768
   768
   769
   769
   769
   769
- 762 39. Mazari FAK, Khan JA, Carradice D, Samuel N, Abdul Rahman MNA, Gulati S, et al.
   763 Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined
   764 treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg. 2012
   765 Jan;99(1):39–48.
- 42 766 40. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, et al. Comparative Efficacy of
  43 767 Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent
  44 768 Claudication: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2017 Apr
  46
- 47 770 41. Dua A, Gologorsky R, Savage D, Rens N, Gandhi N, Brooke B, et al. National assessment of
  48 771 availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease
  49 772 patients with intermittent claudication. J Vasc Surg. 2020 May;71(5):1702–7.
- 773 42. Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exercise
  774 services in patients with peripheral artery disease in the United Kingdom. Vascular. 2022
  775 Oct;30(5):874–81.
- 776
  776
  777
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  778
  78
  78
  79
  79
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
  70
- 58
  59
  60
  779
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  780
  <li

## BMJ Open

BMJ Open

Martin BJ, Arena R, Haykowsky M, Hauer T, Austford LD, Knudtson M, et al. 45. Cardiovascular fitness and mortality after contemporary cardiac rehabilitation. Mayo Clin Proc. 2013 May;88(5):455-63. 46. Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023 Feb 7;44(6):452-69. Tegegne TK, Rawstorn JC, Nourse RA, Kibret KT, Ahmed KY, Maddison R. Effects of 47. exercise-based cardiac rehabilitation delivery modes on exercise capacity and health-related quality of life in heart failure: a systematic review and network meta-analysis. Open Heart. 2022 Jun;9(1). Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise-48. based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. Eur J Heart Fail. 2018 Dec;20(12):1735-43. Ahden S, Ngo V, Hoskin J, Mach V, Magharious S, Tambar A, et al. Inclusion of People 49. With Peripheral Artery Disease in Cardiac Rehabilitation Programs: A Pan-Canadian Survey. Heart Lung Circ. 2021 Jul;30(7):1031-43. Siercke M, Jørgensen LP, Missel M, Thygesen LC, Møller SP, Sillesen H, et al. 50. Cardiovascular Rehabilitation Increases Walking Distance in Patients With Intermittent Claudication. Results of the CIPIC Rehab Study: A Randomised Controlled Trial. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2021 Nov;62(5):768-76. Devrome AN, Aggarwal S, McMurtry MS, Southern D, Hauer T, Lamb B, et al. Cardiac 51. rehabilitation in people with peripheral arterial disease: A higher risk population that benefits from completion. Int J Cardiol. 2019 Jun 15;285:108-14. 52. Ambrosetti M, Temporelli PL, Faggiano P, Febo O, Diaco T, Favretto G, et al. Lower extremities peripheral arterial disease among patients admitted to cardiac rehabilitation: the THINKPAD registry. Int J Cardiol. 2014 Feb 1;171(2):192-8. Jeger RV, Rickenbacher P, Pfisterer ME, Hoffmann A. Outpatient rehabilitation in patients 53. with coronary artery and peripheral arterial occlusive disease. Arch Phys Med Rehabil. 2008 Apr;89(4):618–21. Tam MC, Longenecker CT, Chow C, Vest M, Sukeena R, Madan Mohan SK, et al. Occult 54. peripheral artery disease is common and limits the benefit achieved in cardiac rehabilitation. Vasc Med Lond Engl. 2016 Apr;21(2):130-6. Anghel R, Adam CA, Mitu O, Marcu DTM, Onofrei V, Roca M, et al. Cardiac Rehabilitation 55. and Mortality Risk Reduction in Peripheral Artery Disease at 6-Month Outcome. Diagn Basel Switz. 2022 Jun 20;12(6). Sami F, Ranka S, Lippmann M, Weiford B, Hance K, Whitman B, et al. Cardiac 56. rehabilitation in patients with peripheral arterial disease after revascularization. Vascular. 2021 Jun;29(3):350-4. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 57. 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. Verdicchio C, Freene N, Hollings M, Maiorana A, Briffa T, Gallagher R, et al. A Clinical 58. Guide for Assessment and Prescription of Exercise and Physical Activity in Cardiac Rehabilitation. A CSANZ Position Statement. Heart Lung Circ. 2023 Sep;32(9):1035-48. 

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- Sanderson B, Askew C, Stewart I, Walker P, Gibbs H, Green S. Short-term effects of cycle 59. and treadmill training on exercise tolerance in peripheral arterial disease. J Vasc Surg. 2006 Jul;44(1):119-27. 60. Wood RE, Sanderson BE, Askew CD, Walker PJ, Green S, Stewart IB. Effect of training on the response of plasma vascular endothelial growth factor to exercise in patients with peripheral arterial disease. Clin Sci Lond Engl 1979. 2006 Dec;111(6):401-9. Tew GA, Humphreys L, Crank H, Hewitt C, Nawaz S, Al-Jundi W, et al. The development 61. and pilot randomised controlled trial of a group education programme for promoting walking in people with intermittent claudication. Vasc Med Lond Engl. 2015 Aug;20(4):348-57. Astley CM, Beleigoli A, Tavella R, Hendriks J, Gallagher C, Tirimacco R, et al. Assessing 62. the quality of cardiac rehabilitation programs by measuring adherence to the Australian quality indicators. BMC Health Serv Res. 2022 Feb 28;22(1):267. 63. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81. Martinez CA, Carmeli E, Barak S, Stopka CB. Changes in pain-free walking based on time in 64. accommodating pain-free exercise therapy for peripheral arterial disease. J Vasc Nurs Off Publ Soc Peripher Vasc Nurs. 2009 Mar;27(1):2-7. 65. Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise intensity terminology. J Sci Med Sport. 2010 Sep;13(5):496–502. 66. Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Med J Aust. 2016 Aug 1;205(3):128-33. Australian Government Department of Health and Aged Care. Physical activity and exercise 67. guidelines for all Australians [Internet]. Australian Government; 2021. Available from: https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians#order-the-guidelines Australian Government Department of Health and Aged Care. The Australian Dietary 68. Guidelines [Internet]. 2019. Available from: https://www.health.gov.au/resources/publications/the-australian-dietary-guidelines Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for 69. reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726–32. 70. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Golledge J, Yip L, Fernando ME, Pinchbeck J, Rowbotham S, Jenkins J, et al. Relationship 71. between requirement to stop during a six-minute walk test and health-related quality of life, physical activity and physical performance amongst people with intermittent claudication. Ann Vasc Surg. 2021 Oct;76:363-9. McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al. Prognostic value of 72. functional performance for mortality in patients with peripheral artery disease. J Am Coll Cardiol. 2008 Apr 15;51(15):1482-9.
- McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based 73. functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg. 2008 Nov;48(5):1231-7, 1237.e1.


## BMJ Open

BMJ Open

Birkett ST, Harwood AE, Caldow E, Ibeggazene S, Ingle L, Pymer S. A systematic review of 74. exercise testing in patients with intermittent claudication: A focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions. PloS One. 2021;16(5):e0249277. 75. Gardner AW, Montgomery PS, Wang M. Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med Lond Engl. 2018 Aug;23(4):349-57. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests 76. for evaluation of claudication. Med Sci Sports Exerc. 1991 Apr;23(4):402-8. Gardner AW, Skinner JS, Vaughan NR, Bryant CX, Smith LK. Comparison of three 77. progressive exercise protocols in peripheral vascular occlusive disease. Angiology, 1992 Aug;43(8):661–71. 78. Leeper NJ, Myers J, Zhou M, Nead KT, Syed A, Kojima Y, et al. Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease. J Vasc Surg. 2013 Mar;57(3):728–33. 79. Harber MP, Kaminsky LA, Arena R, Blair SN, Franklin BA, Myers J, et al. Impact of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since 2009. Prog Cardiovasc Dis. 2017 Jul;60(1):11-20. 80. Chong PFS, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The intermittent claudication questionnaire: a patient-assessed condition-specific health outcome measure. J Vasc Surg. 2002 Oct;36(4):764–71; discussion 863-864. Regensteiner J, Steiner J, Panzer R, Hiatt W. Evaluation of walking impairment by 81. questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142-152. Hildebrand M, VAN Hees VT, Hansen BH, Ekelund U. Age group comparability of raw 82. accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc. 2014 Sep;46(9):1816-24. 83. Migueles JH, Cadenas-Sanchez C, Ekelund U, Delisle Nyström C, Mora-Gonzalez J, Löf M, et al. Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med Auckl NZ. 2017 Sep;47(9):1821-45. 84. Airlie J, Forster A, Birch KM. An investigation into the optimal wear time criteria necessary to reliably estimate physical activity and sedentary behaviour from ActiGraph wGT3X+ accelerometer data in older care home residents. BMC Geriatr. 2022 Feb 17;22(1):136. Choi L, Ward SC, Schnelle JF, Buchowski MS. Assessment of wear/nonwear time 85. classification algorithms for triaxial accelerometer. Med Sci Sports Exerc. 2012 Oct;44(10):2009-16. Evenson KR, Buchner DM, Morland KB. Objective measurement of physical activity and 86. sedentary behavior among US adults aged 60 years or older. Prev Chronic Dis. 2012;9:E26. 87. Kelly LA, McMillan DG, Anderson A, Fippinger M, Fillerup G, Rider J. Validity of actigraphs uniaxial and triaxial accelerometers for assessment of physical activity in adults in laboratory conditions. BMC Med Phys. 2013 Nov 26;13(1):5. Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, et al. Amount of 88. time spent in sedentary behaviors in the United States, 2003-2004. Am J Epidemiol. 2008 Apr 1;167(7):875-81. 

#### McDermott MM, Spring B, Berger JS, Treat-Jacobson D, Conte MS, Creager MA, et al. 89. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA. 2018 Apr 24;319(16):1665-76. 90. Hernandez H, Myers SA, Schieber M, Ha DM, Baker S, Koutakis P, et al. Quantification of Daily Physical Activity and Sedentary Behavior of Claudicating Patients. Ann Vasc Surg. 2019 Feb;55:112-21. Gerage AM, Correia M de A, Oliveira PML de, Palmeira AC, Domingues WJR, Zeratti AE, 91. et al. Physical Activity Levels in Peripheral Artery Disease Patients. Arg Bras Cardiol. 2019;113(3):410-6. 92. Gardner AW, Montgomery PS, Wang M, Shen B. Minimal clinically important differences in daily physical activity outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med Lond Engl. 2022 Apr;27(2):142-9. Hurtig-Wennlöf A, Hagströmer M, Olsson LA. The International Physical Activity 93. Questionnaire modified for the elderly: aspects of validity and feasibility. Public Health Nutr. 2010 Nov;13(11):1847-54. Gardner AW, Montgomery PS. Comparison of three blood pressure methods used for 94. determining ankle/brachial index in patients with intermittent claudication. Angiology. 1998 Sep;49(9):723-8. 95. Brevetti G, Silvestro A, Schiano V, Chiariello M, Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003 Oct 28;108(17):2093-8. 96. Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534-47. Bailey TG, Birk GK, Cable NT, Atkinson G, Green DJ, Jones H, et al. Remote ischemic 97. preconditioning prevents reduction in brachial artery flow-mediated dilation after strenuous exercise. Am J Physiol Heart Circ Physiol. 2012 Sep 1;303(5):H533-538. Kals J, Lieberg J, Kampus P, Zagura M, Eha J, Zilmer M. Prognostic impact of arterial 98. stiffness in patients with symptomatic peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2014 Sep;48(3):308-15. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010 Feb 2;121(4):505-11. Hwang MH, Yoo JK, Kim HK, Hwang CL, Mackay K, Hemstreet O, et al. Validity and 100. reliability of aortic pulse wave velocity and augmentation index determined by the new cuff-based SphygmoCor Xcel. J Hum Hypertens. 2014 Aug;28(8):475–81. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al. 101. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertens Dallas Tex 1979. 2015 Sep;66(3):698–722. Sandberg A, Cider Å, Jivegård L, Nordanstig J, Wittboldt S, Bäck M. Test-retest reliability, 102. agreement, and minimal detectable change in the 6-minute walk test in patients with intermittent claudication. J Vasc Surg. 2020 Jan;71(1):197-203.

1 2		BMJ (			njopen-zuz4-u89zu3 d by copyright, inclu			Page 26	of 28
3 4 5 984 6 985		le of participant enrolment, intervention, and assessment	t		including fo	1			
7	MILESTONES	ACTIVITY	Screen	Baseline (Pre	-interventign)	Post-int	tervention	Follow-up	
8	WEEK		-	8	34				
9	VISIT (timepoint)		1	2	3 elg	4	5	6	
10 11 12	RECRUITEMENT	Patient identification	Х		4. Lo d to t				
13		Pre-screen checklist for eligibility	Х						
14	ENROLEMENT &	Consent	Х		Superieur (Al Superieur (Al Stand data				
15	SCREENING	Confirm eligibility	Х		nd o	-			
16		Demographics and health history	Х		a In Jata				
17 18		Familiarisation with six-minute walk test	Х		<u> </u>				
18	RANDOMISATION	Stratification & randomisation							
20	INTERVENTION Usual care plus community-based CR program (weeks 2 to 7)								
21	CONTROL	Usual care (weeks 2 to 7)							
	PRIMARY OUTCOME	Six-minute walk test		X	aini	Х		Х	
23	SECONDARY	Treadmill walking test & cardiorespiratory fitness test with ECG*			X ng,		X		
24 25	OUTCOMES	Quality of life (WIQ, ICQ)		Х	an 🛱	Х		Х	
26		Physical activity levels (7-day accelerometer, physical activity survey)		X	d si	Х		Х	
27	EXPLORATORY	Ankle-to-brachial systolic blood pressure index		X	mil	Х		Х	
28	OUTCOMES	Brachial artery flow-mediated dilation assessment		X	ar t	Х		Х	
29		Arterial stiffness assessments (AIx, carotid-femoral artery PWV)		X	ech	Х		Х	
30		Markers of CVD (total cholesterol, LDL, HDL triglycerides, HbA1c)		Х	Inol	5		Х	
32       986         32       987         33       988         34       989         35       990         36       991         37       992         38       993         39       40         41       42         43       44         45       45	<ul> <li>b) community-based caliboration regarding for the control of the state and end of the procedure (e.g., open surgical vs endovascular procedure) and time since procedure (&lt;12 weeks). Outcome measures will be assessed at baseline (week 1), at the end of the intervention / usual care period (week 8) and again at 6-month follow-up (week 34). *As the treadmill walking test and the cardiorespiratory fitness test are secondary outcomes participants will be given the option to opt out of performing those assessments. For the post-intervention assessments at weeks 8 and 34, the assessment window have be extended by up to 7 days to accommodate unforeseen circumstances (e.g., participant illness). CR, cardiovascular rehabilitation; ECG, electrocardiogram; WIQ, walking importance questionnaire; ICQ, intermittent claudication questionnaire; AIx, augmentation index; PWV, pulse wave velocity; CVD, cardiovascular disease; LDL, low-density lipoprotein; HbA1c, haemoglobin A1c.</li> <li>For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml</li> </ul>						for type of end of the participants will vs to ermittent		



Week		Treadmill walking			bilitation exercise program				by copyright, Copyrigh			
	Walking bouts	Bout duration	Total time	Exercise	Sets	Repetitions	Total time	Igkercinge	Sets	Duration	Total time	
			10 minutes	1) Sit-to-stand	2	12		1) Upright rowing dumbbells)	4	1 minute		
1	5	2 minutes		2) Seated leg extensions	2	12	10 minutes	2) Arm cycling o b	3	1 minute	20 minutes	
				3) Standing calf raises	1	12		3) Ski ergom	3	1 minute		
				1) Sit-to-stand	2	12		1) Upright rop in the umbbells)	3	1 minute		
2	7	2 minutes	14 minutes	2) Seated leg extensions	2	12	12 minutes	2) Arm cycling of	2	1 minute	14 minutes	
				3) Standing calf raises	2	12		3) Ski ergometry 2	2	1 minute		
				1) Sit-to-stand	2	12		1) Upright rox is the dumbbells)	2	1 minute	10 minutes	
3	10	2 minutes	20 minutes	2) Seated leg extensions	2	12	10 minutes	2) Arm cycling o a	2	1 minute		
				3) Standing calf raises	1	12		3) Ski ergometre o	1	1 minute		
4	12	2		1) Sit-to-stand	2	12	9	1) Upright rowing #lumbbells)	2	1 minute		
4	12	2 minutes	24 minutes	2) Standing calf raises	2	12	8 minutes	2) Arm cycling B	2	1 minute	8 minutes	
5	14	2 minutes	tes 28 minutes	1) Sit-to-stand	2	12	6 minutes	1) Upright roading adumbbells)	2	1 minute	C minutes	
3				2) Standing calf raises	1	12	ommutes	2) Arm cycling •	1	1 minute	6 minutes	
6	15	2 minutes	30 minutes	1) Sit-to-stand	1	12	4 minutes	1) Upright roming dumbbells)	2	1 minute	6 minutes	
•			50 minutes	2) Standing calf raises	1	12	4 minutes	2) Arm cycling Z.	1	1 minute	0 minutes	
	Intensity prog	gression criteria		Intensi	ity progres	ssion criteria		E Progr	am progres	sion criteria		
Par ma: sca (ou djust speed a ) watts for th Par Hea 30	e next walking bout i ticipant completes wa ximal claudication pa le) or rate of perceive t of 10) by the end of ind/or gradient of trea e next walking bout i ticipant fails to comp art rate exceeds 90% seconds te of perceived exertion	alking bout without a in (number 3-4 on c of exertion on Borg s the walking bout. dmill to decrease the f: lete walking bout of predicted maximu	laudication pain scale is less than 3 e power output by um heart rate for	optimal exercise Exercise does r claudication pa 3 (out of 10) by Decrease repetitions and/o Participant is u exercise techni	se technique not induce ain or rate of y the end of pr weight for able to co que	moderate to near of perceived exer of the set	r-maximal tion is less than rith optimal	The aim of the upper body activit treadmill water in a final lower limit Taiprogress the exerci- ingrease treadmill wa To regress the exercis- ingrease upper body a og i. 2025 a	o resistance o ise program lking time	exercises. , reduce upper bod	y activity time and	

### Saving Legs & Lives: The efficacy of a community-based cardiovascular rehabilitation program versus usual care on exercise capacity and quality of life in patients who have undergone lower limb revascularisation for peripheral arterial disease: Protocol for a single centre randomisedcontrolled trial

	1
Journal:	BMJ Open
Manuscript ID	bmjopen-2024-089203.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Oct-2024
Complete List of Authors:	Feka, Krist; University of the Sunshine Coast, School of Health; Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service Jha, Pankaj; Sunshine Coast University Hospital, Vascular Surgery Aust, Michelle; Sunshine Coast University Hospital, Cardiology Scott, Joseph; University of the Sunshine Coast, School of Education and Tertiary Access Schaumberg, Mia; University of the Sunshine Coast, School of Health Stanton, Tony; Sunshine Coast University Hospital, Cardiology Askew, Christopher; University of the Sunshine Coast, School of Health; Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service Trial Group, Saving Legs & Lives Trial Group; University of the Sunshine Coast, School of Health
<b>Primary Subject Heading</b> :	Sports and exercise medicine
Secondary Subject Heading:	Cardiovascular medicine, Rehabilitation medicine, Surgery
Keywords:	VASCULAR SURGERY, Exercise Test, Quality of Life, Cardiovascular Disease, Exercise

## SCHOLARONE<sup>™</sup> Manuscripts

### BMJ Open

BMJ Open

# 1 Title:

Saving Legs & Lives: The efficacy of a community-based cardiovascular rehabilitation
program versus usual care on exercise capacity and quality of life in patients who have
undergone lower limb revascularisation for peripheral arterial disease: Protocol for a single
centre randomised-controlled trial

# 7 Authors:

Krist Feka<sup>1,2</sup>, Pankaj Jha<sup>3</sup>, Michelle Aust<sup>4</sup>, Joseph J. Scott<sup>5</sup>, Mia Schaumberg<sup>1,2</sup>, Tony
Stanton<sup>4</sup>, Christopher D. Askew<sup>1,2</sup> on behalf of the Saving Legs & Lives Trial Group

## 11 Saving Legs & Lives Trial Group

12 Kim Greaves, Norman Morris, Fraser D. Russell, Meegan A. Walker, Mathew J. Summers,

13 Jill O'Donnell, Karl Schulze, Rebecca J. Magee, Daniel McGlade, Vivienne Moult, Amanda

14 Shepherd, Michael D. Shanahan, Tuppence Richman, Caitlin Coppock, Helen J. Rodgers,

15 Ashley R. Samarasinghe, Damien P. Kerley, Lisa M. Polowyi

## 17 Affiliations:

18 <sup>1</sup>VasoActive Research Group, School of Health, University of the Sunshine Coast, Australia

- <sup>35</sup> 19 <sup>2</sup>Sunshine Coast Health Institute, Sunshine Coast Hospital and Health Service, Australia
  - <sup>20</sup> <sup>3</sup>Department of Vascular Surgery, Sunshine Coast University Hospital, Australia
  - <sup>4</sup>Department of Cardiology, Sunshine Coast University Hospital, Australia
  - <sup>5</sup>School of Education and Tertiary Access, University of the Sunshine Coast, Australia

## 24 Corresponding Author:

- 4748 25 Professor Christopher D. Askew
  - 26 VasoActive Research Group, School of Health, University of the Sunshine Coast
  - 27 90 Sippy Downs Dr, Sippy Downs, Sunshine Coast, QLD 4556, Australia
- <sup>53</sup><sub>54</sub> 28 Tel: +61 7 5456 5961 / 0412 332 987
- 56 29 Email: caskew@usc.edu.au
- 60 31

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

### 

## 32 ABSTRACT:

**Introduction:** Peripheral artery disease (PAD) is an atherosclerotic condition characterised by stenosis or occlusion of the arteries in the lower limbs. Patients with PAD commonly report intermittent claudication (leg pain/discomfort) during physical activities, which significantly limits the ability to walk and perform activities of daily living. Supervised exercise training is an effective therapy that can improve walking capacity in people with PAD. Emerging evidence also suggests that supervised exercise therapy following lower limb revascularisation can further enhance walking capacity when compared with revascularisation alone. However, access to dedicated exercise programs for patients with PAD is limited in most countries, and there is a need to test the efficacy of alternative rehabilitation strategies and referral pathways. This randomised-controlled study aims to assess the efficacy of a cardiovascular rehabilitation program versus usual care on walking capacity and quality of life in patients who have undergone lower limb revascularisation for PAD. 

Methods and analysis: This will be a single-centre, prospective, parallel group, randomised-controlled trial. Sixty-six participants who have undergone a lower limb revascularisation procedure for PAD, in the previous 12 months will be randomly allocated to a cardiovascular rehabilitation program or a usual care (control) group. The cardiovascular rehabilitation program will include two supervised exercise sessions per week for 6 weeks primarily consisting of intermittent treadmill walking at a moderate exercise intensity, and home-based walking advice. During the 6-week program, participants will also attend one education seminar (5.5 hours) which will cover topics such as diet, medications, exercise training, and lifestyle modifications for the management of cardiovascular diseases. The control group will receive usual care and medical advice from their local doctor and vascular surgeon. The primary outcome will be 6-minute walk distance. Secondary outcomes include pain-free walking distance during the 6-minute walk test, maximal and pain-free walking time during a graded treadmill walking test, cardiorespiratory fitness, self-reported walking capacity, disease-specific quality of life, and self-reported and objectively measured physical activity levels. Exploratory outcomes include brachial artery flow-mediated dilation, arterial stiffness, ankle-brachial blood pressure index, and biomarkers of cardiovascular disease risk. Outcomes will be assessed at baseline (week 1), following the cardiovascular rehabilitation / usual care period (week 8), and again at 6-month follow-up (week 34). 

Ethics and dissemination: This study has received ethics approval from the Human Research
Ethics Committees (HREC) of Queensland Health Metro North Hospital and Health Service
(94155), and the University of the Sunshine Coast (S231914). Findings from this study will be
disseminated in peer-reviewed journals and through national and international conference
presentations.

- 68 Trial registration number: ACTRN12623000190606

BMJ Open

1 2		
3 4 5	71	STRENGTHS AND LIMITATIONS OF THIS STUDY:
6 7	72	• The primary outcome of this study, 6-minute walk distance, is an important clinical
8	73	endpoint which correlates with mortality and morbidity rates in people with peripheral
9	74	artery disease.
10 11	75	• This study includes a large number of outcome measures aiming to assess the efficacy
12	76	of cardiovascular rehabilitation on walking capacity, cardiorespiratory fitness, disease-
13 14	77	specific quality of life, accelerometer-derived physical activity, and cardiovascular
14	78	function.
16	79	• The same investigators who will deliver the cardiovascular rehabilitation program will
17 18	80	also be involved in the collection of outcome data; however, to reduce the risk of bias
19	81	all data analysis will be undertaken in blinded fashion using coded data.
20	82	
21 22	83	
23	84	
24		
25 26	85	
27	86	
28 29	87	
29 30	07	
31	88	
32 33	89	all data analysis will be undertaken in blinded fashion using coded data.
34		
35	90	
36 37	91	
38	92	
39	92	
40 41	93	
42	94	
43		
44 45	95	
46	96	
47 48	97	
48 49	57	
50	98	
51 52	99	
53		
54	100	
55 56	101	
57	100	
58 59	102	
59 60	103	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

### **INTRODUCTION:**

Peripheral artery disease (PAD) is an atherosclerotic condition characterised by stenosis or occlusion of the arteries of the lower limbs. Worldwide, PAD affects over 230 million adults and its prevalence is expected to further increase over the coming years due to the ageing of the population <sup>1</sup>. People with PAD are limited by intermittent claudication (leg pain/discomfort) which significantly impairs walking capacity, physical activity levels and quality of life <sup>2-4</sup>. Reduced walking capacity and physical inactivity further contribute to the elevated risk of secondary cardiovascular events (stroke, myocardial infarction, cardiovascular death) and associated hospitalisation <sup>5–8</sup>. 

The initial treatment for PAD includes medical management of symptoms and cardiovascular disease risk factors with pharmacotherapies and lifestyle modification <sup>9</sup>. In patients with advanced PAD, including limiting claudication or chronic limb-threatening ischemia, lower limb revascularisation procedures are indicated to restore blood flow and 'save' the affected limb<sup>9</sup>. Lower limb revascularisation procedures are associated with improvements in limb blood flow <sup>10</sup>, walking capacity <sup>11</sup>, and quality of life <sup>12,13</sup>. However, despite improvements in limb blood flow, the improvements in walking capacity are generally only modest after lower limb revascularisation (~60% improvement) when compared with exercise therapy (~110%) <sup>14</sup>. Furthermore, the benefits of revascularisation for walking capacity and quality of life are short-lived, with prospective studies reporting deteriorations in walking capacity as early as 12 months after revascularisation <sup>15–17</sup>. Reintervention rates are also high in people with PAD with a meta-analysis of 52 studies (N=6,769 patients) reporting a reintervention rate of 18.2% (95%CI 14.5 – 22.6) at 12 months following endovascular revascularisation <sup>18</sup>. This highlights an important limitation of lower limb revascularisation procedures for the long-term durability, and improvement of walking capacity in patients with PAD. 

Supervised exercise is an effective therapy that is widely recommended in several international guidelines for the management of patients with PAD <sup>9,19–22</sup>. A large body of evidence suggests that supervised exercise programs, incorporating aerobic and resistance exercises of the lower limbs, improve walking capacity <sup>23–25</sup>, physical activity levels <sup>26,27</sup> and quality of life <sup>28,29</sup> in patients with PAD. A commonly used assessment of walking capacity for patients with PAD is the 6-minute walk test; and evidence shows gains in 6-minute walk distance ranging between 45-80 meters following supervised exercise programs <sup>26,30–34</sup>. Beyond the recommendation that supervised exercise should be included as part of the initial treatment of PAD, there is emerging evidence that outcomes following lower limb revascularisation can also be enhanced when combined with exercise therapy <sup>35–37</sup>. This aligns with a recent systematic review that reported significant improvements in maximum walking distance (mean difference range: 82-321 m) and pain-free walking distance (mean difference range: 38-408 m) favouring a combined therapy approach over supervised exercise training or revascularisation alone <sup>38</sup>. Post-revascularisation exercise therapy has also been associated with reduction in the need for reintervention when compared with revascularisation <sup>39</sup> or supervised exercise therapy alone (odds ratio 0.19 [95%CI 0.09 – 0.40] P<0.0001) <sup>40</sup>. 

### **BMJ** Open

Despite this strong evidence supporting the benefits of supervised exercise therapy, access to dedicated exercise programs is very limited for patients with PAD. Previous studies report that as few as 43-48% of vascular units in the United States and the United Kingdom have access to dedicated supervised exercise programs for the referral of patients with PAD<sup>41,42</sup>. Similarly, a survey of 378 vascular surgeons across 43 European countries reported that only 30% (N=115/378) of surgeons have access to supervised exercise programs for the referral of patients with PAD<sup>43</sup>. This highlights a need for alternative rehabilitation strategies and referral pathways to increase the access to supervised exercise therapy for patients with PAD. 

Cardiovascular rehabilitation is a well-established multidisciplinary approach for the care and rehabilitation of patients with heart disease, particularly those recovering from myocardial infarction or cardiac surgery <sup>44</sup>. Cardiovascular rehabilitation (CR) programs typically consist of supervised exercise training, dietary and lifestyle advice, psychological support, and education on the management of cardiovascular disease risk factors. Studies report that CR programs are cost-effective for improving functional capacity, physical activity levels and quality of life, and reducing the risk of secondary cardiovascular events in patients with cardiac diseases <sup>45–48</sup>. While CR programs are widely accessible in most countries, patients with PAD are historically seen as out of scope and are not usually referred for CR <sup>44,49</sup>. To date very few studies have investigated the effectiveness of routine CR for patients with PAD <sup>50–55</sup>. Most of these studies have been limited to the investigation of patients with coronary artery disease referred for CR who also had PAD as a comorbidity <sup>51–54</sup>. In Canada, of 23,215 patient referrals with coronary artery disease, 5.9% (N=1,366 patients) were identified as having a comorbidity of PAD <sup>51</sup>. The identified patients with PAD had significantly impaired cardiorespiratory fitness and a lower 10-year survival rate when compared with patients without PAD. Importantly, this study demonstrated that completion of CR led to significant reductions in mortality rate (adjusted hazard ratio 0.62 [95%CI 0.57 - 0.67]) in patients with PAD, when compared with patients who did not attend CR <sup>51</sup>. 

Recently, a small (N=20 participants), non-randomised pilot study of CR in patients who had undergone lower limb revascularisation for PAD, reported that CR was safe and feasible, and led to greater improvements in 6-minute walk distance (mean difference: 53 m; P=0.04) when compared with usual care <sup>56</sup>. These findings highlight the potential for CR to be used as a standard referral pathway for patients with PAD who are recovering from a lower limb revascularisation procedure. To test this, we will conduct a randomised-controlled trial to assess the efficacy of a 6-week community-based CR program versus usual care on walking capacity and quality of life in patients who have recently (< 12 months) undergone lower limb revascularisation for PAD. 

**Primary** aim 

To assess the efficacy of a 6-week community-based CR exercise program versus usual care on 6-minute walk distance in patients who have recently (< 12 months) undergone lower limb revascularisation for PAD. 

Secondary aims 

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

To assess the efficacy of a 6-week community-based CR exercise program on: 1) pain-free walking distance during the 6-minute walk test, 2) maximal walking time and pain-free walking time during a graded treadmill walking test, 3) cardiorespiratory fitness measured as peak oxygen uptake during a graded treadmill walking test, 4) disease-specific quality of life and self-reported functional capacity, and 5) self-reported and objectively measured physical activity levels. 

### **Exploratory** aims

To assess the efficacy of a 6-week community-based CR exercise program on: 1) brachial artery flow-mediated dilation, 2) arterial stiffness (augmentation index, carotid-femoral artery pulse wave velocity), 3) ankle-brachial blood pressure index, and 4) circulating biomarkers of cardiovascular disease risk. 

### 

### **METHODS AND ANALYSIS**

Study design and overview 

An overview of the study is shown in Figure 1. This is a single centre, prospective, parallel-group, randomised-controlled trial conducted at the University of the Sunshine Coast and the Sunshine Coast University Hospital (Australia). Patients with PAD who have recently ( < 12 months) undergone a lower limb revascularisation procedure will be identified and randomly allocated to either usual care or usual care plus a 6-week community-based CR program (N=33 per group; refer to power and sample size estimate). Participants allocated to the usual care group will receive usual care and medical advice from their local doctor and vascular surgeon. The community-based CR program will comprise two supervised exercise sessions per week for 6 weeks, home-based exercise advice, and an education seminar (5.5 hours). The CR program will be delivered by the Cardiovascular Rehabilitation Service of the Sunshine Coast University Hospital. Primary, secondary, and exploratory outcomes will be assessed at baseline (week 1), after the completion of the CR program / usual care period (week 8) and again 6 months after the completion of the CR program / usual care period (week 34). Maximal exercise assessments such as graded treadmill walking tests will be conducted at the Clinical Investigations Unit at the Sunshine Coast University Hospital to facilitate access to medical supervision. Other outcome measures will be conducted at the VasoActive Laboratory at the University of the Sunshine Coast. As per Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), a schedule of participant enrolment, intervention and assessments is presented in Table 1<sup>57</sup>. The study commenced in April 2024, and data collection is planned to be completed in January 2026. 

1 2 3		
3 4 5	221	Participants & eligibility criteria
6	222	Potential participants will be identified from the Sunshine Coast region through: 1) an existing
7 8	223	database of participants who have previously provided consent to be contacted, 2) collaborating
9	224	vascular surgery clinics including the Sunshine Coast University Hospital, and 3) community
10	225	sources and advertising.
11 12	225	
13	226	Participants will be eligible to participate in the study if they:
14 15	227	1. Are 18 years of age or older and have a formal diagnosis of PAD made by a vascular
16	228	surgeon.
17	229	2. Have undergone a lower limb revascularisation procedure (endovascular procedure,
18 19	230	open surgical procedure or hybrid procedure) in the previous 12 months.
20	231	3. Have clearance to participate from their treating vascular surgeon, including
21	232	verification that they have adequately recovered from any lower limb revascularisation
22 23	233	procedure.
23	234	4. Can understand and communicate in English sufficient to provide informed consent.
25	<b>7</b> 25	Participants will be avaluded from participation if they must any of the following criteria:
26 27	235	Participants will be excluded from participation if they meet any of the following criteria:
28	236	1. Unable to walk independently (e.g., depend on assistance from a walking aid).
29	237	2. Previous lower limb amputation or current tissue necrosis (ulceration or gangrene) that
30 31	238	limits the ability to undertake walking tests.
32	239	3. Deemed not eligible to participate in CR by the CR clinical staff as per standard
33	240	contraindications for exercise <sup>58</sup> . These contraindications include unstable angina, acute
34	241	heart failure, recent cerebrovascular event, uncontrolled resting hypertension,
35 36	242	symptomatic hypotension, uncontrolled diabetes, uncontrolled sinus tachycardia,
37	243	uncontrolled/complex arrythmias.
38	244	4. Currently participating in a supervised exercise rehabilitation program.
39 40	245	5. Terminal illness or other medical condition or planned treatment that may affect the
41	246	ability to participate in or complete the trial.
42	247	Intervention
43 44	247	Intervention
45	248	Eligible participants will be randomised in equal proportions (1:1) to one of the study groups.
46 47	249	1. Usual care (control group).
47	275	1. Osuar care (control group).
49	250	2. Usual care plus a 6-week community-based CR program (intervention group).
50		
51 52	251	Usual care
53		
54	252	All participants will continue to receive usual care and medical advice from their local doctor
55 56	253	and vascular surgeon throughout the study. Usual care for PAD may include management of
57	254	cardiovascular disease risk factors with lifestyle modifications (e.g., smoking cessation, dietary
58	255	modifications) and pharmacotherapies <sup>9</sup> . While usual care for PAD will not be altered by this
59 60	256	protocol, upon consent to the study each participant's local doctor and vascular surgeon will
00		

Page 7

### BMJ Open

be contacted to request to provide their best possible medical care throughout the study.
Furthermore, in order to assess the efficacy of the CR program, each participant's local doctor
and vascular surgeon will be requested to refrain from giving specific advice regarding exercise
until the completion of the study.

# 1011 261 Usual care plus community-based CR program

In addition to usual care, participants who are randomised to the community-based CR program will be referred to the CR program of the Sunshine Coast Hospital and Health Service. The CR program will be delivered at a community fitness facility (The Sports Hub, Bokarina, QLD 4575, Australia). The CR program will be structured in accordance with current exercise recommendations for people with PAD <sup>9,19–22</sup>. The CR program will include twelve 60-minute sessions of supervised exercises, delivered twice per week over a period of 6 weeks, and one education seminar (5.5 hours with breaks). While the recommended duration of supervised exercise training for patients with PAD is 12 weeks <sup>19,20</sup>, improvements in walking capacity are reported after 3-6 weeks <sup>59-61</sup>. Furthermore, the recommended duration for CR ranges between 6-12 weeks <sup>62</sup>. To ensure outcomes are applicable to a wide range of CR programs, the minimum duration for CR was selected (i.e., 6 weeks). During the 6-week CR program participants will also be provided with exercise guidelines and advice to complete at least three home-based walking sessions per week. Following the completion of the CR program, participants will be provided with individualised exercise and physical activity advice with the goal to meet the recommended 150-300 minutes of moderate intensity physical activity levels per week 58. 

The program exercise sessions will be supervised by CR staff (nurses, exercise physiologist) and research personnel. The research personnel will be responsible for the prescription and progression of the exercises. As outlined in the Supplementary Table 1, the supervised exercise sessions will primarily consist of bouts of intermittent treadmill walking that are interspersed by periods of upper body activity and lower limb resistance exercises. Each supervised exercise session will last for 60 minutes, including a warm-up and a cool-down (10 minutes each). The total duration of treadmill walking for each session will be 10 minutes (e.g., 5 x 2-minute bouts) at the beginning of the program (i.e., week 1) and will progress to 30 minutes (e.g., 15 x 2-minute bouts) by the end of the program (i.e., week 6). The total duration of upper body and lower limb resistance training for each session will begin at 30 minutes (e.g., 15 x 2-minute bouts) at the beginning of the program and will decrease to 10 minutes (e.g., 5 x 2-minute bouts) by the end of the program. Exercise intensity and severity of claudication pain will be monitored with the modified rate of perceived exertion Borg scale and the intermittent claudication pain scale, respectively <sup>63,64</sup>. Participants will be instructed to exercise at moderate to near-maximal claudication pain thresholds (i.e., 3/4 on claudication scale) or if asymptomatic, exercise at a moderate exercise intensity (i.e., 3/10 on Borg scale) <sup>19,65</sup>. The initial exercise intensity will be individually prescribed based on the exercise workload achieved during the baseline exercise tests (e.g., workload achieved at stage prior to treadmill test cessation). 

### **BMJ** Open

The home-based walking sessions will also align with the current PAD exercise recommendations 9,19-22. Participants will be provided with individualised weekly walking goals which will be set and reviewed by the study team. During the home-based walking sessions, participants will be instructed to complete intermittent bouts of walking separated by periods of rest. Participants will be instructed to complete their walking sessions outdoors (e.g., local neighbourhood and parks). Similar to the supervised exercise sessions, the total duration of walking for each home-based session will begin at 10 minutes (e.g., 5 x 2-minute bouts) at the beginning of the program (i.e., week 1) and will progress to 30 minutes (e.g., 15 x 2-minute bouts) by the end of the program (i.e., week 6). The total period of rest for each home-based walking session will be 20 minutes at the beginning of the program (e.g., 10 x 2-minute bouts) and will decrease until participants are able to walk continuously for 30 minutes. Exercise intensity and severity of claudication pain will be self-monitored using the modified rate of perceived exertion Borg scale, and the intermittent claudication pain scale <sup>63,64</sup>. Participants will be instructed to walk at moderate to near-maximal claudication pain thresholds (i.e., 3/4 on claudication scale) or if asymptomatic, walk at a moderate exercise intensity (i.e., 3/10 on Borg scale) <sup>19,65</sup>. Participants will be provided with a diary to record their home-based walking sessions. 

Participants in the CR program will attend one education seminar (5.5 hours with breaks) during the 6-week CR program. The education seminar will be delivered by health specialists (e.g., nurse, dietitian, psychologist, exercise physiologist) and will cover topics such as diet, medications, exercise training, physical activity, and lifestyle modifications for the management and prevention of cardiovascular diseases. The seminar information will be based on the current Australian guidelines for the management of acute coronary syndromes <sup>66–68</sup>. 

### Adherence

Strategies are incorporated into the protocol to promote and monitor adherence to the study intervention. The importance of attending the weekly supervised exercise sessions and accumulating the recommended weekly amount of exercise and physical activity levels will be explained to the participants in the participant information and consent form (PICF) and upon starting the CR program. Participants will also be provided with individualised weekly goals for the supervised and the home-based exercise sessions which will be set and reviewed by the study team. Adherence to the supervised and home-based exercise sessions will be assessed by recording the number of exercise sessions that participants complete each week against the goal/target for that specific week. Participants will keep a daily diary to record their home-based exercise sessions that they complete during the 6-week CR program. Attendance to the education seminar will be assessed using an attendance checklist. The assessment of protocol adherence for the purpose of statistical analysis is described in the statistical analysis section. 

Screening and enrolment (visit 1) 

Prior to screening assessments, participants will be required to provide their informed consent to participate in the study which will occur at the commencement of the initial study visit (visit 1). A trained study staff member authorised by the Principal Investigator will take the 

### BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

participant through the information sheet and obtain informed consent. All participants will be
fully informed of the potential risks and benefits of the study. Participants will be screened for
co-morbidities and cardiovascular risk factors prior to inclusion in the study. During this visit,
prescribed medications will be captured, and anthropometric measurements (e.g., height,
weight) and resting blood pressure will be conducted. Participants will also be familiarised
with the 6-minute walk test to minimise test variability.

## 13343Randomisation and blinding

Following baseline outcome measures (i.e., visit 3), participants will be randomly allocated to either the usual care group (N=33) or the usual care plus community-based CR exercise group (N=33). To ensure allocation concealment, randomisation will be generated using a secure, independent web-based randomisation system (SealedEnvelope.com). Prior to randomisation, participants will be stratified to account for type of procedure (e.g., open surgical vs endovascular procedure) and time since procedure (<12 weeks vs > 12 weeks). This will allow stratification of participants who have recently undergone a revascularisation procedure (< 12) weeks) from those who have undergone a revascularisation procedure more than 12 weeks ago and have fully resumed normal activities of daily living, recreation, and work activities. Block randomisation, using random block sizes of two to four participants will be used to ensure that group allocation at any point in time remains similar. Enrolment, allocation, follow-up, and final analysis will be conducted and reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement for randomised clinical trials <sup>69</sup>. 

The same investigators who will deliver the CR program will also be involved in the collection of outcome data. Therefore, participants and data collectors will not be blinded to group allocation. While it is not feasible to blind participants and investigators to group allocation in an exercise intervention study, all data analysis will be undertaken in blinded fashion using coded data. 

# 40<br/>41362Outcome measures and procedures

As outlined in Table 1, primary, secondary, and exploratory outcomes will be assessed at baseline (week 1), after the completion of the 6-week CR program / usual care period (week 8) and again 6 months after the completion of the CR program / usual care period (week 34). During weeks 1 and 8, participants will carry out the assessments over two visits to ensure that participants are sufficiently recovered between walking tests. As the treadmill test is a secondary outcome measure, participants will be given the option to opt out of performing this test. The treadmill test requires participants to walk until maximal exertion. Although this is an important outcome measure, only 34 participants are required to establish an effect (refer to power and sample size estimate). Therefore, participants who are unwilling to exert themselves to maximal effort, or those who are unable to maintain the walking speed of the treadmill will be given the option to opt out of this test. At 6-month follow-up (week 34) participants will make a single visit for the assessment of the 6-minute walking test, quality of life, self-reported functional capacity, physical activity levels, vascular function, and biomarkers of cardiovascular disease risk. The 6-month follow-up visit aims to provide an indication of 

BMJ Open

BMJ Open

377 longer-term durability of the effect of CR following revascularisation. For the post-intervention
378 and follow-up assessments at weeks 8 and 34, the assessment window may be extended by up
379 to 7 days to accommodate unforeseen circumstances (e.g., participant illness).

- 9 380 **Primary outcome**
- 11 381 Six-minute walk test (6MWT):

The 6MWT will be conducted at weeks 1, 8, and 34. Change in 6-minute walk distance between
baseline and week 8 is the primary outcome for the study. Change in the pain-free walking
distance during the 6MWT is a secondary outcome measure.

As per standard procedures, a course of 30 meters length is marked out in a covered area at least 2 meters in width, with a cone at each end 70. Chairs are also placed every 10 meters along the course so that participants can sit and rest during the test if needed. Participants will be asked to walk up and down the course for 6 minutes and to complete as many laps and cover as much distance as possible in that time. Participants will be asked to indicate to the test supervisor when the onset of claudication occurs, and then to rate the severity of their claudication/discomfort using a hand-signal at the completion of each lap (i.e., every 60 meters) using the claudication rating scale <sup>64</sup>. During the test, heart rate will be continually monitored with a heart rate monitor and recorded at the end of each lap. During the test, participants can stop walking and rest if their claudication pain becomes intolerable; however, the timing continues and participants are requested to resume walking as soon as possible. At the end of the test, the number and timing of any rest breaks, the time and distance to the onset of claudication (pain-free walking distance) and the total distance walked (6-minute walk distance) are recorded. At the end of the test, participants will be asked to provide a rating of their general exertion using the modified rate of perceived exertion Borg Scale <sup>63</sup>. 

Walking capacity measured during the 6MWT has been chosen as the primary outcome as it has excellent test-retest reliability (interclass correlation coefficient = 0.970, 95% confidence intervals 0.950 to 0.981, N=173)<sup>71</sup>, and it correlates strongly with a range of relevant clinical outcomes including physical activity <sup>72</sup>, patient-reported outcomes, as well as cardiovascular morbidity and mortality associated with PAD <sup>7</sup>. Based on this strong reliability, a reported advantage of the 6MWT for clinical trials is that there is no learning effect <sup>73</sup>. Nonetheless, participants will be familiarised with the 6MWT prior to the baseline assessment in the current study. This approach is consistent with recommended practice and reporting of performance outcomes for clinical trials in patients with PAD 74. The minimal clinically important difference (MCID) for 6-minute walk distance has been established for people with and without PAD. Based on the change in 6-minute walk distance with exercise therapy and the corresponding change in reported physical function, the MCID thresholds are 12 meters (small effect), 32 meters (moderate effect), and 34 meters (large effect) <sup>75</sup>. 

- 56 413 Secondary outcome measures
   57
- 58 414 Graded treadmill walking test:

### BMJ Open

The graded treadmill walking test including measures of maximum walk time and pain-free walking time will be performed at weeks 1 and 8. The Gardner-Skinner protocol will be used, which was specifically developed for the assessment of walking capacity in patients with PAD <sup>76,77</sup>. The treadmill will start at 3.2 km/h at a 0% incline, and then every 2 minutes the gradient of the treadmill will increase by 2%. Adjustments will be made to the treadmill protocol using standardised procedures for participants who are unable to maintain the 3.2 km/h treadmill speed. The treadmill test will be conducted and supervised by an exercise physiologist, a cardiac technician, and a medical doctor. During the test participants will be monitored with a continuous 12-lead electrocardiogram, and heart rate and blood pressure will be measured and recorded at the end of each stage (i.e., every 2 minutes). At the end of the test, participants will be asked to rate the severity of their claudication pain in each leg using the claudication scale, and to provide a rating of their general exertion using the modified rate of perceived exertion Borg scale <sup>63</sup>. The MCID values for small, moderate and large changes in maximum treadmill walking time after supervised exercise training are 121, 141, and 241 (seconds), respectively, in patients with PAD <sup>75</sup>. 

5 430 Cardiorespiratory fitness:

Cardiorespiratory fitness (peak oxygen uptake) will be assessed during the graded treadmill walking test at weeks 1 and 8. Cardiorespiratory fitness is a strong predictor of cardiovascular disease and all-cause mortality rates in patients with PAD <sup>78,79</sup>. Oxygen uptake (VO<sub>2</sub>) will be continuously measured with a portable VO<sub>2</sub> system (K5, COSMED, Italy), and a breath-by-breath gas exchange and ventilation face mask. Peak oxygen uptake will be determined as the highest 15-second average during the final 60 seconds of peak exercise. 

3536 437 Quality of life:

Disease-specific quality of life will be assessed using the Intermittent Claudication Questionnaire (ICQ) at weeks 1, 8 and 34. The ICQ is a self-administered tool consisting of 16 items that focus on limitations imposed by claudication while performing various tasks, such as walking specific distances or performing activities of daily living <sup>80</sup>. The instrument is scored by summing the patient responses to individual items, which are all equally weighted, and transformed to a 0 to 100 composite score, where 0 is the best score. The composite score will be calculated and used as the outcome for analysis. 

<sup>47</sup><sub>48</sub> 445 Self-reported walking capacity:

Self-reported walking capacity will be assessed using the Walking Impairment Questionnaire (WIQ) at weeks 1, 8 and 34. The WIQ is a PAD-specific measure of self-reported difficulty during walking with 3 domains: walking distance, walking speed, and stair climbing <sup>81</sup>. Each domain is scored on a scale from 0 to 100 (100 indicating the best possible score). A small, moderate, and large MCID for each of the three WIQ domain scores are: 6, 14, 23 for walking distance; 4, 11, 18 for walking speed; and 6, 15, 23 for stair climbing, respectively <sup>75</sup>. 

58 452 Physical activity levels:59

# **BMJ** Open

Objectively assessed physical activity: Free living physical activity levels will be objectively assessed using a GT9XActiGraph accelerometer (ActiGraph, Pensacola, FL, USA) at weeks 1, 8 and 34. Participants will be instructed to wear the device on their non-dominant wrist for 7 full days at each assessment point <sup>82</sup>. At the end of the recording period, the accelerometer is removed by the participant and returned to the research team (in person or by reply-paid delivery) for data upload, quality assurance and analysis. The ActiGraph accelerometer will be initialised to collect raw data at 100 Hz<sup>83</sup>. The in-built inclinometer will also enable the assessment of body position (i.e., sitting/lying vs standing). At each assessment period, a minimum wear-time criteria of 4 days and 600 minutes per day will be applied <sup>84</sup>. The ActiLife software (version 6.13.5; AcriGraph LLC) will be utilised to process the raw data to create 60-second epochs<sup>83</sup>. The data will be processed using the Choi algorithm within the ActiLife software to define wear and non-wear minutes <sup>85</sup>. The primary outcome measure of physical activity will be steps per day. Other outcome measures will include sedentary time, and time spent (mins/day) engaging in light, moderate and vigorous physical activity. During the 7-day monitoring period, participants will also keep a brief daily physical activity diary to record periods of sleep, work, non-wear time, and structured exercise that are essential for analysis and cannot be inferred from the monitor data alone. The ActiGraph accelerometer has been reported to be reliable and valid in the assessment of walking, body posture, and sedentary behaviour during free-living activity <sup>86–88</sup>, and when used in patients with PAD <sup>89–91</sup>. The MCID values for small, moderate and large changes in total daily steps after supervised exercise training are 569, 1,423 and 2,277 (steps/day), respectively, in patients with PAD <sup>92</sup>. 

Self-reported physical activity: Self-reported physical activity levels will be assessed using the International Physical Activity Questionnaire for elderly (IPAQ-E) at weeks 1, 8 and 34. The IPAQ-E is a self-reported questionnaire which has been validated for use for individuals over the age of 65 93. The IPAQ-E consists of questions about frequency (days per week) and time (minutes per day) spent sitting, walking, and performing physical activities of moderate and vigorous intensity. All self-reported activity domains (sitting, walking, moderate and vigorous physical activities) have been reported to positively correlate with corresponding variables objectively assessed by accelerometers <sup>93</sup>. 

**Exploratory outcomes** 

Ankle to brachial blood pressure index (ABI): 

The ABI of both legs will be measured at weeks 1, 8 and 34. After resting in a supine position for 10 minutes, brachial and ankle blood pressures will be measured. Brachial blood pressures will be measured in both arms using an automated blood pressure monitor <sup>94</sup>. Systolic blood pressure of the dorsalis pedis artery and posterior tibial artery at the left and right ankles will also be measured using a manual cuff sphygmomanometer and handheld 5-7 MHz Doppler ultrasound probe. The average of the closest two recordings at each artery will be recorded. The ABI for each leg will be calculated by dividing the higher dorsalis pedis artery or posterior tibial artery value by the highest brachial artery value obtained from either side <sup>59</sup>. 

Brachial artery flow-mediated dilation (FMD): 

#### **BMJ** Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Brachial artery FMD will be measured in response to a reactive hyperaemia test (cuff occlusion) at weeks 1, 8 and 34. Brachial artery FMD is an independent predictor of cardiovascular events in patients with PAD 95. As per standard procedures 96, brachial artery FMD will be measured with participants in the supine position after 10 minutes of rest. This measurement will involve a rapid inflation of a pressure cuff positioned at the forearm. A 10-MHz multi-frequency linear array probe, attached to a high-resolution ultrasound machine (Terason, Burlington, US) will be used to image the brachial artery (2 cm proximal to the elbow). The ultrasound settings will be optimised for each individual and will be kept constant between all assessments. Continuous Doppler velocity will also be obtained using the ultrasound at an insolation angle of 60°. Following baseline assessments, reactive hyperaemia will be induced by inflating the cuff to 200 mmHg for 5 minutes. Artery diameter and flow recordings will resume 30 seconds before cuff deflation and continue for 3 minutes thereafter <sup>97</sup>. Brachial artery FMD will be expressed as a relative change (percent change) in peak arterial diameter from baseline (pre cuff inflation) to post cuff deflation. The analysis of the brachial artery FMD will be undertaken using a continuous edge-detection and wall-tracking software. 

Arterial stiffness: 

Arterial stiffness outcomes incorporate measures of augmentation index (AIx) and carotid-femoral artery pulse wave velocity (PWV) and will be assessed at weeks 1, 8 and 34. Arterial stiffness is an independent predictor of cardiovascular disease and all-cause mortality rates in patients with PAD <sup>98,99</sup>. After resting in the supine position for 10 minutes, brachial artery pulse waves will be obtained by partially inflating a cuff over the right brachial artery using a SphygmoCor XCEL system (AtCor Medical Pty Ltd, Sydney, Australia) and following standard guidelines (100,101). The brachial waveforms will be used to generate central aortic pressure waveforms, and to determine AIx, which is the ratio of wave reflection amplitude relative to central pulse pressure. For the PWV assessment, the carotid-femoral PWV will be measured using the applanation tonometry technique. A hand-held tonometer probe (AtCor Medical Pty Ltd, Sydney, Australia) will be held against the skin surface over the right carotid artery to obtain carotid-artery pulse waves, and a pressure cuff will be placed around the right upper thigh to record femoral artery pulse waves. The distance from the carotid site above the suprasternal notch to the proximal edge of a thigh cuff over the femoral artery will be measured using a tape measure over the body area. The carotid and femoral pulse waves will be recorded simultaneously, and the femoral pulse wave requires the thigh cuff to be partially inflated. The PWV will then be automatically calculated as the ratio of the distance between the pulse measuring sites to the time delay between the carotid and femoral pulse waves. PWV will be recorded as the average of triplicate measurements. 

Biomarkers of cardiovascular disease (CVD) risk: 

Biomarkers of CVD risk will be assessed at weeks 1 and 34. The most recent blood test (within 8 weeks of baseline and within 8 weeks of follow-up visit) will be retrieved from the medical records of each participant. Biomarkers of CVD risk will include total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, and haemoglobin A1c levels. 

### BMJ Open

BMJ Open

# 533 Sample size calculations

534 Sample size calculations were conducted for the primary outcome 6-minute walk distance and
535 the secondary outcome maximal walking time during the graded treadmill walking test.

10 536 6MWT:

Previous studies that assessed the effects of post-revascularisation exercise therapy indicated a potential effect of 53.2 m with a standard deviation of 81 m for 6-minute walk distance <sup>56,102</sup>. This would provide a medium effect size of 0.65. To establish this effect from baseline to week 8 with 80% power and an alpha 0.05, 30 participants would be required in each group. Allowing for 10% dropout, 33 participants will be recruited in each group (total N=66). 

19 542 Graded treadmill walking test:20

A previous study that assessed the effects of post-revascularisation exercise therapy indicated a potential effect of 5 minutes and 46 seconds with a standard deviation of 6 minutes and 13 seconds for maximal walking time during the graded treadmill walking test <sup>37</sup>. This would provide a large effect size of 0.89. To establish this effect from baseline to week 8 with 80% power and an alpha 0.05, 17 participants would be required in each group (total N=34). As this outcome of maximal walking time during the treadmill test is a secondary outcome, participants will be given the option to opt out of performing this test during the trial. 

### 31 550 Statistical analysis

Data analysis will follow the CONSORT statement for randomised-controlled trials <sup>69</sup>. All data collected will be deidentified and coded throughout the trial. The data collected will remain coded for participant confidentiality purposes. Baseline data for the two groups will be provided using counts and percentages, and means and standard deviations (or non-parametric equivalents) for categorical variables. Furthermore, tables will show the outcome measures at weeks 8 and 34 and percent changes from baseline. 

The primary analysis will be performed based on the intention-to-treat principle, where all participants will be analysed as per their allocation, regardless of the treatment they received. Non-adherence will be assessed through per-protocol analyses. Per protocol analysis will primarily include participants that attend at least 70% of the supervised CR exercise sessions (i.e., 9 exercise sessions overall) during the 6-week intervention period. The total number of supervised exercise sessions completed will be included in the analysis as a covariate. 

Statistical analyses will be conducted using the IBM SPSS software (SPSS Inc, Chicago, IL). The data will be tested for normality using the Shapiro-Wilk test and will be considered normally distributed when P > 0.05. Analyses will be conducted using analysis of variance (ANOVA) for repeated measures. The primary comparison will be change in 6-minute walk distance from baseline to post intervention (week 8) in the CR versus the usual care group. Additional analyses will be performed from baseline to 6-month follow-up timepoint (week 34). As required, confounding variables (including comorbidities, age, sex, smoking behaviour, medications) will be adjusted for using analysis of covariance (ANCOVA). In all analyses, P 

#### BMJ Open

Page 16 of 29

< 0.05 will be considered statistically significant. Post-hoc analysis will be performed when a</li>
 significant effect is present.

# 573 Data management

All data collected during the study will be coded and stored for a minimum of 15 years. Prospective participants will initially be assigned a screening number, and upon consent into the study they will be assigned a participant identification code. A coding log will be maintained and kept in a secure location (hard copy in locked cabinet and electronic copy on password protected file) in accordance with the International Council on Harmonisation Good Clinical Practice (GCP) guidelines, the study data management plan, and the data security policy of the University of the Sunshine Coast. The only personnel who will have access to participants' individual identity are the Principal Investigator (CDA) and authorised project staff. Access to the coding log would only occur in the case where further medical history information is required in relation to a specific participant, in cases of emergency (e.g., to identify and contact next of kin), or during the investigation of any events (e.g., serious adverse event). 

All individual participant information will be de-identified in the reporting of data and resulting publications or presentations to fully protect the confidentiality of participants. Participants will be informed in the PICF that information or reports from the study will be prepared and will be submitted for publication. Participant information will normally be presented as group data. If necessary, information obtained from specific individuals may be presented; however, names will not be used to identify the individuals. Participants will only be identified in such publications by an identification number and possibly their age and gender. 

# <sup>36</sup> <sup>37</sup> <sup>36</sup> Adverse events

Information on all adverse events (study-related and non-study related) will be recorded immediately in the trial adverse event report form and in the appropriate case report form for the relevant participant. All clearly related signs, symptoms, and abnormal procedural results will be recorded. For all recorded adverse events, the Principal Investigator or delegate will determine the adverse event's causality to the intervention and the severity or intensity of the event. The clinical course of each event will be followed until resolution, stabilisation, or until it has been determined that the study intervention or participation is not the cause. All logged events will be summarised and reported to the participant's general practitioner and the relevant human research ethics committees and governance agencies as part of the reporting requirements. 

52 604 

# 605 PATIENT AND PUBLIC INVOLVEMENT 55

- 606 No patient and public involvement.

### 60 608 ETHICS AND DISSEMINATION

Page 17 of 29

**BMJ** Open

**BMJ** Open

This study has received ethics approval from the Human Research Ethics Committees (HREC) of Queensland Health Metro North Hospital and Health Service (94155), and the University of the Sunshine Coast (S231914). Any protocol amendments will be submitted to the aforementioned HREC for approval. Findings from this study will be disseminated in peer-reviewed journals and through national and international conference presentations. 

#### **AUTHORS' CONTRIBUTION**

CDA is the guarantor for the study and takes overall responsibility. KF and CDA conceptualised the study protocol and are responsible for ethical approvals. JJS assisted with protocol development and is responsible for physical activity outcomes. PJ has oversight of participant screening recruitment and the main study site. KF and MA will be responsible for the delivery of the cardiovascular rehabilitation intervention. KF will be involved in the collection of all outcome data. CDA, TS, and MS will provide oversight of data collection including the supervision of trial personnel and will support the analysis and interpretation of findings. All authors critically reviewed the study protocol and provided input to all aspects of the design and plan. All authors reviewed and edited the manuscript and approved the final version. The Saving Legs & Lives Trial Group consists of clinical investigators who are responsible for the screening and recruitment of participants and will provide support during data collection and data analysis activities including the delivery of the cardiovascular rehabilitation intervention. 4.6 

#### **FUNDING STATEMENT**

This work is supported by a Sunshine Coast Health Institute (SCHI) Collaborative Seed Grant Scheme (Grant ID number: 2020-01) awarded to CDA (Principal Investigator). KF is supported by a collaborative University of the Sunshine Coast and Sunshine Coast Hospital and Health Service scholarship as well as a PhD Top-Up Scholarship Award from the Queensland Cardiovascular Research Network (QCVRN). The aforementioned funders had no input in the design of the study and will have no role in the collection, management, analysis, and interpretation of the data or decision to submit this work for publication. 

#### **COMPETING INTERESTS STATEMENT**

The authors declare no competing interests. 

#### REFERENCES

Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and 1. national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019 Aug;7(8):e1020-30. 

Gardner AW, Montgomery PS, Scott KJ, Afaq A, Blevins SM. Patterns of ambulatory activity 2. in subjects with and without intermittent claudication. J Vasc Surg. 2007 Dec;46(6):1208–14. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, et al. The ankle 3. brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002 Jun 18;136(12):873-83. 4. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med Lond Engl. 2008 Feb;13(1):15-24. 5. Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis. 2020 Jan;293:94-100. 6. Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, et al. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust. 2012 Feb 20;196(3):193-7. McDermott MM, Greenland P, Tian L, Kibbe MR, Green D, Zhao L, et al. Association of 6-7. Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. J Am Heart Assoc. 2015 Jul 28;4(7). 8. Gardner AW, Addison O, Katzel LI, Montgomery PS, Prior SJ, Serra MC, et al. Association between Physical Activity and Mortality in Patients with Claudication. Med Sci Sports Exerc. 2021 Apr 1;53(4):732–9. 9. Nordanstig J, Behrendt CA, Baumgartner I, Belch J, Bäck M, Fitridge R, et al. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2023 Nov 8;S1078-5884(23)00741-4. 10. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology. 1993 Jan;44(1):1–10. 11. Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018 Mar 8;3(3):CD010512. Je HG, Kim BH, Cho KI, Jang JS, Park YH, Spertus J. Correlation between Patient-Reported 12. Symptoms and Ankle-Brachial Index after Revascularization for Peripheral Arterial Disease. Int J Mol Sci. 2015 May 18;16(5):11355-68. Devine EB, Alfonso-Cristancho R, Yanez ND, Edwards TC, Patrick DL, Armstrong CAL, et 13. al. Effectiveness of a Medical vs Revascularization Intervention for Intermittent Leg Claudication Based on Patient-Reported Outcomes. JAMA Surg. 2016 Oct 19;151(10):e162024. Perkins JMT, Collin J, Creasy TS, Fletcher EWL, Morris PJ. Reprinted Article "Exercise 14. Training Versus Angioplasty for Stable Claudication. Long and Medium Term Results of a Prospective, Randomised Trial". Eur J Vasc Endovasc Surg. 2011 Sep 1;42:S41-5. 

### **BMJ** Open

3			
4 5 6 7	687 688 689	15.	van Hattum ES, Tangelder MJD, Lawson JA, Moll FL, Algra A. The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up. J Vasc Surg. 2011 Mar;53(3):643–50.
8 9 10 11	690 691 692	16.	Wann-Hansson C, Hallberg IR, Risberg B, Lundell A, Klevsgard R. Health-related quality of life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J Adv Nurs. 2005 Aug;51(3):227–35.
12 13 14 15 16 17	693 694 695 696	17.	Djerf H, Millinger J, Falkenberg M, Jivegård L, Svensson M, Nordanstig J. Absence of Long- Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv. 2020 Jan;13(1):e008450.
18 19 20 21	697 698 699	18.	Mustapha JA, Finton SM, Diaz-Sandoval LJ, Saab FA, Miller LE. Percutaneous Transluminal Angioplasty in Patients With Infrapopliteal Arterial Disease: Systematic Review and Meta-Analysis. Circ Cardiovasc Interv. 2016 May;9(5):e003468.
22 23 24 25	700 701 702	19.	Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, et al. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019 Jan 22;139(4):e10–33.
26 27 28 29	703 704 705	20.	Askew CD, Parmenter B, Leicht AS, Walker PJ, Golledge J. Exercise & Sports Science Australia (ESSA) position statement on exercise prescription for patients with peripheral arterial disease and intermittent claudication. J Sci Med Sport. 2014 Nov;17(6):623–9.
30 31 32 33	706 707 708	21.	Tew GA, Harwood AE, Ingle L, Chetter I, Doherty PJ. The bases expert statement on exercise training for people with intermittent claudication due to peripheral arterial disease. Sport Exerc Sci. 2018.
<ul> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> </ul>	709 710 711 712 713 714 715 716	22.	Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763–816.
44 45 46 47	717 718 719	23.	Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med Auckl NZ. 2015 Feb;45(2):231–44.
48 49 50	720 721	24.	Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD000990.
51 52 53	722 723	25.	Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 Sep 27;274(12):975–80.
54 55 56 57 58 59	724 725 726 727	26.	Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc. 2001 Jun;49(6):755–62.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746	<ol> <li>28.</li> <li>29.</li> <li>30.</li> <li>31.</li> <li>32.</li> <li>33.</li> </ol>	<ul> <li>Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med Lond Engl. 2015 Feb;20(1):30–40.</li> <li>Lanzi S, Calanca L, Berchtold A, Mazzolai L. Improvement in 6-Minute Walking Distance after Supervised Exercise Training Is Related to Changes in Quality of Life in Patients with Lower Extremity Peripheral Artery Disease. J Clin Med. 2021 Jul 28;10(15).</li> <li>Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg. 2012 May;55(5):1346–54.</li> <li>Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity progressive resistance training improves flat-ground walking in older adults with symptomatic peripheral arterial disease. J Am Geriatr Soc. 2013 Nov;61(11):1964–70.</li> <li>Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med. 2002 Nov;252(5):448–55.</li> <li>McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent</li> </ul>
734 735 736 737 738 739 740 741 742 743 744 745 746	<ul><li>30.</li><li>31.</li><li>32.</li></ul>	<ul> <li>after Supervised Exercise Training Is Related to Changes in Quality of Life in Patients with Lower Extremity Peripheral Artery Disease. J Clin Med. 2021 Jul 28;10(15).</li> <li>Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg. 2012 May;55(5):1346–54.</li> <li>Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity progressive resistance training improves flat-ground walking in older adults with symptomatic peripheral arterial disease. J Am Geriatr Soc. 2013 Nov;61(11):1964–70.</li> <li>Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med. 2002 Nov;252(5):448–55.</li> <li>McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise</li> </ul>
737 738 739 740 741 742 743 743 744 745 746	31. 32.	<ul> <li>claudication. J Vasc Surg. 2012 May;55(5):1346–54.</li> <li>Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity progressive resistance training improves flat-ground walking in older adults with symptomatic peripheral arterial disease. J Am Geriatr Soc. 2013 Nov;61(11):1964–70.</li> <li>Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med. 2002 Nov;252(5):448–55.</li> <li>McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise</li> </ul>
739 740 741 742 743 744 745 746	32.	<ul> <li>progressive resistance training improves flat-ground walking in older adults with symptomatic peripheral arterial disease. J Am Geriatr Soc. 2013 Nov;61(11):1964–70.</li> <li>Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med. 2002 Nov;252(5):448–55.</li> <li>McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise</li> </ul>
742 743 744 745 746		on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. J Intern Med. 2002 Nov;252(5):448–55. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise
745 746	33.	
747		claudication: a randomized controlled trial. JAMA. 2009 Jan 14;301(2):165–74.
748 749 750	34.	Whipple MO, Burt MA, Pergolski AL, McArthur P, Treat-Jacobson D, Salisbury DL. Uptake and outcomes of supervised exercise therapy for peripheral artery disease: The importance of vascular medicine specialists at a large midwestern health care system during the first 5 years of CMS reimbursement. Vasc Med Lond Engl. 2024 Apr;29(2):112–9.
751 752 753 754	35.	Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial. JAMA. 2015 Nov 10;314(18):1936– 44.
755 756 757	36.	Badger SA, Soong CV, O'Donnell ME, Boreham CAG, McGuigan KE. Benefits of a supervised exercise program after lower limb bypass surgery. Vasc Endovascular Surg. 2007 Mar;41(1):27–32.
758 759 760	37.	Kruidenier LM, Nicolaï SP, Rouwet EV, Peters RJ, Prins MH, Teijink JAW. Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a randomized clinical trial. J Vasc Interv Radiol JVIR. 2011 Jul;22(7):961–8.
761 762 763 764	38.	Menêses AL, Ritti-Dias RM, Parmenter B, Golledge J, Askew CD. Combined Lower Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial Disease: A Systematic Review of Randomised Controlled Trials. Sports Med Auckl NZ. 2017 May;47(5):987–1002.
766	39.	Mazari FAK, Khan JA, Carradice D, Samuel N, Abdul Rahman MNA, Gulati S, et al. Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg. 2012 Jan;99(1):39–48.
	756 757 758 759 760 761 762 763 764 765	756         757         758       37.         759         760         761       38.         762         763         764         765       39.         766         767

# BMJ Open

2 3			
4 5 6 7 8	769 770 771 772	40.	Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, et al. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2017 Apr 10;10(7):712–24.
9 10 11 12 13	773 774 775	41.	Dua A, Gologorsky R, Savage D, Rens N, Gandhi N, Brooke B, et al. National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. J Vasc Surg. 2020 May;71(5):1702–7.
13 14 15 16 17	776 777 778	42.	Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exercise services in patients with peripheral artery disease in the United Kingdom. Vascular. 2022 Oct;30(5):874–81.
18 19 20 21	779 780 781	43.	Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2012 Dec;44(6):569–75; discussion 576.
22 23 24	782 783	44.	Supervia M, Turk-Adawi K, Lopez-Jimenez F, Pesah E, Ding R, Britto RR, et al. Nature of Cardiac Rehabilitation Around the Globe. EClinicalMedicine. 2019 Aug;13:46–56.
25 26 27 28	784 785 786	45.	Martin BJ, Arena R, Haykowsky M, Hauer T, Austford LD, Knudtson M, et al. Cardiovascular fitness and mortality after contemporary cardiac rehabilitation. Mayo Clin Proc. 2013 May;88(5):455–63.
29 30 31 32	787 788 789	46.	Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023 Feb 7;44(6):452–69.
33 34 35 36 37	790 791 792 793	47.	Tegegne TK, Rawstorn JC, Nourse RA, Kibret KT, Ahmed KY, Maddison R. Effects of exercise-based cardiac rehabilitation delivery modes on exercise capacity and health-related quality of life in heart failure: a systematic review and network meta-analysis. Open Heart. 2022 Jun;9(1).
38 39 40 41 42 42	794 795 796 797	48.	Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise- based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. Eur J Heart Fail. 2018 Dec;20(12):1735–43.
43 44 45 46 47	798 799 800	49.	Ahden S, Ngo V, Hoskin J, Mach V, Magharious S, Tambar A, et al. Inclusion of People With Peripheral Artery Disease in Cardiac Rehabilitation Programs: A Pan-Canadian Survey. Heart Lung Circ. 2021 Jul;30(7):1031–43.
48 49 50 51 52	801 802 803 804	50.	Siercke M, Jørgensen LP, Missel M, Thygesen LC, Møller SP, Sillesen H, et al. Cardiovascular Rehabilitation Increases Walking Distance in Patients With Intermittent Claudication. Results of the CIPIC Rehab Study: A Randomised Controlled Trial. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2021 Nov;62(5):768–76.
53 54 55 56	805 806 807	51.	Devrome AN, Aggarwal S, McMurtry MS, Southern D, Hauer T, Lamb B, et al. Cardiac rehabilitation in people with peripheral arterial disease: A higher risk population that benefits from completion. Int J Cardiol. 2019 Jun 15;285:108–14.
57 58 59 60	808 809 810	52.	Ambrosetti M, Temporelli PL, Faggiano P, Febo O, Diaco T, Favretto G, et al. Lower extremities peripheral arterial disease among patients admitted to cardiac rehabilitation: the THINKPAD registry. Int J Cardiol. 2014 Feb 1;171(2):192–8.

Jeger RV, Rickenbacher P, Pfisterer ME, Hoffmann A. Outpatient rehabilitation in patients

 53.

5 6 7	812 813		with coronary artery and peripheral arterial occlusive disease. Arch Phys Med Rehabil. 2008 Apr;89(4):618–21.
8 9 10 11	814 815 816	54.	Tam MC, Longenecker CT, Chow C, Vest M, Sukeena R, Madan Mohan SK, et al. Occult peripheral artery disease is common and limits the benefit achieved in cardiac rehabilitation. Vasc Med Lond Engl. 2016 Apr;21(2):130–6.
12 13 14 15 16	817 818 819	55.	Anghel R, Adam CA, Mitu O, Marcu DTM, Onofrei V, Roca M, et al. Cardiac Rehabilitation and Mortality Risk Reduction in Peripheral Artery Disease at 6-Month Outcome. Diagn Basel Switz. 2022 Jun 20;12(6).
17 18 19 20	820 821 822	56.	Sami F, Ranka S, Lippmann M, Weiford B, Hance K, Whitman B, et al. Cardiac rehabilitation in patients with peripheral arterial disease after revascularization. Vascular. 2021 Jun;29(3):350–4.
21 22 23 24	823 824 825	57.	Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200–7.
25 26 27 28	826 827 828	58.	Verdicchio C, Freene N, Hollings M, Maiorana A, Briffa T, Gallagher R, et al. A Clinical Guide for Assessment and Prescription of Exercise and Physical Activity in Cardiac Rehabilitation. A CSANZ Position Statement. Heart Lung Circ. 2023 Sep;32(9):1035–48.
29 30 31 32	829 830 831	59.	Sanderson B, Askew C, Stewart I, Walker P, Gibbs H, Green S. Short-term effects of cycle and treadmill training on exercise tolerance in peripheral arterial disease. J Vasc Surg. 2006 Jul;44(1):119–27.
33 34 35 36	832 833 834	60.	Wood RE, Sanderson BE, Askew CD, Walker PJ, Green S, Stewart IB. Effect of training on the response of plasma vascular endothelial growth factor to exercise in patients with peripheral arterial disease. Clin Sci Lond Engl 1979. 2006 Dec;111(6):401–9.
37 38 39 40	835 836 837	61.	Tew GA, Humphreys L, Crank H, Hewitt C, Nawaz S, Al-Jundi W, et al. The development and pilot randomised controlled trial of a group education programme for promoting walking in people with intermittent claudication. Vasc Med Lond Engl. 2015 Aug;20(4):348–57.
41 42 43 44 45	838 839 840	62.	Astley CM, Beleigoli A, Tavella R, Hendriks J, Gallagher C, Tirimacco R, et al. Assessing the quality of cardiac rehabilitation programs by measuring adherence to the Australian quality indicators. BMC Health Serv Res. 2022 Feb 28;22(1):267.
46 47 48	841 842	63.	Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–81.
49 50 51 52	843 844 845	64.	Martinez CA, Carmeli E, Barak S, Stopka CB. Changes in pain-free walking based on time in accommodating pain-free exercise therapy for peripheral arterial disease. J Vasc Nurs Off Publ Soc Peripher Vasc Nurs. 2009 Mar;27(1):2–7.
53 54 55	846 847	65.	Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise intensity terminology. J Sci Med Sport. 2010 Sep;13(5):496–502.
56 57 58 59 60	848 849 850 851	66.	Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Med J Aust. 2016 Aug 1;205(3):128–33.

### BMJ Open


852 853 854 855	67.	Australian Government Department of Health and Aged Care. Physical activity and exercise guidelines for all Australians [Internet]. Australian Government; 2021. Available from: https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians#order-the-guidelines
856 857 858	68.	Australian Government Department of Health and Aged Care. The Australian Dietary Guidelines [Internet]. 2019. Available from: https://www.health.gov.au/resources/publications/the-australian-dietary-guidelines
859 860	69.	Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726–32.
861 862	70.	ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111–7.
863 864 865 866	71.	Golledge J, Yip L, Fernando ME, Pinchbeck J, Rowbotham S, Jenkins J, et al. Relationship between requirement to stop during a six-minute walk test and health-related quality of life, physical activity and physical performance amongst people with intermittent claudication. Ann Vasc Surg. 2021 Oct;76:363–9.
867 868 869	72.	McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al. Prognostic value of functional performance for mortality in patients with peripheral artery disease. J Am Coll Cardiol. 2008 Apr 15;51(15):1482–9.
870 871 872 873	73.	McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg. 2008 Nov;48(5):1231–7, 1237.e1.
874 875 876 877	74.	Birkett ST, Harwood AE, Caldow E, Ibeggazene S, Ingle L, Pymer S. A systematic review of exercise testing in patients with intermittent claudication: A focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions. PloS One. 2021;16(5):e0249277.
878 879 880	75.	Gardner AW, Montgomery PS, Wang M. Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med Lond Engl. 2018 Aug;23(4):349–57.
881 882	76.	Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991 Apr;23(4):402–8.
883 884 885	77.	Gardner AW, Skinner JS, Vaughan NR, Bryant CX, Smith LK. Comparison of three progressive exercise protocols in peripheral vascular occlusive disease. Angiology. 1992 Aug;43(8):661–71.
886 887 888	78.	Leeper NJ, Myers J, Zhou M, Nead KT, Syed A, Kojima Y, et al. Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease. J Vasc Surg. 2013 Mar;57(3):728–33.
889 890 891	79.	Harber MP, Kaminsky LA, Arena R, Blair SN, Franklin BA, Myers J, et al. Impact of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since 2009. Prog Cardiovasc Dis. 2017 Jul;60(1):11–20.
	<ul> <li>853</li> <li>854</li> <li>855</li> <li>856</li> <li>857</li> <li>858</li> <li>859</li> <li>860</li> <li>861</li> <li>862</li> <li>863</li> <li>864</li> <li>865</li> <li>866</li> <li>867</li> <li>868</li> <li>869</li> <li>870</li> <li>871</li> <li>872</li> <li>873</li> <li>874</li> <li>875</li> <li>876</li> <li>877</li> <li>878</li> <li>879</li> <li>80</li> <li>881</li> <li>882</li> <li>883</li> <li>884</li> <li>885</li> <li>886</li> <li>887</li> <li>888</li> <li>889</li> <li>890</li> </ul>	853         854         855         856         857         859         861         862         863         863         864         865         866         870         871         872         873         874         875         876         877         878         878         878         879         881         76.         883         885         886         887         888         889         79.

1 2 3			
4 5 6 7	892 893 894	80.	Chong PFS, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The intermittent claudication questionnaire: a patient-assessed condition-specific health outcome measure. J Vasc Surg. 2002 Oct;36(4):764–71; discussion 863-864.
8 9 10	895 896	81.	Regensteiner J, Steiner J, Panzer R, Hiatt W. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142-152.
11 12 13 14	897 898 899	82.	Hildebrand M, VAN Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc. 2014 Sep;46(9):1816–24.
15 16 17 18 19 20	900 901 902 903	83.	Migueles JH, Cadenas-Sanchez C, Ekelund U, Delisle Nyström C, Mora-Gonzalez J, Löf M, et al. Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med Auckl NZ. 2017 Sep;47(9):1821–45.
21 22 23 24	904 905 906	84.	Airlie J, Forster A, Birch KM. An investigation into the optimal wear time criteria necessary to reliably estimate physical activity and sedentary behaviour from ActiGraph wGT3X+ accelerometer data in older care home residents. BMC Geriatr. 2022 Feb 17;22(1):136.
25 26 27 28 29 30 31	907 908 909	85.	Choi L, Ward SC, Schnelle JF, Buchowski MS. Assessment of wear/nonwear time classification algorithms for triaxial accelerometer. Med Sci Sports Exerc. 2012 Oct;44(10):2009–16.
	910 911	86.	Evenson KR, Buchner DM, Morland KB. Objective measurement of physical activity and sedentary behavior among US adults aged 60 years or older. Prev Chronic Dis. 2012;9:E26.
32 33 34 35	912 913 914	87.	Kelly LA, McMillan DG, Anderson A, Fippinger M, Fillerup G, Rider J. Validity of actigraphs uniaxial and triaxial accelerometers for assessment of physical activity in adults in laboratory conditions. BMC Med Phys. 2013 Nov 26;13(1):5.
36 37 38 39	915 916 917	88.	Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, et al. Amount of time spent in sedentary behaviors in the United States, 2003-2004. Am J Epidemiol. 2008 Apr 1;167(7):875–81.
40 41 42 43 44 45	918 919 920 921	89.	McDermott MM, Spring B, Berger JS, Treat-Jacobson D, Conte MS, Creager MA, et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA. 2018 Apr 24;319(16):1665–76.
46 47 48 49	922 923 924	90.	Hernandez H, Myers SA, Schieber M, Ha DM, Baker S, Koutakis P, et al. Quantification of Daily Physical Activity and Sedentary Behavior of Claudicating Patients. Ann Vasc Surg. 2019 Feb;55:112–21.
49 50 51 52 53 54 55 56 57 58 59 60	925 926 927	91.	Gerage AM, Correia M de A, Oliveira PML de, Palmeira AC, Domingues WJR, Zeratti AE, et al. Physical Activity Levels in Peripheral Artery Disease Patients. Arq Bras Cardiol. 2019;113(3):410–6.
	928 929 930	92.	Gardner AW, Montgomery PS, Wang M, Shen B. Minimal clinically important differences in daily physical activity outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med Lond Engl. 2022 Apr;27(2):142–9.

1 2 3			
4 5 6 7	931 932 933	93.	Hurtig-Wennlöf A, Hagströmer M, Olsson LA. The International Physical Activity Questionnaire modified for the elderly: aspects of validity and feasibility. Public Health Nutr. 2010 Nov;13(11):1847–54.
8 9 10 11	934 935 936	94.	Gardner AW, Montgomery PS. Comparison of three blood pressure methods used for determining ankle/brachial index in patients with intermittent claudication. Angiology. 1998 Sep;49(9):723–8.
12 13 14 15	937 938 939	95.	Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to anklebrachial pressure index. Circulation. 2003 Oct 28;108(17):2093–8.
16 17 18 19 20	940 941 942	96.	Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534–47.
20 21 22 23 24	943 97. 944 945		Bailey TG, Birk GK, Cable NT, Atkinson G, Green DJ, Jones H, et al. Remote ischemic preconditioning prevents reduction in brachial artery flow-mediated dilation after strenuous exercise. Am J Physiol Heart Circ Physiol. 2012 Sep 1;303(5):H533-538.
25 26 27 28	946 947 948	98.	Kals J, Lieberg J, Kampus P, Zagura M, Eha J, Zilmer M. Prognostic impact of arterial stiffness in patients with symptomatic peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2014 Sep;48(3):308–15.
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	949 950 951	99.	Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010 Feb 2;121(4):505–11.
	952 953 954	100.	Hwang MH, Yoo JK, Kim HK, Hwang CL, Mackay K, Hemstreet O, et al. Validity and reliability of aortic pulse wave velocity and augmentation index determined by the new cuff-based SphygmoCor Xcel. J Hum Hypertens. 2014 Aug;28(8):475–81.
	955 956 957 958	101.	Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertens Dallas Tex 1979. 2015 Sep;66(3):698–722.
	959 960 961	102.	Sandberg A, Cider Å, Jivegård L, Nordanstig J, Wittboldt S, Bäck M. Test-retest reliability, agreement, and minimal detectable change in the 6-minute walk test in patients with intermittent claudication. J Vasc Surg. 2020 Jan;71(1):197–203.
46 47 48	962		
48 49 50 51 52 53 54 55 56 57 58 59 60			

		BMJ Open BMJ Open BMJ Open BMJ Open	Page 26 of 29
		BMJ Open SY 2	
1 2		9h t, 08	
2			
4 5	963	FIGURE CAPTIONS	
6 7	964	Figure 1. Overview of the Saving Legs and Lives study.	
8	965	CR, cardiovascular rehabilitation; 6MWT, six-minute walk test; AIx, augmentation index; PWV, pulse ware pelocity; WIQ, walking impairment	
9	966	questionnaire; ICQ, intermittent claudication questionnaire; VO <sub>2peak</sub> , peak oxygen uptake.	
10 11	967	1ted 1024.	
12	968		
13 14	969		
15	970 071		
16 17	971 972		
18	972 973		
19 20	974	je i	
20 21	975	Al the second se	
22	976	raini jõe	
23 24	977		
25	978	CR, cardiovascular rehabilitation; 6MWT, six-minute walk test; AIx, augmentation index; PWV, pulse version of the second	
26 27	979	sini mi	
28	980		
29 30	981	ech une	
31	982		
32	983 984	ogies.	
33 34	985	at	
35	986	Agence	
36 37	987		
38	988		
39 40	989	Bibliogra	
41		aphique	
42 43			
43 44		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
45			
46			

Page 27	7 of 29	BMJ	Open	i jopen-2024-009203 4 by copyright, inclu					
		BMJ	Open		en-zuz4-u copyright				
1			•		ight				
2			t, in						
3									
4 5	990 TABLES		ding						
	991 Table 1. Schedule of participant enrolment, intervention, and assessment <b>55</b>								
7	MILESTONES	ACTIVITY	Screen	Baseline (Pre	-interventign	Post-int	ervention	Follow-up	
8	WEEK		0				8	34	
9 10	VISIT (timepoint)		1	2	3 reigi	4	5	6	
10	RECRUITEMENT	Patient identification	X		internet				
12		Pre-screen checklist for eligibility	X		to te	<b>)</b>			
13	ENROLEMENT &	Consent	X		e Sup				
14 15	SCREENING	Confirm eligibility	X		ext and da	) 			
16		Demographics and health history	X						
17		Familiarisation with six-minute walk test	X		ata mi				
18	RANDOMISATION	Stratification & randomisation			x ni.				
19 20	INTERVENTION	Usual care plus community-based CR program (weeks 2 to 7)			<u> </u>				
20 21	CONTROL	Usual care (weeks 2 to 7)	5.			<b>6</b>			
22	PRIMARY OUTCOME	Six-minute walk test		X	rair	X		X	
23	SECONDARY	Treadmill walking test & cardiorespiratory fitness test with ECG*			Xing		X		
24	OUTCOMES	Quality of life (WIQ, ICQ)		Х	, an	Х		Х	
25 26		Physical activity levels (7-day accelerometer, physical activity survey)		Х	nd s	Х		Х	
27	EXPLORATORY	Ankle-to-brachial systolic blood pressure index		X	mi t	Х		Х	
28	OUTCOMES	Brachial artery flow-mediated dilation assessment		X	lar 1	Х		Х	
29		Arterial stiffness assessments (AIx, carotid-femoral artery PWV)		Х	ect un	Х		Х	
30 31		Markers of CVD (total cholesterol, LDL, HDL triglycerides, HbA1c)		X	on o	<b>X</b>		Х	
32 33 34 35 36 37	Note: All participants will continue to receive usual care and medical advice from their general practitioner (local doctor) and vascular surg@n, and they will be randomly allocation to a community-based cardiovascular rehabilitation program (intervention) or usual care group (control) for 6-weeks. Prior to randomisation par@ipages will be stratified to account for type of procedure (e.g., open surgical vs endovascular procedure) and time since procedure (<12 weeks vs > 12 weeks). Outcome measures will be assessed at baseline (week 1), at the end of the intervention / usual care period (week 8) and again at 6-month follow-up (week 34). *As the treadmill walking test and the cardiorespiratory fittings test are secondary outcomes participants will be given the option to opt out of performing those assessments. For the post-intervention assessments at weeks 8 and 34, the assessment window may be estended by up to 7 days to accommodate unforeseen circumstances (e.g., participant illness). CR, cardiovascular rehabilitation; ECG, electrocardiogram; WIQ, walking imperment questionnaire; ICQ, intermittent claudication questionnaire; AIx, augmentation index; PWV, pulse wave velocity; CVD, cardiovascular disease; LDL, low-density lipoprotein; HbA1c, haemoglobin A1c. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml								



Page 29 of 1 2	f 29					BMJ (	Open		njopen-2024-089203 o 1 by copyright, includi				
2 3 4	Suppl	lementary Ta	ble 1. Cardiov	ascular rehal	vilitation exercise program				- includ				
5		Treadmill walking			Lower limb resistance exercises				C Upper body continuous movements / activities				
6	Week	Walking bouts	Bout duration	Total time	Exercise	Sets	Repetitions	Total time	Iskercine	Sets	Duration	Total time	
7 8 9	1	5	2 minutes	10 minutes	<ol> <li>1) Sit-to-stand</li> <li>2) Seated leg extensions</li> <li>3) Standing calf raises</li> </ol>	2 2 1	12 12 12	10 minutes	1) Upright row in the dimensional states of	4 3 3	1 minute 1 minute 1 minute	20 minutes	
10 11 12	2	7	2 minutes	14 minutes	<ol> <li>Sit-to-stand</li> <li>Seated leg extensions</li> <li>Standing calf raises</li> </ol>	2 2 2 2	12 12 12 12	12 minutes	1) Upright rowing Sumbbells)         2) Arm cycling g         3) Ski ergometry C	3 2 2	1 minute 1 minute 1 minute	14 minutes	
13 14 15	3	10	2 minutes	20 minutes	<ol> <li>Sit-to-stand</li> <li>Seated leg extensions</li> <li>Standing calf raises</li> </ol>	2 2 1	12 12 12	10 minutes	1) Upright row is allowed by a second	2 2 1	1 minute 1 minute 1 minute	10 minutes	
16 17	4	12	2 minutes	24 minutes	<ol> <li>Sit-to-stand</li> <li>Standing calf raises</li> </ol>	2 2	12 12	8 minutes	1) Upright rowing thumbbells) 2) Arm cycling D	2 2	1 minute 1 minute	8 minutes	
18 19	5	14	2 minutes	28 minutes	<ol> <li>1) Sit-to-stand</li> <li>2) Standing calf raises</li> </ol>	2	12 12	6 minutes	1) Upright roz (2) Atumbbells) 2) Arm cycling · 5	2	1 minute 1 minute	6 minutes	
20 21	6	15	2 minutes	30 minutes	1) Sit-to-stand 2) Standing calf raises	1	12 12	4 minutes	1) Upright rowing orumbbells) 2) Arm cycling	2	1 minute 1 minute	6 minutes	
22		Intensity pro	gression criteria	•		ty progres	ssion criteria			m progress	sion criteria	•	
23 24 25 26 27 28 29 30 31 32 33 34 35	10 watts for th Pa ma sca (ou Adjust speed a 10 watts for th Pa 4 Ba Ba Ba Ba Ba Ba Ba Ba Ba Ba	and/or gradient of tree ne next walking bout i rticipant completes war aximal claudication pa ale) or rate of perceive at of 10) by the end of and/or gradient of tree ne next walking bout i rticipant fails to comp eart rate exceeds 90% seconds te of perceived exerti- articipant fails to comp at or rest up to the end	<ul> <li>Participant is able to perform 12 repetitions with ease and optimal exercise technique</li> <li>Exercise does not induce moderate to near-maximal claudication pain or rate of perceived exertion is less than 3 (out of 10) by the end of the set</li> <li>Decrease repetitions and/or weight for the next set if:         <ul> <li>Participant is unable to complete the set with optimal exercise technique</li> <li>Rate of perceived exertion is 8 or above (out of 10)</li> </ul> </li> </ul>			The aim of the upper body activit treadmill was ing and lower limb • Taiprogress the exerci ingrease treadmill wal • To reguess the exercis ingrease upper body a og is 2025 at Age	resistance of the second secon	exercises. , reduce upper bod	ly activity time and				
36 37 38 39 40 41 42 43 44 45				For pee	r review only - http://b	mjopen.	.bmj.com/site	e/about/guid	nce Bibliographique de I elines.xhtml el				